[
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Martin Plöderl’s website",
    "section": "",
    "text": "I am a clinical psychologist and psychotherapist working in the field of crisis intervention and suicide prevention. I am mainly working in clinical practice but I am also doing research and education.\nBesides work I am also a cyclist, love good coffee, nature, photography, and I am keeper of a small herd of chicken."
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "This site is in experimental status. It was created with Quarto using RStudio."
  },
  {
    "objectID": "index.html#papers-in-peer-reviewed-journals",
    "href": "index.html#papers-in-peer-reviewed-journals",
    "title": "Martin Plöderl’s Website",
    "section": "",
    "text": "Amendola, S., Plöderl, M., & Hengartner, M. P. (2024). Suicide rates and prescriptions of antidepressants. Trends in the United States, 1999-2020,  by Sex and Race/Ethnicity. Crisis,\nhttps://doi.org/10.1027/0227-5910/a000941\n\n\nHorowitz, M., Naudet, F., & Plöderl, M (2024). Correspondence to ‘Esketamine Nasal Spray versus Quetiapine for Resistant Depression’. New England Journal of Medicine 390:1, https://www.nejm.org/doi/10.1056/NEJMc2313230.\n\nKostic, M., Plöderl, M., Hengartner, M. P., Buzejic, Jelena (2024). Suicidality emerging from rapid venlafaxine discontinuation: a challenge - dechallenge - rechallenge case report. Journal of Clinical Psychiatry. https://doi.org/10.4088/JCP.23cr14930\n\nPichler, E.-M., Fartacek, M., Miller-Döbeling, B., Walter, M., & Plöderl. M. (2024). Too early to add lithium to drinking water? No association between lithium and suicides in a pre-registered Swiss study. Journal of Affective Disorders, 367, 598-605. https://doi.org/10.1016/j.jad.2024.08.239 (open access).\n\nPlöderl, M. (2024). “Reanalysis of a Tryptophan Meta-analysis.” Meta-Psychology. https://doi.org/10.15626/MP.2023.3716.\n\nPlöderl, M., Pichler, E.-M., Westerlund, J., Niederseer, D., & Fartacek, C. (2024). Daylight-Saving-Time was not associated with a Change in Suicide Rates in Austria, Switzerland, and Sweden. European Journal of Public Health, https://doi.org/10.1093/eurpub/ckae061.\n\nTeismann, T., & Plöderl, M. (2024). Suizid-Screenings: eine Kritik. Suizidprophylaxe 51 (2), 34-40.\n\nPlöderl, M. (2023). Psychopharmaka und Suizid. Wissenschaftliche Herausforderungen und Befundlage. Kerbe 4, 22-23.\n\nFartacek, C., Kunrath, S., Aichhorn, W., & Plöderl, M. (2023). Therapeutic alliance and change in suicide ideation among psychiatric inpatients at risk for suicide. Journal of Affective Disorders, 15, 793-798. https://doi.org/10.1016/j.jad.2022.12.028 (open access).\n\nHengartner, M. P. & Plöderl, M. (2023). No clear evidence of reduced brain serotonin capacity in patients with depression. Biological Psychiatry 93(12): e61. https://doi.org/10.1016/j.biopsych.2022.11.020\n\nMoncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., Plöderl, M., & Horowitz, M. A. (2023). The serotonin hypothesis of depression: both long discarded and still supported? Molecular Psychiatry, 1-4. https://doi.org/10.1038/s41380-023-02094-z\n\nPichler, E-M., Plöderl, M., Rainer, L., Gilhofer, T., Michel, J., van der Stouwe, J. G., Luesch, T. F., Schmied, C. M., Kawohl, W., Konschnabl, J., Niederseer, D. (2023). Alive and Kicking \n– Suicide Rates and Major Soccer Events in Austria, Germany, and Switzerland. European Journal of Public Health, 33, 424–429. https://doi.org/10.1093/eurpub/ckad042 (open access).\n\nPlöderl, M., Amendola, S., & Hengartner, M. P. (2023). Observational studies of antidepressant use and suicide risk are selectively published in psychiatric journals. Journal of Clinical Epidemiology. https://doi.org/10.1016/j.jclinepi.2023.07.015 (open access).\n\nPlöderl, M., Fartacek, C., Kapitany, T., Schrittwieser, U., & Niederkrotenthaler, T. (2023). Effects of gatekeeper trainings from the Austrian national suicide prevention program. Frontiers in Psychiatry, 14, 1118319. https://doi.org/10.3389/fpsyt.2023.1118319\n\nPlöderl, M. & Hengartner, M. P. (2023). Effect of the FDA black box suicidality warnings for antidepressants on suicide rates in the USA – signal or noise? Crisis 44, 128-134. https://doi.org/10.1027/0227-5910/a000843. Download accepted version.\n\nPlöderl, M., Horowitz, M. A., Hengartner, M. P. (2023). Re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et al.—Concerning Harm–Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder. Journal of Child and Adolescent Psychopharmacology, 33(7), 295-296. https://doi.org/10.1089/cap.2023.0029 See thread.\n\nPlöderl, M., & Naudet, F. (2023). Severe methodological problems in a recent review and analysis of the association between lithium concentration in potable water and suicide rates. International Clinical Psychopharmacology, 38, 406-407. https://doi.org/10.1097/yic.0000000000000484\n\nPlöderl, M., Westerlund, J., Hökby, S., Hadlaczky, G., & Hengartner, M.P. (2023). Increased suicide risk among younger women in winter during full moon in northern Europe. An artifact or a novel finding? Molecular Psychiatry 28, 901–907. https://doi.org/10.1038/s41380-022-01823-0 (open access).\n\nHengartner, M. P. & Plöderl, M. (2022). Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ idence-Based Medicine, 27, 69-73 . https://doi.org/10.1136/bmjebm-2020-111600. Download accepted manuscript.\n\nKirchner, S., Till, B., Plöderl, M., & Niederkrotenthaler, T. (2022). Effects of ‘It get’s better’ suicide prevention videos on lesbian, gay, bisexual, transgender, or queer youth or youth of other sexual or gender minorities: A randomised controlled trial. LGBT Health, 9(6), 436-446. https://doi.org/10.1089/lgbt.2021.0383 (open access).\n\nMoncrieff, J.,  Plöderl, M. , Nabi, Z.,  Stansfeld, J., & Wood, L. (2022). Evidence does not confirm that lithium prevents suicide: a reply to Bschor et al. Epidemiology and Psychiatric Sciences. https://doi.org/10.1017/S2045796022000737 (open access).\n\nMundle, G., Plöderl, M., & Mahler, L. (2022). Sexual minorities between equality and exclusion. Psychiatria Hungarica, 37(4), 308-318.\n\nNabi, Z.,  Stansfeld, J., Plöderl, M. Wood, L., & Moncrieff, J. (2022). Effects of lithium on suicide and suicidal behaviour: a systematic review and meta-analysis of randomised trials. Epidemiology and Psychiatric Sciences. https://doi.org/10.1017/S204579602200049X (open access). \n \nPlöderl, M. & Hengartner, M. P. (2022). Learning about the course of suicidal behaviour but not about the effects of SSRIs. Neuropsychopharmacoloy 47, 803.  https://doi.org/10.1038/s41386-021-01224-x   Read here \n\nPlöderl, M., Hengartner, M.P., & Volkmann, C. (2022). Suizidpräventive Effekte von Ketamin und Esktetamin. Nervenheilkunde, 41, 240-245. https://doi.org/10.1055/a-1761-3192. PDF.\n\nPlöderl, M., Mestel, R., & Fartacek, C. (2022). Differences by sexual orientation in treatment outcome and satisfaction with treatment among inpatients of a German psychiatric clinic. PLoS One, 17(1): e0262928. https://doi.org/10.1371/journal.pone.0262928 (open access)."
  },
  {
    "objectID": "publications/index.html",
    "href": "publications/index.html",
    "title": "Publications",
    "section": "",
    "text": "Preprints\nLyus, R., Naudet, F., van Valkenhoef, G., & Plöderl, M. (2025, September 10). A Re-Appraisal of three network meta-analyses to explain the discrepancy in findings for the efficacy of fluoxetine for the treatment of depression in children and adolescents. https://doi.org/10.1101/2025.09.07.25334757\nPlöderl, M., Cooper, R., Walker, T., Shah, V., Horowitz, M., Volkmann, C., Moncrieff, J. (2025, August 21). Effects of ketamine and esketamine on death, suicidal behaviour, and suicidal ideation in psychiatric disorders: A systematic review and meta-analysis. http://medrxiv.org/lookup/doi/10.1101/2025.08.19.25333796\nPlöderl, M. (2025, February 27). Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. https://doi.org/10.31219/osf.io/tv823_v1\nXu, C., Kim, T., Plöderl, M., Kennedy, K. P., Kirsch, I. Amsterdam, J. D., Pigott, H. E. (2025, October 30). Restoring STAR*D: A RIAT Reanalysis of Medication Augmentation Therapy After Failed SSRI Treatment Using Patient-Level Data with Fidelity to the Original Research Protocol. https://doi.org/10.1101/2025.10.27.25338365\nXu, C., Kim, T. T., Kirsch, I., Plöderl, M., Amsterdam, J. D., Pigott, H. E. (2025, February 12). Restoring STAR*D: A Reanalysis of Drug-Switch Therapy After Failed SSRI Treatment Using Patient-Level Data with Fidelity to the Original STAR*D Research Protocol. https://doi.org/10.1101/2025.02.10.25321991\n\n\nPeer Reviewed Papers\nPlöderl, M., Horowitz, M., Naudet, F., Warren, J., and Moncrieff, J. (subm.). Concerning harm/benefit ratio of escitalopram for pediatric generalized anxiety disorder. A critical viewpoint on the evidence and approval process. International Journal of Risk and Safety in Medicine.\nPlöderl, M., Hussey, I., Ostacher, M. (in press). Trustworthiness issues in Yari-Renani and Zari’s (2025) study “Advancing depression treatment: a multi-center randomized controlled trial of dynamic interpersonal therapy versus CBT and pharmacotherapy on symptoms, sleep, and cognition” Psychiatry Research. Preprint: https://doi.org/10.31234/osf.io/tr42m_v1\nPlöderl, M., Lyus, R., Horowitz, M., Moncrieff, J. (2026). Reply to Boussageon at al.’s “Some additional comments on the evidence for fluoxetine in pediatric depression.” Journal of Clinical Epidemiology. https://doi.org/10.1016/j.jclinepi.2026.112138\nPlöderl, M., Lyus, R., Horowitz, M., Moncrieff, J. (2026). The loss of efficacy of fluoxetine in pediatric depression: explanations, lack of acknowledgment, and implications for other treatments. Journal of Clinical Epidemiology, 189, 112016. https://doi.org/10.1016/j.jclinepi.2025.112016 Preprint\nPlöderl, M., & Moncrieff, J. (2026). Potentially problematic research practices in a study on ketamine for pediatric depression. American Journal of Psychiatry. 183, 82-83. https://doi.org/10.1176/appi.ajp.20250497\nXu, C., Naudet, F., Kim, T., Hengartner, M. P., Horowith, M. A., Moncrieff, J., Pigott, E., Plöderl, M. (2026). Results of finite mixture models remain inconsistent. Reply to Stone. Journal of Clinical Epidemiology, 189, 112022. https://doi.org/10.1016/j.jclinepi.2025.112022\nCristea, I., Plöderl, M., & Naudet, F. (2025). Letter in reply to Janik A, Qiu X, Lane R, et al. Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry, 83, 103. 10.1001/jamapsychiatry.2025.3242\nHengartner, M. P., Plöderl, M., Read, J. (2025). Short-term trials underestimate antidepressant withdrawal effects. JAMA Psychiatry, 82, 1255. https://doi.org/10.1001/jamapsychiatry.2025.3166\nHorowitz, M., Hengartner, M. P., Plöderl, M., & Moncrieff, J. (2025). False reassurances based on inadequate data not helpful. Psychological Medicine, 55, e309. https://doi.org/10.1017/S0033291725102092\nMoncrieff, J., Hobday, H., Sorensen, A., Read, J., Plöderl, M., Hengartner, M. P., Barkholt Kamp, C., Jakobsen, J. C., Juul, S., Davies, J., & Horowitz, M. (2025). Evidence on antidepressant withdrawal: a critique and re-analysis of a recent systematic review. Psychological Medicine, 55, e191, 1–17. https://doi.org/10.1017/S0033291725100652\nMoncrieff, J., Stansfield, J., Wood, L., & Plöderl, M. (2025). Uncertainty about lithium and suicide: a response to Nassir Ghaemi. Journal of Psychopharmacology, 39, 1201-1203. https://doi.org/10.1177/02698811251346706\nPadberg, T., & Plöderl, M. (2025). Die Geschichte des medizinischen Modells der Depression - mit (fast) all ihren Vor- und Nachteilen. Kontext, 56 (2), 125-137. Mit einer Replik auf Prof. Norman, S. 143 - 150. https://doi.org/10.13109/kont.2025.56.2.125\nPlöderl, M. (2025). Multiple Errors in the Meta-Analysis by Zhang et al. (2025). European Child & Adolescent Psychiatry. https://doi.org/10.1007/s00787-025-02717-6\nXu, C., Naudet, F., Kim, T., Hengartner, M. P., Horowith, M. A., Kirsch, I., Moncrieff, J., Pigott, E., Plöderl, M. (2025). Large responses to antidepressants or methodological artifacts? A secondary analysies of STAR*D, a single-arm, open-label, non- industry antidepressant trial. Journal of Clinical Epidemiology, 187, 111943. https://doi.org/10.1016/j.jclinepi.2025.111943\nAmendola, S., Plöderl, M., & Hengartner, M. P. (2024). Suicide rates and prescriptions of antidepressants. Trends in the United States, 1999-2020,  by Sex and Race/Ethnicity. Crisis, 45, 225-233\nhttps://doi.org/10.1027/0227-5910/a000941\n\nFartacek, C., Fartacek, R., Schiepek, G. K., Sturm, J., Aichhorn, W., Plöderl, M. (2024). Dynamic association between suicidal ambivalence and suicide risk among individuals with a history of suicide attempts. Suicide and Life-Threatening Behavior, 54, 860-868. https://doi.org/10.1111/sltb.13096\n\nHorowitz, M., Naudet, F., & Plöderl, M (2024). Correspondence to ‘Esketamine Nasal Spray versus Quetiapine for Resistant Depression’. New England Journal of Medicine 390:1, https://www.nejm.org/doi/10.1056/NEJMc2313230.\n\nKostic, M., Plöderl, M., Hengartner, M. P., Buzejic, Jelena (2024). Suicidality emerging from rapid venlafaxine discontinuation: a challenge - dechallenge - rechallenge case report. Journal of Clinical Psychiatry. https://doi.org/10.4088/JCP.23cr14930\n\nPichler, E.-M., Fartacek, M., Miller-Döbeling, B., Walter, M., & Plöderl. M. (2024). Too early to add lithium to drinking water? No association between lithium and suicides in a pre-registered Swiss study. Journal of Affective Disorders, 367, 598-605. https://doi.org/10.1016/j.jad.2024.08.239\n\nPlöderl, M. (2024). “Reanalysis of a Tryptophan Meta-analysis.” Meta-Psychology. https://doi.org/10.15626/MP.2023.3716\n\nPlöderl, M., Pichler, E.-M., Westerlund, J., Niederseer, D., & Fartacek, C. (2024). Daylight-Saving-Time was not associated with a Change in Suicide Rates in Austria, Switzerland, and Sweden. European Journal of Public Health, https://doi.org/10.1093/eurpub/ckae061\n\nTeismann, T., & Plöderl, M. (2024). Suizid-Screenings: eine Kritik. Suizidprophylaxe 51 (2), 34-40.\n\nPlöderl, M. (2023). Psychopharmaka und Suizid. Wissenschaftliche Herausforderungen und Befundlage. Kerbe 4, 22-23. Download\n\nFartacek, C., Kunrath, S., Aichhorn, W., & Plöderl, M. (2023). Therapeutic alliance and change in suicide ideation among psychiatric inpatients at risk for suicide. Journal of Affective Disorders, 15, 793-798. https://doi.org/10.1016/j.jad.2022.12.028\n\nHengartner, M. P. & Plöderl, M. (2023). No clear evidence of reduced brain serotonin capacity in patients with depression. Biological Psychiatry 93(12): e61. https://doi.org/10.1016/j.biopsych.2022.11.020 Download accepted version\n\nMoncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., Plöderl, M., & Horowitz, M. A. (2023). The serotonin hypothesis of depression: both long discarded and still supported? Molecular Psychiatry, 1-4. https://doi.org/10.1038/s41380-023-02094-z\n\nPichler, E-M., Plöderl, M., Rainer, L., Gilhofer, T., Michel, J., van der Stouwe, J. G., Luesch, T. F., Schmied, C. M., Kawohl, W., Konschnabl, J., Niederseer, D. (2023). Alive and Kicking – Suicide Rates and Major Soccer Events in Austria, Germany, and Switzerland. European Journal of Public Health, 33, 424–429. https://doi.org/10.1093/eurpub/ckad042\n\nPlöderl, M., Amendola, S., & Hengartner, M. P. (2023). Observational studies of antidepressant use and suicide risk are selectively published in psychiatric journals. Journal of Clinical Epidemiology. https://doi.org/10.1016/j.jclinepi.2023.07.015\n\nPlöderl, M., Fartacek, C., Kapitany, T., Schrittwieser, U., & Niederkrotenthaler, T. (2023). Effects of gatekeeper trainings from the Austrian national suicide prevention program. Frontiers in Psychiatry, 14, 1118319. https://doi.org/10.3389/fpsyt.2023.1118319\n\nPlöderl, M. & Hengartner, M. P. (2023). Effect of the FDA black box suicidality warnings for antidepressants on suicide rates in the USA – signal or noise? Crisis 44, 128-134. https://doi.org/10.1027/0227-5910/a000843. Download accepted version.\n\nPlöderl, M., Horowitz, M. A., Hengartner, M. P. (2023). Re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et al.—Concerning Harm–Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder. Journal of Child and Adolescent Psychopharmacology, 33(7), 295-296. https://doi.org/10.1089/cap.2023.0029\n\nPlöderl, M., & Naudet, F. (2023). Severe methodological problems in a recent review and analysis of the association between lithium concentration in potable water and suicide rates. International Clinical Psychopharmacology, 38, 406-407. https://doi.org/10.1097/yic.0000000000000484 Download accepted manuscript\n\nPlöderl, M., Westerlund, J., Hökby, S., Hadlaczky, G., & Hengartner, M.P. (2023). Increased suicide risk among younger women in winter during full moon in northern Europe. An artifact or a novel finding? Molecular Psychiatry 28, 901–907. https://doi.org/10.1038/s41380-022-01823-0\n\nHengartner, M. P. & Plöderl, M. (2022). Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ idence-Based Medicine, 27, 69-73 . https://doi.org/10.1136/bmjebm-2020-111600. Download accepted manuscript.\n\nKirchner, S., Till, B., Plöderl, M., & Niederkrotenthaler, T. (2022). Effects of ‘It get’s better’ suicide prevention videos on lesbian, gay, bisexual, transgender, or queer youth or youth of other sexual or gender minorities: A randomised controlled trial. LGBT Health, 9(6), 436-446. https://doi.org/10.1089/lgbt.2021.0383\n\nMoncrieff, J.,  Plöderl, M. , Nabi, Z.,  Stansfeld, J., & Wood, L. (2022). Evidence does not confirm that lithium prevents suicide: a reply to Bschor et al. Epidemiology and Psychiatric Sciences. https://doi.org/10.1017/S2045796022000737\n\nMundle, G., Plöderl, M., & Mahler, L. (2022). Sexual minorities between equality and exclusion. Psychiatria Hungarica, 37(4), 308-318.\n\nNabi, Z.,  Stansfeld, J., Plöderl, M. Wood, L., & Moncrieff, J. (2022). Effects of lithium on suicide and suicidal behaviour: a systematic review and meta-analysis of randomised trials. Epidemiology and Psychiatric Sciences. https://doi.org/10.1017/S204579602200049X   \nPlöderl, M. & Hengartner, M. P. (2022). Learning about the course of suicidal behaviour but not about the effects of SSRIs. Neuropsychopharmacoloy 47, 803.  https://doi.org/10.1038/s41386-021-01224-x Read here\n\nPlöderl, M., Hengartner, M.P., & Volkmann, C. (2022). Suizidpräventive Effekte von Ketamin und Esktetamin. Nervenheilkunde, 41, 240-245. https://doi.org/10.1055/a-1761-3192. PDF.\n\nPlöderl, M., Mestel, R., & Fartacek, C. (2022). Differences by sexual orientation in treatment outcome and satisfaction with treatment among inpatients of a German psychiatric clinic. PLoS One, 17(1): e0262928. https://doi.org/10.1371/journal.pone.0262928\n\nAmendola, S., Plöderl, M., & Hengartner, M. P. (2021). Did the introduction and increased prescribing of antidepressants lead to changes in long-term trends of suicide rates? European Journal of Public Health, 31(2), 291-297. https://doi.org/10.1093/eurpub/ckaa204\n\nHengartner, M. P., & Plöderl, M. (2021). Prophylactic effects or withdrawal reactions? An analysis of time-to-event data from antidepressant relapse prevention trials submitted to the FDA. Therapeutic Advances in Psychopharmacology 11, https://doi.org/10.1177/20451253211032051\n\nHengartner, M. & Plöderl, M. (2021). Suicidality and other severe psychiatric events with duloxetine: Re-analysis of safety data from a placebo-controlled trial for juvenile fibromyalgia The International Journal of Risk & Safety in Medicine, 32(3), 209-218. https://doi.org/10.3233/JRS-200033. Download.\n\nHengartner, M. P., Plöderl, M., Amendola, S., Kindler, S., Bschor, T., & Kaminski, J. A. (2021). Suicide risk with selective serotonin reuptake inhibitors and other new-generation serotonergic-noradrenergic antidepressants in adults: a meta-analysis of observational studies. Journal of Epidemiology and Community Mental Health, 75, 523-530. https://doi.org/10.1136/jech-2020-214611  Download preprint\n\nKirchner, S., Till, B., Plöderl, M., & Niederkrotenthaler, T. (2021). It Gets Better Videos for Suicide Prevention in LGBTIQ+ Adolescents. Crisis, 42 (2), 92-99. https://doi.org/10.1027/0227-5910/a000691\n\nPlöderl, M. (2021). Suicide over the course of the day, week, and life. Psychiatria Danubina, 33,  438-445. https://doi.org/10.24869/psyd.2021.438\n\nPlöderl, M., & Hengartner, M.P. (2021). Moon and suicide: a true effect or a false-positive finding? Molecular Psychiatry, 26, 4564-4565.  https://doi.org/10.1038/s41380-020-00942-w  Download pre-print\n\nPlöderl, M. & Padberg, T. (2021). Antidepressiva. Wirksam und gut verträglich? Psychotherapie im Dialog, 22 (3), 44-48. doi: 10.1055/a-1215-1638. PDF. Langfassung\n\nPlöderl, M. & Volkmann, C. (2021). Esketamin. Ein berechtigter Hype in der Suizidprävention? Suizidprophylaxe, 48, 10-14. Download\n\nHengartner, M. P., Plöderl, M., Braillon, A., Jakobsen, J. C., Gluud, C. (2020). Comment on PANDA: Small short-term benefits but unknown risks of potentially serious long-term harms (Letter to the editor). Lancet Psychiatry 7(1). https://doi.org/10.1016/S2215-0366(19)30381-5\nHengartner, M. P., Jakobsen, J. C., Sorensen, A., & Plöderl, M. (2020). Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials. PloS One 15(2): e0229381. https://doi.org/10.1371/journal.pone.0229381\n\nKirchner, S., Till, B., Plöderl, M., & Niederkrotenthaler, T. (2020). Perceptions of LGBQ youth and experts of suicide prevention video messages targeting LGBQ youth: Qualitative study. BMC Public Health 20, 1845 https://doi.org/10.1186/s12889-020-09853-5\n\nPlöderl, M. (2020). Antidepressiva in der Suizidprävention. Ein Update. Psychologie in Österreich, 1/2020, 34-39. Download\nPlöderl, M., Hengartner, M. P., Bschor, T., & Kaminski, J. (2020). Commentary to “Antidepressants and suicidality: A re-analysis of the re-analysis”. Journal of Affective Disorders 273, 252-253. https://doi.org/10.1016/j.jad.2020.04.025. Download pre-print.\n\nPlöderl, M., Kunrath, S., & Fartacek, C. (2020). God bless you? The association of religion and spirituality with reduction of suicide ideation and length of hospital stay among psychiatric patients at risk for suicide. Suicide and Life-Threatening Behavior 50, 95-110. https://doi.org/10.1111/sltb.12582. Download accepted version.\n\nVolkmann, C. M., Hengartner, M. P., & Plöderl, M. (in press, than not published). The hope for personalized antidepressant treatment may not be warranted. JAMA Psychiatry.\nNote: this was a letter to the editor in response to a publication by Maslej et al. We have been informed that our letter was accepted for publication. However, the original paper of Maslej et al. was then retracted, with our letter being one of the reasons for retraction. See here. Our manuscript is available here.\n\nVolkmann, C., Plöderl, M., Hengartner, M.P. (2020). Comment on Osler et al: Misinterpretation of pre-post differences invalidates the authors’ conclusions. Acta Psychiatrica Scandinavica, 140, 589-59. https://doi.org/10.1111/acps.13110 Download accepted version\nPlöderl, M., Hengartner, M. P. (2019). What are the chances for personalized treatment with antidepressants? Detection of patient by treatment interaction with variance ratio meta-analysis. BMJ Open 9 (12).  https://doi.org/10.1136/bmjopen-2019-034816\nFeigelman, W., Plöderl, M., Cerel, J., Rosen, Z. (2019). Research note on whether sexual minority individuals are over-represented among completed suicides’ casualties. Crisis 41, 229-232. https://doi.org/10.1027/0227-5910/a000626. Download.\nHengartner, M.P., & Plöderl, M. (2019). Newer-generation antidepressants and suicide risk in randomized controlled trials: A re-analysis of the FDA database. Psychotherapy and Psychosomatics, 88, 247–248. https://doi.org/10.1159/000501215.\n\nHengartner, M.P., & Plöderl, M. (2019). Reply to the Letter to the Editor: “Newer-Generation Antidepressants and Suicide Risk: Thoughts on Hengartner and Plöderl’s Re-Analysis”. Psychotherapy and Psychosomatics, 88, 371-372.https://doi.org/10.1159/000502485.\n\nHengartner, M. P., & Plöderl, M. (2019). Starting two antidepressants to prevent suicide: A potentially dangerous recommendation? Australian and New Zealand Journal of Psychiatry, 53, 82-83. https://doi.org/10.1177/0004867418816811. Download\n\nHoyer, J., Mestel, R., Boos, A., Bördlein, C., Oude-Aost, J., Plöderl, M. & Walz, D. (2019). Leserbrief zum Artikel von Christof T. Eschenröder, “Angstreduktion und Traumabewältigung durch Klopfen - Imaginative Konfrontation mit sensorischer Stimulierung und kognitiver Umstrukturierung als wirksame Behandlungsmethode” in VPP 3/2018, S. 669-684. Verhaltenstherapie und psychosoziale Praxis, 51(1), 47-4. Download\n\nPlöderl, M. (2019). Antidepressiva in der Suizidprävention. Eine kritische Bestandsaufnahme. Suizidprophylaxe, 46, 53-64. Download. \nPlöderl, M., & Hengartner, M. P. (2019). Guidelines for the pharmacological acute treatment of major depression: Conflicts with current evidence as demonstrated with the German S3 Guidelines. BMC Psychiatry 19(1):265.  https://doi.org/10.1186/s12888-019-2230-4. For a project description, manuscript drafts, additional material, and rejections/reviews in German psychiatric journals, see osf.io/4kh2a\nPlöderl, M., & Hengartner, M. P. (2019). Antidepressiva wirken! Oder doch nicht? Skeptiker 2/2019, 72-78. Erhältlich hier. Download. Antwort auf Gegenargumente\nSalway, T., Plöderl, M., Liu, J., Gustafson, P. (2019). Effects of multiple forms of information bias on estimated prevalence of suicide attempts by sexual orientation: An application of a Bayesian misclassification correction method to data from a systematic review. American Journal of Epidemiology, 188, 239-249. https://doi.org/10.1093/aje/kwy200\nHengartner, M. P., & Plöderl, M. (2018). Statistically significant antidepressant-placebo differences on subjective symptom-rating scales do not proof that the drugs work: Effect size and method bias matters! Frontiers in Psychiatry. https://www.frontiersin.org/articles/10.3389/fpsyt.2018.00517/full\nHengartner, M. P., & Plöderl, M. (2018). False beliefs in adacemic psychiatry: The case of antidepressant drugs. Ethical Human Psychology and Psychiatry, 20. doi: 10.1891/1559-4343.20.1.6 Download\nKralovec, K., Kunrath, S., Fartacek, C., Pichler, E.-M., & Plöderl, M. (2018). The gender-specific associations between religion/spirituality and suicide risk in a sample of Austrian psychiatric inpatients. Suicide and Life-Threatening Behavior, 48(3), 281-293. http://dx.doi.org/10.1111/sltb.12349. Download.\n\nMahler, L., Mundle, G., & Plöderl, M. (2018). Wirkungen und Nebenwirkungen des Krankheitskonzepts “Homosexualität”. Fortschritte der Neurologie und Psychiatrie, 86, 469-476. https://doi.org/10.1055/a-0653-7177\n\nNiederseer, D., Bracher, I., Stadlmayr, A., Huber-Schönauer, U., Plöderl, M., Obeid, S., … & Patsch, W. (2018). Association between Cardiovascular Risk and Diabetes with Colorectal Neoplasia: A Site-Specific Analysis. Journal of Clinical Medicine, 7(12), 484. https://www.mdpi.com/2077-0383/7/12/484/htm\nPlöderl, M., & Hengartner, M. P. (2018). Antidepressant prescription rates and suicide attempt rates from 2004 to 2016 in a nationally representative sample of adolescents in the United States. Epidemiology and Psychiatric Sciences, 1-3.https://doi.org/10.1017/S2045796018000136\n\nPlöderl, M., & Fartacek, C. (2018). Known but unpredictable - an argument for complexity. Letter in response to Large et al. (2017) Known unknowns and unknown unknowns in suicide risk assessment: Evidence from meta-analyses of aleatory and epistemic uncertainty. BJPsych Bulletin.https://doi.org/10.1192/bjb.2018.12\n\nFartacek, C., Nindl, T., Dinhobl, R., & Plöderl, M. (2017). Notfallpläne zur Rückfallprophylaxe suizidalen Verhaltens für die existenzanalytische Praxis. Existenzanalyse, 34 (2), 107-111. Download.\n\nPlöderl, M., Kunrath, S., Cramer, R., Wang, J., Hauer, L., & Fartacek, C. (2017). Sexual orientation differences in treatment expectation, alliance, and outcome among patients at risk for suicide in a public psychiatric hospital. BMC Psychiatry. http://dx.doi.org/10.1186/s12888-017-1337-8.\n\nCramer, R. J., Burks, A.C., Plöderl, M., & Durgampudi, P. (2017). Minority stress model components and affective well-being in a sample of sexual orientation minority adults living with HIV/AIDS. AIDS Care. https://doi.org/10.1080/09540121.2017.1327650\n\nNiederseer, D., Stadlmayr, A., Huber-Schönauer, U., Plöderl, M., Schmied, C., Lederer, D., … & Datz, C. (2017). Cardiovascular risk and known coronary artery disease are associated with colorectal adenoma and advanced neoplasia. Journal of the American College of Cardiology, 69(18), 2348-2350. http://dx.doi.org/10.1016/j.jacc.2017.02.065\nPlöderl, M. (2016). LSBTI und psychische Gesundheit: Fakten und Erklärungsansätze. Psychotherapie-Wissenschaft, 2. Download\nPlöderl, M. (2016). Out in der Schule? Bullying und Suizidrisiko bei LGBTI Jugendlichen. Suizidprophylaxe. 43, 7-13. Download\n\nFartacek, C., Schiepek, G., Kunrath, S., Fartacek, R., & Plöderl, M. (2016). Real-time monitoring of nonlinear suicidal dynamics: methodology and a demonstrative case report. Frontiers in Psychology. http://dx.doi.org/10.3389/fpsyg.2016.00130\n\nPlöderl, M., Tremblay, P. (2015). Mental health of sexual minorities. A systematic review. International Review of Psychiatry, 27, 367-385.http://dx.doi.org/10.3109/09540261.2015.1083949 Download accepted manuscript\n\nWang, J., Plöderl, M., Häusermann, M., & Weiss, M. G. (2015). Understanding suicide attempts among gay men from their self-perceived causes. Journal of Nervous and Mental Disease, 203, 499-506. http://dx.doi.org/10.1097/NMD.0000000000000319 Download\n\nPlöderl, M., Fartacek, C., Kunrath, S., Pichler, E.M., Fartacek, R., Datz, C., & Niederseer, D. (2015). Nothing like Christmas: Suicides during Christmas and other holidays in Austria. European Journal of Public Health, 25, 410-413. http://dx.doi.org/10.1093/eurpub/cku169.\n\nFartacek, C., Kralovec, K., Pichler, E-M., Fartacek, R., Plöderl, M. (2014). Notfallpläne zur Rückfallprävention von suizidalem Verhalten. Suizidprophylaxe, 157, 68-72. Download\n\nKralovec, K., Fartacek, C., Fartacek, R., Plöderl, M. (2014). Religion and suicide risk in lesbian, gay, and bisexual Austrians. Journal of Religion and Health, 53, 413-423. http ://dx.doi.org/10.1007/s10943-012-9645-2. Download accepted manuscript\n\nNiederseer, D., Mörtl, H., Liebensteiner, M. C., Egger, A.,Thaler, C. W., Plöderl, M., … & Raschner, C. (2014). General fatigue and joint position sense in male elite handball players. Deutsche Zeitschrift für Sportmedizin, 65, 149-153. Download\n\nPlöderl, M. (2014). Bayesian advice for gaydar-based picking up: Commentary on Lyons, Lynch, Brewer, and Bruno (2013). Archives of Sexual Behavior, 43, 7-9. http://dx.doi.org/10.1007/s10508-013-0178-x. Download\nPlöderl, M., Sellmeier, M., Fartacek, C., Pichler, E-M., Fartacek, R., Kralovec, K. (2014). Explaining the suicide risk of sexual minority individuals by contrasting the minority stress model with suicide models. Archives of Sexual Behavior, 43, 1559-1570. http://dx.doi.org/10.1007/s10508-014-0268-4 Download accepted manuscript\n\nPlöderl. M., Tremblay, P. (2014). Complementing remarks to Skerrett (2014) ‘Suicides among LGBT populations in Australia: An analysis of the Queensland suicide register’. Asia-Pacific Psychiatry, 6, 350-351. http://dx.doi.org/10.1111/appy.12136\n\nNeunhäuserer, D., Sturm, J., Baumgartlinger, M., Niederseer, D., Ledl-Kurkowski, E., Steidle, E., Plöderl, M., Fartacek, C., Kralovec, K., Fartacek, R., Niebauer, J. (2013). Hiking in suicidal patients: Neutral effects on markers of suicidality. American Journal of Medicine, 126, 927-930. http://dx.doi.org/10.1016/j.amjmed.2013.05.008 Download\n\nNiederseer, D., Thaler, C. W., Egger, A., Niederseer, M. C.,Plöderl, M., & Niebauer, J. (2013). Watching soccer is not associated with an increase in cardiac events. International Journal of Cardiology. https://doi.org/10.1016/j.ijcard.2013.10.066\n\nPlöderl, M., Wagenmakers, E. J., Tremblay, P., Ramsay, R., Kralovec, K., Fartacek, C., Fartacek, R. (2013). Suicide risk and sexual orientation. A critical review. Archives of Sexual Behavior, 42, 715-727. https://doi.org/10.1007/s10508-012-0056-y. Download.\n\nSchiepek, G., Tominschek, I., Heinzel, S., Aigner, M., Dold, M.,Unger, A., Lenz, G., Windischberger, C., Moser, E., Plöderl, M., Lutz, J., Meindl, T., Zaudig, M., Pogarell, O., & Karch, S. (2013). Discontinuous patterns of brain activation in the psychotherapy process of obsessive compulsive disorder: Converging results from repeated fMRI and daily self-reports. PloS one. https://doi.org/10.1371/journal.pone.0071863\n\nSturm, J., Plöderl, M., Fartacek, C., Kralovec, K., Neunhäuserer, D., Niederseer, D., Hitzl, W., Niebauer, J., Schiepek, G., Fartacek, R. (2012). Physical exercise through mountain hiking in high-risk suicide patients. A randomized crossover trial. Acta Psychiatrica Scandinavica, 126, 467-475. https://doi.org/10.1111/j.1600-0447.2012.01860.x Download\n\nKralovec, K., Fartacek, R., Plöderl, M., Fartacek, C., Aichhorn, W. (2011). Low serum lithium associated with immoderate use of Coca-Cola Zero. Journal of Clinical Psychopharmacology, 31, 543-544. https://doi.org/10.1097/JCP.0b013e318222bb44\n\nPlöderl, M., Kralovec, K., Yazdi, K., & Fartacek, R. (2011). A closer look on self-reported suicide attempts. False positives and false negatives. Suicide and Life-Threatening Behavior, 41, 1-5. https://doi.org/10.1111/j.1943-278X.2010.00005.x Download\n\nSchiepek, G., Fartacek, C., Sturm, J., Kralovec, K., Fartacek, R., & Plöderl, M. (2011). Nonlinear dynamics. Theoretical perspectives and application to suicidology. Suicide and Life-Threatening Behavior, 41, 661-675. https://doi.org/10.1111/j.1943-278X.2011.00062.x Download\n\nDinhobl, R., Aistleitner, U., Plöderl, M., & Fartacek, C.(2010). Dialektische Verhaltenstherapieelemente in der existenzanalytisch geprägten stationären Krisenintervention mit suizidalen Borderline-Patienten. Suizidprophylaxe, 143, 155-160 . Download\n\nFartacek, C., Plöderl, M., Kralovec, C., & Fartacek, R. (2010). Aggression und Impulsivität als Risikofaktoren für Suizidversuche bei Patienten mit Anpassungsstörung. Suizidprophylaxe, 37, 101-105. Download\n\nPlöderl, M., Fartacek, H., & Fartacek, R. (2010). Lebenswert. Ein schulisches Suizidpräventionsprogramm. Suizidprophylaxe, 143, 148-154. Download\n\nPlöderl, M., Faistauer, G., & Fartacek, R. (2010). The contribution of schools to the feeling of acceptance and the risk of suicide attempts among Austrian gay and bisexual males. Journal of Homosexuality, 57, 819-841. https://doi.org/10.1080/00918369.2010.493401 Download accepted manuscript\n\nPlöderl, M., Kralovec, K., & Fartacek, R. (2010). The relation between sexual orientation and suicide attempts in Austria. Archives of Sexual Behavior, 39 , 1403-1414. https://doi.org/10.1007/s10508-009-9597-0 Download accepted manuscript\n\nPlöderl, M., Kralovec, K., Fartacek, C., & Fartacek, R. (2010). Aggressivität, Impulsivität und die Entscheidung zu einer Suizidmethode. Suizidprophylaxe, 140, 3-7. Download\n\nKralovec, K., Plöderl, M., Aistleitner, U., Fartacek, C., & Fartacek, R. (2009). Sind Nahtoderlebnisse nach Suizidversuchen bedeutsam für die weitere Suizidrisikoeinschätzung? Neuropsychiatrie, 23, 184-186. Download\n\nKralovec, K., Plöderl, M., Yazdi, K., & Fartacek, R. (2009). Die Rolle von Religion und Religiosität in der Suizidologie. Psychiatrie und Psychotherapie, 5, 17-20. Open access. http://dx.doi.org/10.1007/s11326-009-0039-3\n\nPlöderl, M., Kralovec, K.,Fartacek, C., & Fartacek, R. (2009). Homosexualität als Risikofaktor für Depression und Suizidalität bei Männern. Blickpunkt der Mann, 7, 28-37. Download\n\nPlöderl, M., & Fartacek, R. (2009). Childhood gender nonconformity and childhood harassment as predictors of suicidality among gay, lesbian, bisexual, and heterosexual Austrians. Archives of Sexual Behavior, 38, 400-410. https://doi.org/10.1007/s10508-007-9244-6 Download\n\nPlöderl, M., Yazdi, K., Kralovec, K., & Fartacek, R. (2007). Geschlechtsrollennonkonformität in der Kindheit als Suizidrisikofaktor am Beispiel von homo- und bisexuellen Personen. Psychiatrie & Psychotherapie, 3, 81-85. http://dx.doi.org/10.1007/s11326-007-0060-3 \n\nRothuber, H., Kralovec, K., Yazdi, K., Plöderl, M., & Mitterauer, B. (2007). Loss of self-understanding: A behavior-oriented model of depression. Medical Science Monitor, 13 , 264-269. Download. \n\nPlöderl, M., Sauer, J., & Fartacek, R. (2006). Suizidalität und psychische Gesundheit von homo- und bisexuellen Männern und Frauen. Eine Metaanalyse internationaler Zufallsstichproben. Verhaltenstherapie und Psychosoziale Praxis, 38, 537-558. Download\nPlöderl, M., & Fartacek, R. (2005). Suicidality and associated risk factors among lesbian, gay, and bisexual compared to heterosexual Austrian adults. Suicide and Life-Threatening Behavior, 35(6), 661-670. https://doi.org/10.1521/suli.2005.35.6.661\nPlöderl (2004). Homosexualität und Krisenintervention. Wissenswertes für den klinischen Alltag. Suizidprophylaxe, 117 , 4-10. Download\n\n\n\n\nBooks and Book Chapters\nFartacek, C., Plöderl, M., Schiepek, G. (2020). Alternatives to Suicide: A Nonlinear Dynamic Perspective. In: Page, A. & Stritzke, W. (Eds.). Alternatives to suicide. Beyond risk and toward a life worth living  (p 111-134). London: Academic Press. https://doi.org/10.1016/B978-0-12-814297-4.00006-6\nPlöderl, M. (2019) Suizidrisiko bei LSBTI*. In: S. Timmermanns & M. Böhm (Hrsg.). Sexuelle und geschlechtliche Vielfalt. Interdisziplinäre Perspektiven aus Wissenschaft und Praxis (S. 291-306). Beltz Juventa. \nPlöderl, M., & Winkler, R. (2019). Sexuelle Orientierung im Gesundheitswesen. Umgang mit einer unsichtbaren Diversity-Dimension. In: Steger, F. (Hrsg.). Diversity in Healthcare (S. 299-317). Freiburg: Alber Verlag. \nPlöderl, M., Mahler, L., Nieder, T., & Mundle, G. (2018). LGBTI and Mental Health. In: D. Bhugra, K. S. Bhui, S. Wong, & S. Gilman (Eds.). Oxford Textbook of Public Mental Health (p. 225-234). Oxford: Oxford University Press. Google Books\nWolfersdorf, M., & Plöderl, M. (2015). Geschlechterunterschiede bei Suizid und Suizidalität. In: P. Kolip & K. Hurrelmann (Hrsg.). Handbuch Geschlecht und Gesundheit. Männer und Frauen im Vergleich (S. 265 - 274). Bern: Hogrefe. \nFartacek, C., Plöderl, M., & Schiepek, G. (2014). Idiographisches Systemmonitoring in der Suizidprävention. In I. Sammet, G. Damann & G. Schiepek (Hrsg.). Der psychotherapeutische Prozess. Forschung für die Praxis (S. 82-91). Stuttgart: Kohlhammer.\nPlöderl, M. (2012). Männliche Homosexualität. In Harth, W., Brähler, E., & Schuppe, H. P. (Hrsg.). Praxishandbuch Männergesundheit. Interdisziplinärer Beratungs- und Behandlungsleitfaden (S.277-282). Berlin: MWV Medizinische Wissenschaftliche Verlagsgesellschaft.\nPlöderl, M. (2009). Homosexuelle, bisexuelle und transidente Jugendliche. Grundwissen für das Psychosoziale Handlungsfeld. In: Akzente Salzburg. Impulse. Handbuch für die Jugendarbeit, Band 1. Grundlagen, 3. Aufl., S. 88-97. Salzburg: Verlag Akzente Salzburg.\nPlöderl, M. & Faistauer, G. (2009). Homosexualität. Erfahrung aus Unterrichtsprojekten. In: Pithan, A., Arzt, S., Jakobs, M., & Knauth, T.: Gender - Religion - Bildung: Beiträge zu einer Religionspädagogik der Vielfalt (S. 409-413). Gütersloher Verlagshaus.\nFartacek, R., Fartacek, H., & Plöderl, M. (2008). lebenswert. Suizidprävention in Schulen. Information für Schulleitungen, ProjektorganisatorInnen, BeratungslehrerInnen. Salzburg: Pädagogische Hochschule. \nPlöderl, M., & Fartacek, R. (2007). „Anti-Stress-Training“ im Großarltal. Evaluation eines Projektes zur Gesundheitsförderung und Primärprävention. Deutsches Schulamt Bozen. \nFaistauer, G., & Plöderl, M. (2006). Out in der Schule - Schwule Männer über ihre Schulzeit. HOSI Salzburg. www.hosi.or.at. Download.\nPlöderl, M. (2005). Sexuelle Orientierung, psychische Gesundheit und Suizidalität. Weinheim: Beltz-Verlag. Download"
  },
  {
    "objectID": "CV/index.html",
    "href": "CV/index.html",
    "title": "Curriculum Vitae",
    "section": "",
    "text": "I am currently affiliated with the following institutions:\n\nParacelsus Private Medical University, Salzburg, Austria Link\nCenter for Inpatient Psychotherapy and Crisis Intervention, University Clinic of Psychiatry and Psychotherapy, Christian - Doppler - Klinik, Salzburg, Austria Link\nDepartment of Clinical Psychology, Christian - Doppler - Klinik, Salzburg, Austria Link"
  },
  {
    "objectID": "CV/index.html#education",
    "href": "CV/index.html#education",
    "title": "CV",
    "section": "Education",
    "text": "Education\n\n2014: Habilitation (Venia Docendi) at the Paracelsus Private Medical University\n2006-2012: Psychotherapy (Gesellschaft für Logotherapie und Existenzanalyse, GLE); Licenced Psychotherapist since December 2012 \n2003-2005: Curriculum Clinical Psychology and Health Psychology (BÖP); Licenced Clinical Psychologist and Health Psychologist since May 2005\n2001-2004: Doctoral Study, Department of Psychology, University of Salzburg\n1997-2001: Master Study, Department of Psychology, University of Salzburg\n1986-1991; Technical College for Mechanical Engineering (HTL, Wels)"
  },
  {
    "objectID": "CV/index.html#work",
    "href": "CV/index.html#work",
    "title": "CV",
    "section": "Work",
    "text": "Work\n\nsince 2015: Member of the Expert-Group for the development of Austrians Suicide Prevention Program (SUPRA)\nsince 2007: Gatekeeper-Trainings in Suicide Prevention (since 2016 certified SUPRA Trainer)\nsince 2005: Department for Crisis Intervention and Suicide Prevention (2005-2022), now transformed to Center for Inpatient Psychotherapy and Crisis Intervention, Christian Doppler Klinik, Paracelsus Medical University Salzburg\n2004-2005: Assistant, Dept. of Psychology (Social Psychology), University of Salzburg\n2000-2002: Research Assistant, SFB-012 (Logic & Cognitive Sciences), Univ. Salzburg\n1998-2003: Nightshifts at the Caritas Homeless-Shelter in Salzburg\n1991-1996: Technical Engineer (Sondermaschinenbau), Fa. Innotech (Linz) and Fa. SG-Automatisierungstechnik (Enns)"
  },
  {
    "objectID": "CV/index.html#teaching",
    "href": "CV/index.html#teaching",
    "title": "CV",
    "section": "Teaching",
    "text": "Teaching\n\n2003-2019 (and again starting 2026): University of Salzburg, Department of Psychology, Salzburg, Austria Lectures and seminars in social psychological research methods and suicide prevention\nSince 2007: Paracelsus Private Medical University, Salzburg, Austria Lectures in psychological medicine (suicide prevention, placebo effects) and seminars about clinical research (questionnaires as tools)\n2008 - 12017: University Curriculum Social Psychiatry / Crisis Managament, ProMente Upper Austria Weekend seminars in suicide prevention\nsince 2009: Fachhochschule Salzburg, University of Applied Sciences, Social Work, Austria: Lectures in suicide prevention, diversity management, psychopathology"
  },
  {
    "objectID": "CV/index.html#peer-reviews",
    "href": "CV/index.html#peer-reviews",
    "title": "CV",
    "section": "Peer Reviews",
    "text": "Peer Reviews\n\nGuest Reviewer\nAmerican Journal of Preventive Medicine, American Journal of Public Health, BMC Psychiatry, BMJ Open, BMC Psychiatry, BMC Public Health, British Journal of Psychiatry, Clinical Psychological Science, Crisis, Depression Research and Treatment, Epidemiology and Psychiatric Sciences, Expert Opinion Pharmacotherapy, Frontiers Psychiatry, Frontiers Psychology, Frontiers Psychiatry, International Review of Psychiatry, JAMA, Journal of Affective Disorders, Journal of Epidemiology and Community Health, Journal of Homosexuality, Journal of Lesbian Studies, Lancet Psychiatry, Molecular Psychiatry, Nordic Journal of Psychiatry, Pediatrics, PloS ONE, Psychiatric Research, Psychological Medicine, Psychotherapy and Psychosomatics, Sexual Medicine, Suicide and Life-Threatening Behavior, Social Psychiatry and Psychiatric Epidemiology, Stress and Health, Therapeutic Advances in Psychopharmacology.\n\n\n\nMember of Review Board\nArchives of Sexual Behavior (2011-2019), Existenzanalyse (2017-2020), Journal of the Gay and Lesbian Mental Health (since 2017-2019), Suizidprophylaxe (since 2010)"
  },
  {
    "objectID": "cycling/index.html",
    "href": "cycling/index.html",
    "title": "Cycle Travel",
    "section": "",
    "text": "Hier möchte ich Erfahrungen zum Aufbau von Reiserädern weitergeben. Angefangen hat alles mit der ersten Reise, als ich 17 war. Wir wollten ans Meer. Mit dem Rad. Also haben wir die Karte von Mitteleuropa an die Wand befestigt und einen Dartpfeil geworfen. Das war in der Nähe von Marseilles. In den Sommerferien darauf sind wir in drei Wochen von Oberösterreich aus dorthin geradelt. Mit einem normalen Rennrad, leicht aufgerüstet. Blutige Anfänger waren wir, aber die Leidenschaft begann und lässt mich bis heute nicht los. Es folgten Radreisen quer durch die USA, Indien, Rumänien, Italien, Irland, Frankreich/Spanien, Norwegen. Anfangs sind wir immer mit umgebauten MTB gefahren (bis auf die Premiere nach Frankreich mit dem Rennrad). Stabiler als ein MTB geht es vermutlich nicht. Da gibt es kein Schwingen des Rahmens, auch nicht bei Volllast vorne und hinten. Allerdings ist die Sitzposition für sehr lange Touren m.E. nicht ideal, zumindest bei den heute gängigen Modellen. Wenn man jung und kräftig ist geht natürlich alles. Wer aber so wie ich ein Rennrad gewohnt ist, der weiß die ideale Sitzposition für lange Fahrten zu schätzen. Und da wird es schon schwieriger, ein gute Rad von der Stange zu finden."
  },
  {
    "objectID": "cycling/index.html#reiserad",
    "href": "cycling/index.html#reiserad",
    "title": "Cycle Travel",
    "section": "",
    "text": "Hier möchte ich Erfahrungen zum Aufbau von Reiserädern weitergeben. Angefangen hat alles mit der ersten Reise, als ich 17 war. Wir wollten ans Meer. Mit dem Rad. Also haben wir die Karte von Mitteleuropa an die Wand befestigt und einen Dartpfeil geworfen. Das war in der Nähe von Marseilles. In den Sommerferien darauf sind wir in drei Wochen von Oberösterreich aus dorthin geradelt. Mit einem normalen Rennrad, leicht aufgerüstet. Blutige Anfänger waren wir, aber die Leidenschaft begann und lässt mich bis heute nicht los. Es folgten Radreisen quer durch die USA, Indien, Rumänien, Italien, Irland, Frankreich/Spanien, Norwegen. Anfangs sind wir immer mit umgebauten MTB gefahren (bis auf die Premiere nach Frankreich mit dem Rennrad). Stabiler als ein MTB geht es vermutlich nicht. Da gibt es kein Schwingen des Rahmens, auch nicht bei Volllast vorne und hinten. Allerdings ist die Sitzposition für sehr lange Touren m.E. nicht ideal, zumindest bei den heute gängigen Modellen. Wenn man jung und kräftig ist geht natürlich alles. Wer aber so wie ich ein Rennrad gewohnt ist, der weiß die ideale Sitzposition für lange Fahrten zu schätzen. Und da wird es schon schwieriger, ein gute Rad von der Stange zu finden."
  },
  {
    "objectID": "cycling/index.html#aufbau-surly-reiserad",
    "href": "cycling/index.html#aufbau-surly-reiserad",
    "title": "Cycle Travel",
    "section": "Aufbau Surly Reiserad ",
    "text": "Aufbau Surly Reiserad \nVorüberlegungen (Frühling 2016): \n\nZur Zeit fahre ich das TX Randonneur von der Fahrradmanufaktor. Damit bin ich grundsätzlich recht zufrieden und zur täglichen Fahrt in die Arbeit ist es mein bisher bestes Rad (stabil, schnell, Nabendynamo), quasi ein robustes Rennrad zu einem wirklich akzeptablen Preis (Shimano 105, 1500 Euro). Jedoch wird der Rahmen instabil wenn ich vorne am Lowrider Gepäck auflade und das Fahrgefühl leidet doch sehr darunter. Auf der Bank gibt es ja auch keine Zinsen, also investierte ich in etwas, das mir sinnvoll, nachhaltig, und lustvoll erschien: ein neues Reiserad. Die Recherchen im Netz sind langwierig und ich finde einfach nicht das richtige Rad für mich. Nach ein bisschen Recherche landet man immer wieder beim Long Haul Trucker von Surly (LHT) - natürlich aufgrund der US-Lastigkeit des www. Schließlich fällt die Entscheidung zum Selbstbau. Nicht zuletzt, weil mein Vater, ein gelernter Radmechaniker, mir helfen kann. Hier ist meine Einkaufsliste. Mit gut 1700 Euro komplett erscheint mir das Rad mit den feinen Teilen eher preiswert. \nSchwierig gestaltete sich die Suche nach der passenden Rahmengröße, da ich keine(n) kenne, der/die einen LHT hat. Die Liste hier hat mir sehr geholfen https://docs.google.com/spreadsheets/d/1u1_H6gbuJ0T5Hhk2fjZxO5lWEHhPhOP_PqA05edgBGQ/edit#gid=23\nMit einer “Pubic Bone Height” von 83cm und einer Größe von 179cm hatten die meisten einen 56- oder 58-Rahmen. Nachdem ich mein derzeitiges Rad vermessen und es bestätigte sich das, was man in den Foren liest: der LHT hat ein relativ langes Oberrohr. Deshalb wählte ich dann den 56-Rahmen und war bei der ersten Ausfahrt froh drüber (Surly gibt übrigens detaillierte Angaben zur Rahmengröße und zu den verwendeten Teilen). \n\nDer Blog von Katja und Frank ist sehr hilfreich beim Suchen der passenden Teile http://www.frankbauer.net/blog/2012/08/28/aufbau-eines-reiserads-surly-long-haul-trucker/\nBei Pete Owen fand ich genau die Art von Lenkeraufbau, welche mir am geeignetsten scheint. Die Cross-Lever Bremsen waren des Rätsels Lösung, wie Lenkerendschalthebel UND die Bremshebel am Bullhorn-Lenkerende montierbar sind. http://www.ratracecycles.com/tag/bullhorn-bars/\n\nHabe nämlich festgestellt, dass ich den Untergriff beim Rennradlenker praktisch nie verwende. Beim Wiegetritt ist das Bullhorn der Griffhaltung eines Rennlenkers weitaus überlegen. Wenn ich später noch eine Aero-Position möchte, dann schon gleich einen Triathlonlenker-Aufbau wie bei meinem Rennrad. Die Schalthebel am Rennlenkerende würden außerdem bedeuten, bei jedem Schalten umgreifen zu müssen. Das ist mit der Bullhorn-Lösung nicht nötig. ’Gute Erfahrungen mit einem Bullhorn habe ich seit vielen Jahren am Rennrand, für das Reiserad fand ich sie hier http://www.adamk.ca/tourbike.html\nBremsen: bei der Recherche kam schnell raus, dass es sich um einen Religionsstreit handelt, aus dem man nicht schlau wird. Auf meinem MTB hab ich Hydraulik-Scheibenbremsen und bin begeistert davon. Aber ich habe schon Leute erlebt, die das Quietschen nicht losbekommen haben. Auf einer Radreise wäre das nervtötend. Außerdem fahre ich selbst schon seit der Kindheit mit Cantilever Bremsen, auch auf all meinen bisherigen Radreisen. Dass diese nicht genug Bremskraft hätten, kann ich aus meiner mittlerweile 20-Jährigen Reiseerfahrung nicht bestätigen. Im Gegenteil: die V-Brakes, die mehr Bremskraft haben sollten, stelle ich beim TX-Randonneur nicht fest und die Bremsbeläge sind sofort abgenutzt. Also doch die Tektro-Canti-Bremsen, die auch beim Surly LHT von der Stange montiert sind und die noch dazu günstig sind. Wenn doch die Bremskraft nicht optimal sein sollte, dann sollten Kool-Stop Beläge helfen, so das Internetz (Typ KS-DURADL für die Tektro-Bremsend passend). \n\nKettenlänge = 114 Glieder. Kettenstrebenlänge = 460mm, vorne großes Kettenblatt mit 44 Zähnen, hinten größtes Ritzel mit 32 Zähnen, Umlenkrädchen mit 11 Zähnen, http://www.bikegalerie.de/de/berechnungstools/kettenlaengenberechnung\n\nHabe auch beschlossen, einen Nabendynamo einzubauen, wegen der Beleuchtung, aber vor allem als Stromquelle für das Smartphone, damit ich es als NAVI benutzen kann (Osmand oder Mapfactor Offline Navigationsmöglichkeiten - funktionieren super). Ich hoffe damit die Verirrungen in fremden Ländern minimieren zu können. Vor allem das Rausfinden aus Städten war immer ein Problem. Habe dazu auch den Cycle2Charge Lader bestellt, der scheinbar gut funktioniert (werde berichten). \nWar irritiert über die Schwerggängigkeit des Nabendynamos, wenn ich ihn nach dem Auspacken händisch ausprobierte. Ist aber scheinbar normal (“Polfühligkeit”). Manche im Netz berichten aber auch, dass der Konus bei Shimano oft zu streng eingestellt ist, und dass man aufgrund der Polfühligkeit das auch schwer feststellen kann (war auch so, s.u.). \n\nZusammenbau\n\nBeim Einspeichen der Räder war die deutsche Seite von Sheldon Brown enorm hilfreich (auch die anderen Seiten von ihm zeugen von hoher fachlicher Kompetenz). Eine gute Seele hat sie auf Deutsch übersetzt http://www.sheldonbrown.com/german/wheelbuilding.html. Die Speichenlänge habe ich mit diesem Tool bestimmt:https://spokes-calculator.dtswiss.com/de/\n\nDie Länge passte perfekt, sodass die Nippel genau mit dem Gewindeende abschlossen. Das genaue Spannen und Zentrieren überließ ich meinem Vater, denn dazu braucht es Expertise. \nDas Einpressen der Gabellager gelang nach Abfeilen des Lackes an der Gabel und etwas zusätzlichem Feilen (eine entsprechende Fräse hatten wir leider nicht). Auch das Gabelrohr haben wir einfach mit einer Säge abgeschnitten und dann halbwegs winkelig gefeilt. Macht aber nichts, weil ohnehin ein Distanzring über das Rohrende rausragte - dies war wiederum nötig um das Cycle2Charge Teil ordentlich zu montieren. \n\nEin Problem gab es bei der Montage der Bremsen, bei der eine der vier Bremsen nach dem Festziehen der Schraube blockierte. Zunächst dachte ich, ich hätte die Messinghülse irgendwie gequetscht weil sie zu lange war und feilte sie kürzer. Dann aber wieder das gleiche Problem. Nach längerem Suchen stellte ich fest, dass das Gewinde der Schraube nicht bis zum Schraubenkopf reicht (siehe Bild) und dadurch der Montagebolzen am Rahmen aufgedehnt wurde. So was darf eigentlich nicht sein! Mit einer zusätzlichen Beilagscheibe und dem Abfeilen des Bolzens am Rahmen funktionierte es dann - leider ist nun der Lack ab und ich bin gespannt, was der Rost im Laufe der Zeit anstellt.\n\n\n\nMein Vater hat die Räder super zentriert und gespannt - er macht das nach Gefühl, ohne Stimmgabel oder Mess-Schnickschnack. Die Sputnik Felge hüpfte etwas am Bund, was auch durch Zentrieren nicht gut zu machen war, die Alex Felgen hingegen liefen super rund. \n\nBeim XT-Nabendynamo waren die Lager zu streng eingestellt (wie manche im Netz berichteten) und Papa lockerte sie etwas. \n\nDer Umwerfer vorne war ein Top-Swing Modell, d.h. normalerweise zieht man von oben. Nach einer gewissen Ratlosigkeit und als ich schon fast einen neuen Umwerfer bestellen wollte, entdeckte ich die Dual-Pull-Mechanik des Werfers. Man braucht nur das Seil durch den Umwerfer nach unten leiten, und schon kann man von unten ziehen. \nDie Kombination von Lenkerend-Schalthebel und Cross-Lever Bremsen funktioniert gut, es war ein bisschen Rumspielen nötig, bis ich passende Winkel fand und die Schaltzüge frei verliefen. Auch das Ladegerät war unkompliziert zu montieren und die Kabelverlegung war einfach. Das LG-Handy schaltete gleich beim ersten Testen auf “langsames Aufladen”. Werde unten berichten, wie das Ding im Echtbetrieb funktioniert. \n\nUnd so schaut der LHT nun aus (ohne Lowrider und Licht)\n\n\nEs werde Licht\nDer aufwändigste Teil des Montage war wohl das Licht. Im www gibt es ja auch da zwei Philosophien, nämlich die Kabel “Unterputz” (im Rahmen) oder außen verlegen. Für den LHT habe ich keine gute Quelle im Web gefunden, aber einige Löcher sind vorhanden, so etwa je ein kleines Loch am Ende des Kettenrohres bei der Nabe. Leider war auf dem anderen Ende, nämlich am Beginn des Oberrohrs (Nähe Gabel) kein Loch, und ich wollte auch keines bohren. Auch hier wieder sehr widersprüchliche Infos (Loch = Rahmeninstabilität, Loch = kein Problem). Ich entschloss mich, als Eintrittsloch die Gewindebohrung des unten liegenden Flaschenträgers zu wählen, weil ich mir hier sicher keine Flasche montieren werde (da ist ja immer der Dreck drauf). Das Durchziehen des Drahtes war sehr zeitaufwändig und schwierig und funktionierte nur, nachdem ich das Tretlager nochmal ausbaute. Ich verwendete einen Wollfaden und mittels Staubsauger versuchte ich diesen jeweils bei der Tretlageröffnung heraustzusaugen. Dann zog ich das Kabel mit dem Wollfaden nach. Auch der Einbau der Kunsstofflagerschale war schwierig, weil kaum Platz für das Kabel blieb, gelang aber dann doch."
  },
  {
    "objectID": "cycling/index.html#erste-erfahrungen",
    "href": "cycling/index.html#erste-erfahrungen",
    "title": "Cycle Travel",
    "section": "Erste Erfahrungen",
    "text": "Erste Erfahrungen\nDie erste 100-km Ausfahrt: der Rahmen ist sehr steif, wie sich beim Wiegetritt auf einer steile Schotterstraße herausstellt. Und der LHT läuft super. Einzig die Kettennietung führte z.T. zu Schaltunreinheiten, aber das lässt sich leicht ausbügeln. Ja und der Sattel ist natürlich noch nicht eingefahren. \n\nErste “echte” Ausfahrt mit Gepäck (ohne Low-Rider)\nDas Rad rollt wirklich gut und es fühlt sich steif an, im positiven Sinne. Es hat sich allerdings ein Rupfen beim Bremsen des Vorderrades eingestellt, das zum Teil fast beängstigend ist, und die Gabel biegt sich regelrecht. Scheinbar greifen die Cool-Stop Bremsbeläge zu stark. Habe sie nachgestellt und wieder so, dass sie vorne zuerst bremsen (indem man hinten einen Karton einschiebt und danach die Bremsbacken festzieht, also “toe-in”). Auch das Gabellager war etwas zu locker eingestellt. Jetzt ist das Stottern fast weg. \nDieses Problem ist bei Stahlrahmen bekannt und in der Cyclo-Cross Szene viel Diskutiert (hier). \nBei meinem alten Tourenrad, ein umgebautes MTB, auch mit alten Canti-Bremsen, gab es das Problem überhaupt nicht!\n\nAuf dem LHT sitzt es sich gut, eher sportlich (durch das lange Oberrohr). Beim kurzen Rädertausch mit einem Trekking-Rad wurde das extrem offenbar, und ich konnte mir nicht vorstellen, wie ich früher lange Touren (&gt;120km) auf einem MTB schaffte. Der direkte Vergleich mit meinem alten umgebauten MTB, das ich für 15 Jahre zum Tourenfahren nutzte, war schon bemerkenswert: der LHT schluckt Vibrationen und Stöße wesentlich besser, obwohl ich am MTB recht fette Reifen und weniger Luftdruck hattte. Und die Kraftübertragung ist am LHT (beim Randonneur überhaupt) um Längen besser als am MTB.\nDer neue Brooks-Sattel muss natürlich noch eingeritten werden. Anm: dauerte so in etwa 500km\n\nDer Cycle2Charge-Lader funktioniert gut, es wird ab 12-15km/h geladen, und mein altes LG Optimus verbraucht bei hellster Bildschirmeinstellung und Navigation weniger Strom als aufgeladen wird (bei eher flachen Routen) bzw. hält sich der Akkustand bei hügeligem Gelände siehe hier. \n\nDie erste Härtetest (Salzburg - Spanien, 2500km)\n\nBin nun vollbeladen die erste längere Tour gefahren. Dabei waren einige sehr grobe Schotterstraßen, extrem steile Auf- und Abfahrten (Bremse!) dabei, das ganze voll beladen. Und übrigens auch nach einem Unfall, bei der mich ein Auto von der Seite her gerammt hat. Das Surly und ich haben das überlebt, wenn auch mit Schrammen. \n\nBin wirklich zufrieden mit dem LHT, er fährt sich mit Gepäck wirklich gut. Ganz steif ist er mit zwei Taschen am Low-Rider nicht, aber wesentlich steifer als der TX-Randonneur von der Radmanufaktur. Die Übersetzung machte sich bei den steilen Hügeln echt bezahlt. Bei den extrem steilen Abfahrten waren die Bremsen ok, es kostet allerdings schon etwas Kraft. Das Rupfen der Vordergabel war gar nicht mehr bemerkbar. \n\nGut, dass ich die undichten Schwalbe-Schläuche mit recht billigen Conti-Schläuchen ersetzt hatte, so brauchte ich die drei Wochen nicht mal Luft nachfüllen (nie wieder Schwalbe Schläuche!). Dank des B-17-Sattels hatte ich kaum Probleme mit dem Sitzen.\nDer klappbare Radständer war wichtig, vor allem beim Zelten auf der Wiese, damit ich das Rad nicht umlegen musste (XLC Seitenständer ‘Travel Stand’ KS-S02). Auch mit dem Zelt (MSR Hubba) machte ich gute Erfahrungen. \n\n\nIrgendwo in Frankreich (erstes Bild) und Pamplona (Chasing the Bull-Horn)\nZur Navigation: Der Cycle2Charge Lader hat verlässlich durchgehalten. Das Handy hatte ich bei Schönwetter mit der Finn-Universal Silikonhalterung fixiert, bei Schlechtwetter in der Ortliebe GPS Hülle verstaut. Dabei habe ich das Ladekabel einfach mit eingerollt, und das war durchaus wasserdicht, das Spiegeln der Folie ist ein Problem, aber kein allzu großes. OSM war verlässlich, die Routenplanung mit Cycle Travil zu 98% einwandfrei, manchmal wurde ich aber auf irre Schotterstraßen geführt. \nNachtrag April 2017: Auf der Route Sizilien - Bologna, 1600km, sehr kaputte Straßen und auch Regenwetter war der Cycle2Charge recht verlässlich in Kombination mit dem Moto G3 Handy.\n\nEinschneidende Erlebnisse\nDer B17 war die ersten paar Tausend Kilometer ein Traum, sicher einer der besten Sättel bisher. Nach und nach wurde er aber weniger bequem und Nachspannen half auch nicht. Die Stellen, bei denen die Sitzknochen aufliegen, gaben nach und wanderten nach unten, und der Längsbug drückte unangenehm. Nach ca. 7000km und ein bisschen Recherchieren entschloss ich mich zur Operation und schnitt den Sattel aus. Seitdem fährt er sich wieder bequemer. Ein Langzeittest steht noch aus. \n\n\nNachtrag: es war eine gute Idee, der Sattel fuhr sich deutlich bequemer, und die Spannung hielt sich gut. Allerdings ist mir das Gestell gebrochen (nach ca. 9000km)."
  },
  {
    "objectID": "cycling/index.html#gestohlen",
    "href": "cycling/index.html#gestohlen",
    "title": "Cycle Travel",
    "section": "GESTOHLEN!",
    "text": "GESTOHLEN!\nLeider wurde mein LHT im September 2018 in Antwerpen gestohlen. Was für ein Schock!!! Nach 10.000 wundervollen Kilometern also so ein Ende :-("
  },
  {
    "objectID": "cycling/index.html#also-muss-ein-neuer-lht-her",
    "href": "cycling/index.html#also-muss-ein-neuer-lht-her",
    "title": "Cycle Travel",
    "section": "Also muss ein neuer LHT her…",
    "text": "Also muss ein neuer LHT her…\nNachdem ich mich vom Schock des gestohlenen Rades erholt hatte, kamen die Überlegungen für einen neuen LHT, vor allem, nachdem ich wieder feststellen musste, dass die Reiseräder von der Stange vergleichbar teuer sind und keines nicht so recht meinen Vorstellungen entsprach. Außerdem hatte ich ein paar Teile bereits rumliegen. Hier die Einkaufsliste(ca. 1500 Euro alles zusammen). Und so sieht “Black Beauty” aus"
  },
  {
    "objectID": "CV/index.html#awards",
    "href": "CV/index.html#awards",
    "title": "CV",
    "section": "Awards",
    "text": "Awards\n\nFirst prize at the yearly agpro science award 2005\nPoster Price at the Congress of the DGPPN 2008\nPoster Prices at the Congress of the ÖGPPN 2009 and 2011\nScientific awards of the Paracelsus Medical University Salzburg\nin bronze (2010, 2011, 2012, 2013), silver (2014, 2017), gold (2015, 2018), and platin (2019)"
  },
  {
    "objectID": "CV/index.html#guest-reviewer",
    "href": "CV/index.html#guest-reviewer",
    "title": "Curriculum Vitae",
    "section": "Guest Reviewer",
    "text": "Guest Reviewer\nAmerican Journal of Preventive Medicine, American Journal of Public Health, BMC Psychiatry, BMJ Open, BMC Psychiatry, BMC Public Health, British Journal of Psychiatry, Clinical Psychological Science, Crisis, Depression Research and Treatment, Epidemiology and Psychiatric Sciences, Expert Opinion Pharmacotherapy, Frontiers Psychiatry, Frontiers Psychology, Frontiers Psychiatry, International Review of Psychiatry, JAMA, Journal of Affective Disorders, Journal of Epidemiology and Community Health, Journal of Homosexuality, Journal of Lesbian Studies, Lancet Psychiatry, Molecular Psychiatry, Nordic Journal of Psychiatry, Pediatrics, PloS ONE, Psychiatric Research, Psychological Medicine, Psychotherapy and Psychosomatics, Sexual Medicine, Suicide and Life-Threatening Behavior, Social Psychiatry and Psychiatric Epidemiology, Stress and Health, Therapeutic Advances in Psychopharmacology."
  },
  {
    "objectID": "CV/index.html#member-of-review-board",
    "href": "CV/index.html#member-of-review-board",
    "title": "Curriculum Vitae",
    "section": "Member of Review Board",
    "text": "Member of Review Board\nArchives of Sexual Behavior (2011-2019), Existenzanalyse (2017-2020), Journal of the Gay and Lesbian Mental Health (since 2017-2019), Suizidprophylaxe (since 2010)"
  },
  {
    "objectID": "blogs/index.html",
    "href": "blogs/index.html",
    "title": "Blogs",
    "section": "",
    "text": "A call for evidence based, fear-free practice (October 2025), also on Mad In America\nResponse to “The war on antidepressants” (December 2024)\nWie Effektiv ist Esketamin (December 2024)\nThe chemical imbalance theory of depression: dead, zombie, or alive (November 2024)\nDesperate Measures: Ghaemi’s Response to Our Review of Lithium and Suicide Prevention (July 2024), Blog on Mad in America together with Joanna Moncrieff\nResponse to “The time has come for over-the-counter antidepressants” by Roy Perlis (April 2024)\nAntidepressants and the Tangle of Treatment-Related Suicidality (November 2023) Q & A with Awais Aftab on his blog “Psychiatry at the Margins”\nReally depressed people need antidepressants! Do they? (July 2021), Guest Blog for The Council for Evidence-based Psychiatry. PDF with citations and figures here.\nSuicides Are Increasing – And So Are Antidepressant Prescriptions (August 2018), Blog on Mad in America together with Michael Hengartner"
  },
  {
    "objectID": "blogs/chemical_imbalance/index.html",
    "href": "blogs/chemical_imbalance/index.html",
    "title": "The chemical imbalance theory of depression: dead, zombie, or alive?",
    "section": "",
    "text": "November 23, 2024\nThere is an ongoing and partly very heated debate about the chemical imbalance theory (CI) of depression. Basically it is the theory that depression is the result of a deficit in serotonin or a dysfunction of the serotonergic system. The CI theory sometimes comes along with the assumption that antidepressants (SSRIs, SNRIs) work by correcting the CI. I refer to this as the “pure form” of the CI. Much has been written about the CI theory and I do not want to repeat it here but instead refer to the paper by Joanna Moncrieff and colleagues (Moncrieff et al. 2022) and the controversy around this paper, with lengthy letters to the editor and responses, including one where I was involved (Moncrieff et al. 2023). The main purpose of this blog is to show how alive the CI theory of depression really is. Some say that academic psychiatrists never promoted the CI theory and thus it is a straw man, mainly used by antipsychiatrists. Some say the CI theory of depression was only used by the pharmaceutical companies and this was long ago. However, when I did a quick Google-search using “depression” in January 2021 (search results as PDF), I was surprised that the CI was much alive, even in its pure form, and even in the top 10 search results. In spring 2024, a while after the famous umbrella review, I checked if the information was corrected, but there was not much change at all. I had all this posted on X but deleted all of my tweets because of the problematic leadership of X, and therefore I want to document the search results here. I think this is important as evidence against the denial that I regularly come across in discussions (“no serious academic psychiatrist promoted the CI theory”). I leave it up to you to judge if the CI theory of depression is dead, a zombie, or still alive.\n\n\nIn January 2020 the top hit in the Google search was authored, among others, by a top Austrian academic psychiatrist from the Medical University of Vienna. The text is not available anymore but I saved it here.\n“Was sind die Ursachen einer Depression? Bei einer Depression ist der Stoffwechsel des Gehirns verändert. Die Spiegel der Überträgersubstanzen (Neurotransmitter) Serotonin und Noradrenalin sind bei depressiven Menschen im Vergleich zu Gesunden niedriger.”\n“Wie wird eine Depression behandelt? Bei Patienten mit Depression ist meistens das Gleichgewicht an Signalstoffen im Gehirn gestört.”\n“Die Neurotransmitter stehen beim gesunden Menschen in einem bestimmten Gleichgewicht zueinander. Bei Depressionen ist diese Balance zwischen den Neurotransmittern gestört, was in Symptomen wie gedrückter Stimmungslage, Antriebslosigkeit und Schlafstörungen seinen Niederschlag findet. Insbesondere kommt es bei depressiven Menschen zu einer verminderten Aktivität jener Nervenzellen, die die Neurotransmitter Serotonin, Noradrenalin und Dopamin übertragen. Durch Medikamente zur Behandlung der Depression (Antidepressiva) wird die Konzentration dieser Neurotransmitter an den Synapsen erhöht. Dieser Vorgang benötigt allerdings etwas Zeit, weshalb das Gleichgewicht zwischen den Überträgersubstanzen erst einige Tage bis Wochen nach Therapiebeginn wiederhergestellt ist – und somit auch die depressiven Symptome abklingen. Um die Neurotransmitter wieder ins Gleichgewicht zu bringen, stehen verschiedene medikamentöse Wirkmechanismen zur Verfügung…”\nThis is a definately an example of the CI theory, because it is said that neurotransmitters such as serotonin are reduced among depressed people. Perhaps it even can be interpreted as the pure form of the CI theory, because it is said that it takes days to weeks until antidepressants restore the imbalance.\nThe text was updated when I checked today (November 23, 2024). It is said that the text is in accordance with the medical scientific literature, guidelines, and that it was approved by medical professionals.\nhttps://www.netdoktor.de/krankheiten/depression/\n\nProf. Hegerl is a leading academic psychiatrist in Germany.\nWe are now reading that depression is related to a CI of neurotransmitters, including serotonin.\n\nAntidepressant work by increasing the level of serotonin, the “happy hormone”\n\nThus, there is still the CI theory, but not in its pure form anymore.\n\n\n\nThe second hit was written with the support of leading academic psychiatrists and the editors are professional organizations of psychiatrists and neurologists in Germany and Switzerland. The text is saved here.\nhttps://www.neurologen-und-psychiater-im-netz.org/psychiatrie-psychosomatik-psychotherapie/stoerungen-erkrankungen/depressionen/\nWe can see the CI theory in its pure form, and the text is unchanged when I checked it today (November 24, 2024).\n\n\n\n\nThe third hit was from a major German organization to defeat depression. Responsible for the content is a leading psychiatry professor. Again there is the CI theory of depression.\n\nThe organization changed the text, explicitly saying that serotonine deficit is too simple as an explanation of depression.\nhttps://www.deutsche-depressionshilfe.de/ueber-uns/das-buendnis\n\nHowever, it is also said that depression can be caused by a CI and that antidepressants directly work by targeting at the CI of neurotransmitters.\n\n\n\n\nThe website of the Apotheken-Umschau included a video with a psychiatry professor. Here, a lot was said about lowered serotonin activity, a softened version of the CI theory (Min. 6). Unfortunately, I didn’t save the video. It was also said that antidepressants are safe and effective and do not cause dependency or addiction. I agree with addiction, but there are dependency issues (Massabki and Abi-Jaoude 2020).\nIn November 2024, the CI theory is still present, but somehow weakened\nhttps://www.apotheken-umschau.de/krankheiten-symptome/psychische-krankheiten/depressionen-ursachen-anzeichen-therapie-735639.html\n\n\n\n\nHit #6 again included the CI theory of depression. Stiftung Gesundheitswissen claims to be independent and evidence based.\n\nWhen I accessed the page tod y (November 23, 2024), I saw that the information was updated. The CI theory can now be found in its pure form, but it is said that the exact mechanism is not known.\nhttps://www.stiftung-gesundheitswissen.de/wissen/depression/behandlung-mit-medikamenten\n\n\n\n\nSomeone said that my Google search results might have been influenced by my search history. Thus I tried with DuckDuckGo and also using the Tor-Browser, with very similar result.\nWith DuckDuckGo, the #1 search result was different than in the Google search, leading to a new source with the CI in its pure form, saying that antidepressants restore the imbalance in neurotransmitters. The source is lifeline and it was said that it meets the highest scientific standard.\n\nNow, in November 2024, the information is still the same. https://www.lifeline.de/krankheiten/depression/\nAs a side note, the text says that antidepressants are not causing dependency. Whereas it is true that antidepressants do not cause addiction, it is now more widely acknowledged that dependency is an issue, even in an article in the British Journal of Psychiatry (Massabki and Abi-Jaoude 2020).\n\n\n\n\nBefore 2021 I also searched the web and tweeted about the reusults. I don’t know which exact search terms I used, but I selected results from academic psychiatry.\n\n\nRetrieved January 2020 from https://www.psych.mpg.de/840900/depression. The CI theory of depression can be read in its pure form:\n“Bei der Depression ist das biochemische Gleichgewicht der Signalübertragung gestört. Die Therapie zielt darauf ab, durch Medikamente diese Stoffwechselstörung in den Nervenzellen zu korrigieren.”\nThe website is not available anymore but I saved it here.\n\n\n\nThis was retrieved in January 2020 and I saved it here. The CI theory is proposed:\n“Depressionen haben selten nur einen Auslöser. In aller Regel entwickelt sich die Erkrankung aufgrund von mehreren Faktoren. Das kann zum einen die genetische Veranlagung sein. Zum anderen spielen aber auch körperliche Ursachen eine Rolle – genauso wie Situationen, die über die eigenen Kräfte gehen oder ein Perfektionismus, durch den man sich selbst permanent überfordert. Mögliche Auslöser sind z. B.: ein gestörter Hirnstoffwechsel, in dem die Hirnbotenstoffe Serotonin und/oder Noradrenalin aus der gesunden Balance geraten sind” http://www.klinikum.uni-muenchen.de/Klinik-und-Poliklinik-fuer-Psychiatrie-und-Psychotherapie/de/patient_besuch/krankheitsbilder/depression/index.html\n\n\n\nAlso from January 2020, the information in the text (saved here) points unambiguously to the CI theory:\n„Wie bei jeder Depression weisen Betroffene einen Mangel des Gehirnbotenstoffs Serotonin auf“\nhttp://www.psychiatrie.med.uni-goettingen.de/de/content/patienten/237.html\nNow, in November 2024, the information is still there, even in it’s pure form.\n\nhttps://psychiatrie.umg.eu/patienten-besucher/therapieangebote/lichttherapie/\n\n\n\nFound in January 2020, the CI theory is obvious in this text, saved here:\n“Depression ist nicht gleich Depression: Manche entstehen durch einen Mangel am Botenstoff Serotonin im Gehirn, andere durch einen Mangel an Noradrenalin; ebenfalls ein Botenstoff.”\nThe information is still available here:\nhttps://www.uniaktuell.unibe.ch/2015/die_zwei_arten_depressiv_zu_sein/index_ger.html\n\n\n\nAs already mentioned above, this is the information from psychiatric/neurological associations in Germany and Switzerland. Here is their statement from January 2020. The CI-theory is obvious, and the action of antidepressants suggests that the CI-theory in its pure form is implicated.\n“Viele Untersuchungen deuten darauf hin, dass Depressionen durch typische Veränderungen von Botenstoffen im Gehirn gekennzeichnet sind. Dabei scheinen bestimmte Botenstoffe (so genannte Neurotransmitter wie Serotonin, Dopamin, Noradrenalin, Acetylcholin, Gamma-Aminobuttersäure) aus dem Gleichgewicht geraten zu sein. Depressive Patienten weisen im Vergleich zu Gesunden oft eine erniedrigte Aktivität von Serotonin, Noradrenalin oder Dopamin auf. Diese Annahme wird durch den generellen Wirkmechanismus einer bestimmten Medikamentengruppe, der so genannten „Antidepressiva“, gestützt. Diese Wirkstoffe sorgen für eine Erhöhung bestimmter Botenstoffe im neuronalen System und helfen, die Symptome einer Depression zu mindern bzw. sie zu unterdrücken.”\nThe information can be found in a slightly modified form in November 2024. The pure form of the CI-theory is obvious.\nhttps://www.neurologen-und-psychiater-im-netz.org/psychiatrie-psychosomatik-psychotherapie/stoerungen-erkrankungen/depressionen/ursachen/"
  },
  {
    "objectID": "blogs/chemical_imbalance/index.html#netdoctor-university-of-vienna",
    "href": "blogs/chemical_imbalance/index.html#netdoctor-university-of-vienna",
    "title": "The chemical imbalance theory of depression: dead, zombie, or alive?",
    "section": "",
    "text": "“Was sind die Ursachen einer Depression? Bei einer Depression ist der Stoffwechsel des Gehirns verändert. Die Spiegel der Überträgersubstanzen (Neurotransmitter) Serotonin und Noradrenalin sind bei depressiven Menschen im Vergleich zu Gesunden niedriger.”\n“Wie wird eine Depression behandelt? Bei Patienten mit Depression ist meistens das Gleichgewicht an Signalstoffen im Gehirn gestört.”\n“Die Neurotransmitter stehen beim gesunden Menschen in einem bestimmten Gleichgewicht zueinander. Bei Depressionen ist diese Balance zwischen den Neurotransmittern gestört, was in Symptomen wie gedrückter Stimmungslage, Antriebslosigkeit und Schlafstörungen seinen Niederschlag findet. Insbesondere kommt es bei depressiven Menschen zu einer verminderten Aktivität jener Nervenzellen, die die Neurotransmitter Serotonin, Noradrenalin und Dopamin übertragen. Durch Medikamente zur Behandlung der Depression (Antidepressiva) wird die Konzentration dieser Neurotransmitter an den Synapsen erhöht. Dieser Vorgang benötigt allerdings etwas Zeit, weshalb das Gleichgewicht zwischen den Überträgersubstanzen erst einige Tage bis Wochen nach Therapiebeginn wiederhergestellt ist – und somit auch die depressiven Symptome abklingen. Um die Neurotransmitter wieder ins Gleichgewicht zu bringen, stehen verschiedene medikamentöse Wirkmechanismen zur Verfügung…”\n\n\n\nThings have changed, the source is from 2022 and now from 2022, with the following comment\n\nProf. Hegerl is a leading academic psychiatrist in Germany.\nWe are now reading that depression is related to a CI of neurotransmitters, including serotonin\n\nAntidepressant work by increasing the level serotonin, the “happy hormone”\n\nThus, we have the CI theory, but it is not sure\nDie Neurotransmitter stehen beim gesunden Menschen in einem bestimmten Gleichgewicht zueinander. Bei Depressionen ist diese Balance zwischen den Neurotransmittern gestört, was in Symptomen wie gedrückter Stimmungslage, Antriebslosigkeit und Schlafstörungen seinen Niederschlag findet.\nInsbesondere kommt es bei depressiven Menschen zu einer verminderten Aktivität jener Nervenzellen, die die Neurotransmitter Serotonin, Noradrenalin und Dopamin übertragen. Durch Medikamente zur Behandlung der Depression (Antidepressiva) wird die Konzentration dieser Neurotransmitter an den Synapsen erhöht. Dieser Vorgang benötigt allerdings etwas Zeit, weshalb das Gleichgewicht zwischen den Überträgersubstanzen erst einige Tage bis Wochen nach Therapiebeginn wiederhergestellt ist – und somit auch die depressiven Symptome abklingen.\nUm die Neurotransmitter wieder ins Gleichgewicht zu bringen, stehen verschiedene medikamentöse Wirkmechanismen zur Verfügung:\nAuthors, are among others, academic psychiatrists including leading psychiatrist and KOL Siegfried Kasper.\nWas sind die Ursachen einer Depression?\nBei einer Depression ist der Stoffwechsel des Gehirns verändert. Die Spiegel der Überträgersubstanzen (Neurotransmitter) Serotonin und Noradrenalin sind bei depressiven Menschen im Vergleich zu Gesunden niedriger. \n\nWie wird eine Depression behandelt?\nBei Patienten mit Depression ist meistens das Gleichgewicht an Signalstoffen im Gehirn gestört.\n\n\nAutoren: Dr. med. Matthias Thalhammer, Mag. (FH) Silvia Hecher, MSc\nMedizinisches Review: O. Univ. Prof. Dr. h.c. mult. Dr. med. Siegfried Kasper, Universitätsklinik für Psychiatrie und Psychotherapie, Medizinische Universität Wien\nRedaktionelle Bearbeitung: Dr. med. Lisa Demel, Dr. med. Stefanie Sperlich \nStand der medizinischen Information"
  },
  {
    "objectID": "blogs/chemical_imbalance/index.html#netdoctor",
    "href": "blogs/chemical_imbalance/index.html#netdoctor",
    "title": "The chemical imbalance theory of depression: dead, zombie, or alive?",
    "section": "",
    "text": "In January 2020 the top hit in the Google search was authored, among others, by a top Austrian academic psychiatrist from the Medical University of Vienna. The text is not available anymore but I saved it here.\n“Was sind die Ursachen einer Depression? Bei einer Depression ist der Stoffwechsel des Gehirns verändert. Die Spiegel der Überträgersubstanzen (Neurotransmitter) Serotonin und Noradrenalin sind bei depressiven Menschen im Vergleich zu Gesunden niedriger.”\n“Wie wird eine Depression behandelt? Bei Patienten mit Depression ist meistens das Gleichgewicht an Signalstoffen im Gehirn gestört.”\n“Die Neurotransmitter stehen beim gesunden Menschen in einem bestimmten Gleichgewicht zueinander. Bei Depressionen ist diese Balance zwischen den Neurotransmittern gestört, was in Symptomen wie gedrückter Stimmungslage, Antriebslosigkeit und Schlafstörungen seinen Niederschlag findet. Insbesondere kommt es bei depressiven Menschen zu einer verminderten Aktivität jener Nervenzellen, die die Neurotransmitter Serotonin, Noradrenalin und Dopamin übertragen. Durch Medikamente zur Behandlung der Depression (Antidepressiva) wird die Konzentration dieser Neurotransmitter an den Synapsen erhöht. Dieser Vorgang benötigt allerdings etwas Zeit, weshalb das Gleichgewicht zwischen den Überträgersubstanzen erst einige Tage bis Wochen nach Therapiebeginn wiederhergestellt ist – und somit auch die depressiven Symptome abklingen. Um die Neurotransmitter wieder ins Gleichgewicht zu bringen, stehen verschiedene medikamentöse Wirkmechanismen zur Verfügung…”\nThis is a definately an example of the CI theory, because it is said that neurotransmitters such as serotonin are reduced among depressed people. Perhaps it even can be interpreted as the pure form of the CI theory, because it is said that it takes days to weeks until antidepressants restore the imbalance.\nThe text was updated when I checked today (November 23, 2024). It is said that the text is in accordance with the medical scientific literature, guidelines, and that it was approved by medical professionals.\nhttps://www.netdoktor.de/krankheiten/depression/\n\nProf. Hegerl is a leading academic psychiatrist in Germany.\nWe are now reading that depression is related to a CI of neurotransmitters, including serotonin.\n\nAntidepressant work by increasing the level of serotonin, the “happy hormone”\n\nThus, there is still the CI theory, but not in its pure form anymore."
  },
  {
    "objectID": "blogs/chemical_imbalance/index.html#psychiater-im-netz",
    "href": "blogs/chemical_imbalance/index.html#psychiater-im-netz",
    "title": "The chemical imbalance theory of depression: dead, zombie, or alive?",
    "section": "",
    "text": "The second hit was written with the support of leading academic psychiatrists and the editors are professional organizations of psychiatrists and neurologists in Germany and Switzerland. The text is saved here.\nhttps://www.neurologen-und-psychiater-im-netz.org/psychiatrie-psychosomatik-psychotherapie/stoerungen-erkrankungen/depressionen/\nWe can see the CI theory in its pure form, and the text is unchanged when I checked it today (November 24, 2024)."
  },
  {
    "objectID": "blogs/chemical_imbalance/index.html#findings-from-other-search-engines",
    "href": "blogs/chemical_imbalance/index.html#findings-from-other-search-engines",
    "title": "The chemical imbalance theory of depression: dead, zombie, or alive?",
    "section": "",
    "text": "Someone said that my Google search results might have been influenced by my search history. Thus I tried with DuckDuckGo and also using the Tor-Browser, with very similar result.\nWith DuckDuckGo, the #1 search result was different than in the Google search, leading to a new source with the CI in its pure form, saying that antidepressants restore the imbalance in neurotransmitters. The source is lifeline and it was said that it meets the highest scientific standard.\n\nNow, in November 2024, the information is still the same. https://www.lifeline.de/krankheiten/depression/\nAs a side note, the text says that antidepressants are not causing dependency. Whereas it is true that antidepressants do not cause addiction, it is now more widely acknowledged that dependency is an issue, even in an article in the British Journal of Psychiatry (Massabki and Abi-Jaoude 2020)."
  },
  {
    "objectID": "blogs/chemical_imbalance/index.html#section",
    "href": "blogs/chemical_imbalance/index.html#section",
    "title": "The chemical imbalance theory of depression: dead, zombie, or alive?",
    "section": "",
    "text": "The third hit was from a major German organization to defeat depression. Responsible for the content is a leading psychiatry professor. Again the chemical imbalance myth, again a snapshot from 2021 for the record.\n\nFortunately, the organization changed the text, explicitly saying that the CI is too simple as an explanation of depression.\n\nHowever, it is also said that depression can be caused by a CI"
  },
  {
    "objectID": "blogs/chemical_imbalance/index.html#apotheken-umschau",
    "href": "blogs/chemical_imbalance/index.html#apotheken-umschau",
    "title": "The chemical imbalance theory of depression: dead, zombie, or alive?",
    "section": "",
    "text": "The website of the Apotheken-Umschau included a video with a psychiatry professor. Here, a lot was said about lowered serotonin activity, a softened version of the CI theory (Min. 6). Unfortunately, I didn’t save the video. It was also said that antidepressants are safe and effective and do not cause dependency or addiction. I agree with addiction, but there are dependency issues (Massabki and Abi-Jaoude 2020).\nIn November 2024, the CI theory is still present, but somehow weakened\nhttps://www.apotheken-umschau.de/krankheiten-symptome/psychische-krankheiten/depressionen-ursachen-anzeichen-therapie-735639.html"
  },
  {
    "objectID": "blogs/chemical_imbalance/index.html#stiftung-gesundheitswissen",
    "href": "blogs/chemical_imbalance/index.html#stiftung-gesundheitswissen",
    "title": "The chemical imbalance theory of depression: dead, zombie, or alive?",
    "section": "",
    "text": "Hit #6 again included the CI theory of depression. Stiftung Gesundheitswissen claims to be independent and evidence based.\n\nWhen I accessed the page tod y (November 23, 2024), I saw that the information was updated. The CI theory can now be found in its pure form, but it is said that the exact mechanism is not known.\nhttps://www.stiftung-gesundheitswissen.de/wissen/depression/behandlung-mit-medikamenten"
  },
  {
    "objectID": "blogs/chemical_imbalance/index.html#older-searches",
    "href": "blogs/chemical_imbalance/index.html#older-searches",
    "title": "The chemical imbalance theory of depression: dead, zombie, or alive?",
    "section": "",
    "text": "Before 2021 I also searched the web and tweeted about the reusults. I don’t know which exact search terms I used, but I selected results from academic psychiatry.\n\n\nRetrieved January 2020 from https://www.psych.mpg.de/840900/depression. The CI theory of depression can be read in its pure form:\n“Bei der Depression ist das biochemische Gleichgewicht der Signalübertragung gestört. Die Therapie zielt darauf ab, durch Medikamente diese Stoffwechselstörung in den Nervenzellen zu korrigieren.”\nThe website is not available anymore but I saved it here.\n\n\n\nThis was retrieved in January 2020 and I saved it here. The CI theory is proposed:\n“Depressionen haben selten nur einen Auslöser. In aller Regel entwickelt sich die Erkrankung aufgrund von mehreren Faktoren. Das kann zum einen die genetische Veranlagung sein. Zum anderen spielen aber auch körperliche Ursachen eine Rolle – genauso wie Situationen, die über die eigenen Kräfte gehen oder ein Perfektionismus, durch den man sich selbst permanent überfordert. Mögliche Auslöser sind z. B.: ein gestörter Hirnstoffwechsel, in dem die Hirnbotenstoffe Serotonin und/oder Noradrenalin aus der gesunden Balance geraten sind” http://www.klinikum.uni-muenchen.de/Klinik-und-Poliklinik-fuer-Psychiatrie-und-Psychotherapie/de/patient_besuch/krankheitsbilder/depression/index.html\n\n\n\nAlso from January 2020, the information in the text (saved here) points unambiguously to the CI theory:\n„Wie bei jeder Depression weisen Betroffene einen Mangel des Gehirnbotenstoffs Serotonin auf“\nhttp://www.psychiatrie.med.uni-goettingen.de/de/content/patienten/237.html\nNow, in November 2024, the information is still there, even in it’s pure form.\n\nhttps://psychiatrie.umg.eu/patienten-besucher/therapieangebote/lichttherapie/\n\n\n\nFound in January 2020, the CI theory is obvious in this text, saved here:\n“Depression ist nicht gleich Depression: Manche entstehen durch einen Mangel am Botenstoff Serotonin im Gehirn, andere durch einen Mangel an Noradrenalin; ebenfalls ein Botenstoff.”\nThe information is still available here:\nhttps://www.uniaktuell.unibe.ch/2015/die_zwei_arten_depressiv_zu_sein/index_ger.html\n\n\n\nAs already mentioned above, this is the information from psychiatric/neurological associations in Germany and Switzerland. Here is their statement from January 2020. The CI-theory is obvious, and the action of antidepressants suggests that the CI-theory in its pure form is implicated.\n“Viele Untersuchungen deuten darauf hin, dass Depressionen durch typische Veränderungen von Botenstoffen im Gehirn gekennzeichnet sind. Dabei scheinen bestimmte Botenstoffe (so genannte Neurotransmitter wie Serotonin, Dopamin, Noradrenalin, Acetylcholin, Gamma-Aminobuttersäure) aus dem Gleichgewicht geraten zu sein. Depressive Patienten weisen im Vergleich zu Gesunden oft eine erniedrigte Aktivität von Serotonin, Noradrenalin oder Dopamin auf. Diese Annahme wird durch den generellen Wirkmechanismus einer bestimmten Medikamentengruppe, der so genannten „Antidepressiva“, gestützt. Diese Wirkstoffe sorgen für eine Erhöhung bestimmter Botenstoffe im neuronalen System und helfen, die Symptome einer Depression zu mindern bzw. sie zu unterdrücken.”\nThe information can be found in a slightly modified form in November 2024. The pure form of the CI-theory is obvious.\nhttps://www.neurologen-und-psychiater-im-netz.org/psychiatrie-psychosomatik-psychotherapie/stoerungen-erkrankungen/depressionen/ursachen/"
  },
  {
    "objectID": "blogs/chemical_imbalance/index.html#deutsche-depressionshilfe",
    "href": "blogs/chemical_imbalance/index.html#deutsche-depressionshilfe",
    "title": "The chemical imbalance theory of depression: dead, zombie, or alive?",
    "section": "",
    "text": "The third hit was from a major German organization to defeat depression. Responsible for the content is a leading psychiatry professor. Again there is the CI theory of depression.\n\nThe organization changed the text, explicitly saying that serotonine deficit is too simple as an explanation of depression.\nhttps://www.deutsche-depressionshilfe.de/ueber-uns/das-buendnis\n\nHowever, it is also said that depression can be caused by a CI and that antidepressants directly work by targeting at the CI of neurotransmitters."
  },
  {
    "objectID": "blogs/Esketamin_Wirksamkeit/index.html",
    "href": "blogs/Esketamin_Wirksamkeit/index.html",
    "title": "Wie wirksam ist Esketamin?",
    "section": "",
    "text": "Priv.-Doz. Dr. Martin Plöderl\nStand 10. Dezember 2024, Update 15. Juli 2025\nEsketamin ist ein von der Firma Janssen patentiertes Antinomer von Ketamin und wurde 2019 für die Behandlung der sogenannten “Behandlungsresistenten Depression” von der US-Arzneimittelbehörde FDA (Food and Drug Administration) zugelassen. Die FDA erlaubte Janssen ein Schnellzulassungsverfahren und lockerte sogar die Kriterien für die Zulassung. Im Jahr 2020 ließ die FDA Esketamin auch für die Behandlung von “depression with suicide ideation or behavior”, was von der European Medical Agency in einer deutschen Übersetzung wie folgt zu lesen ist: “als akute Kurzzeitbehandlung, zur schnellen Reduktion depressiver Symptome, die nach ärztlichem Ermessen einem psychiatrischen Notfall entsprechen”. Die Zulassung durch die EMA für beide Indikationen erfolgte kurz nach der Zulassung durch die FDA.\n\n\nMittlerweile hat Esketamin als Behandlungsoption in psychiatrischen Kliniken Einzug gefunden. In Fachartikeln und Behandlungsempfehlungen wird zum Teil recht enthusiastisch über die rasche antidepressive Wirksamkeit von Esketamin berichtet. Doch mit dem Erscheinen der ersten Wirksamkeitsstudien gab es parallel auch viele Bedenken bezüglich des Nutzens und Schadens von Esketamin. Im Folgenden möchte ich vor allem die Wirksamkeit von Esketamin in verständlicher Art beleuchten sodass Sie sich als KlinikerInnen oder PatientInnen selber ein Bild machen können."
  },
  {
    "objectID": "blogs/Esketamin_Wirksamkeit/index.html#studiendesign",
    "href": "blogs/Esketamin_Wirksamkeit/index.html#studiendesign",
    "title": "Wie wirksam ist Esketamin?",
    "section": "Studiendesign ",
    "text": "Studiendesign \nBis dato wurden so gut wie alle Studien zu Esketamin von der Firma Janssen finanziert. Für die Zulassung waren vor allem randomisierte Placebo-kontrollierte Studien maßgeblich (engl. randomized controlled trials, RCTs). Dabei wurden PatientInnen zufällig in (meist zwei) Gruppen eingeteilt. Eine Gruppe erhielt Esketamin, die andere Gruppe Placebo. Zusätzlich zu Esketamin/Placebo erhielten PatientInnen auch eine Standardbehandlung mit herkömmlichen Antidepressiva. In manchen Studien gab es mehrere Gruppen mit verschiedenen Dosen von Esketamin (14mg, 28mg, 56mg, 84mg). Es handelte sich meist um sogenannte Doppelblind-Studien, d.h. sowohl die PatientInnen als auch das Studienpersonal wusste nicht, welche PatientInnen in welche Gruppe zugeordnet wurden. Nach anfänglichen kleineren, sogenannten Phase-2 Studien, wurden größere Phase-3 Studien durchgeführt, die für die Zulassung relevant waren, weil die Größe der Wirksamkeit hier genauer feststellbar war. Die meisten Studien zu Esketamin hatten eine Doppelblind- Behandlungsphase von 4 Wochen, gefolgt von einem Nachbeobachtungsphase von mehreren Wochen."
  },
  {
    "objectID": "blogs/Esketamin_Wirksamkeit/index.html#was-wurde-in-den-studien-gemessen",
    "href": "blogs/Esketamin_Wirksamkeit/index.html#was-wurde-in-den-studien-gemessen",
    "title": "Wie wirksam ist Esketamin?",
    "section": "Was wurde in den Studien gemessen?",
    "text": "Was wurde in den Studien gemessen?\nDas in den Studienplänen vorab festgelegte Hauptergebnis sollte eine Reduktion der Depressionssymptomatik sein, gemessen mit der Montgomery-Åsberg-Depressionsskala (MADRS). Dabei erfassen KlinikerInnen im Interview mit den PatientInnen mittels 10 Fragen verschiedene Depressionssymptome. Man kann bei der MADRS einen Depressionswert zwischen 0 und 60 haben. Eine mittelschwere Depression entspricht etwa einem Wert zwischen 20 und 34 MADRS-Punkten. Das Hauptergebnis der Studien ist der Vergleich zwischen dem Rückgang an MADRS-Depressionswerten in der Esketamingruppe im Vergleich zur Placebogruppe. Man nennt dies “Effektivität”.\nSie können den nun folgenden Exkurs zur klinischen und statistischen Signifikanz überspringen und gleich zu den Wirksamkeitsstudien gehen. Jedoch werden Ihnen diese Begriffe immer wieder unterkommen und es ist hilfreich, sie zu verstehen. \n\nKlinische Signifikanz\nWichtig für die Interpretation der Studienergebnisse ist zu wissen, wie groß die gefundene Effektivität, also der Unterschied zwischen dem MADRS-Depressionswert nach der Behandlung mit Placebo oder Esketamin ist. Vor allem ist zentral, ob die Effektivität von klinischer Bedeutsamkeit ist, also für PatientInnen wirklich einen Unterschied macht. Man spricht hier auch von klinischer Signifikanz oder von (engl.) “minimal important difference”. Wenn man gängige Kriterien für die klinische Signifikanz heranzieht, dann sollten sich PatientInnen mit Esketamin zumindest um 3-9 MADRS-Punkte stärker verbessern als mit Placebo (Hengartner and Plöderl 2018). \n\n\nStatistische Signifikanz\nJede Messung ist mit Unsicherheit verbunden. Mit kleinen Stichproben kann man die Effektivität nur mit großer Unsicherheit schätzen, ähnlich wie die ersten Hochrechnungen bei Wahlergebnissen noch mit Unsicherheit behaftet sind. Je größer die Stichproben werden, umso präziser kann man die Effektivität schätzen. Hier kommt die sogenannte “statistische Signifikanz” ins Spiel, die Ihnen beim Lesen von Fachartikeln regelmäßig unterkommen wird. Auch für die Zulassung von Medikamenten ist die statistische Signifikanz zentral. Hier wird gefordert, dass zumindest zwei Studien statistisch signifikant ausfallen. Leider ist die statistische Signifikanz schwer intuitiv fassbar und das führt zu vielen Missverständnissen. Salopp gesprochen kann man sagen, dass die statistische Signifikanz aussagt, wie sicher man von einem Unterschied größer als Null ausgehen kann, in unserem Fall mehr als Null MADRS-Punkte Unterschied zwischen Placebo und Esketamin. Beim statistischen Signifikanztest geht man von der Annahme aus, dass es keinen Unterschied zwischen Placebo und Esketamin gibt (die Null-Hypothese). Dann wird mathematisch berechnet, wie wahrscheinlich es ist, unter der Annahme der Null-Hypothese, die tatsächlich beobachteten Daten zu erhalten, oder sogar noch stärker von der Null-Hypothese abweichende Daten.  Diese Wahrscheinlichkeit ist der p-Wert, die sogenannte Irrtumswahrscheinlichkeit. Wenn die Wahrscheinlichkeit unter 5% ist, dann spricht man von “statistischer Signifikanz”. Ganz wichtig ist dabei zu wissen, dass die statistische Signifikanz nichts über die Größe des Unterschiedes aussagt, sondern nur, dass ein Null-Unterschied angesichts der beobachteten Daten unwahrscheinlich ist. Bei sehr großen Stichproben werden auch unbedeutendste kleinste Unterschiede statistisch signifikant. Umgekehrt sind bei sehr kleinen Stichproben oft große bedeutsame Unterschiede zwischen Medikamenten und Placebo nicht statistisch signifikant."
  },
  {
    "objectID": "blogs/Esketamin_Wirksamkeit/index.html#ergebnisse-der-zulassungsstudien-transform-1-3",
    "href": "blogs/Esketamin_Wirksamkeit/index.html#ergebnisse-der-zulassungsstudien-transform-1-3",
    "title": "Wie wirksam ist Esketamin?",
    "section": "Ergebnisse der Zulassungsstudien (TRANSFORM 1-3)",
    "text": "Ergebnisse der Zulassungsstudien (TRANSFORM 1-3)\nZur Überprüfung der Wirksamkeit von Esketamin und zur Zulassung führte Janssen eine kleinere Phase-2 Studie (SYNAPSE) mit Esketamin durch (Daly et al. 2018), gefolgt von drei größeren Phase-3 Studien (TRANSFORM 1-3). Die Doppelblindphase dauerte vier Wochen und PatientInnen erhielten hier entweder Placebo oder Esketamin zweimal pro Woche, zusätzlich zu herkömmlichen Antidepressiva. Vorab geplantes Hauptergebnis war die Effektivität nach 4 Wochen, also der Unterschied im Rückgang der Depressionssymptome zwischen Esketamin und Placebo, gemessen mit der MADRS. In den drei TRANSFORM Studien zeigte sich ein Unterschied von maximal 4 Punkten auf der MADRS. Und nur in der TRANSFORM 2 Studie war dieser Unterschied auch statistisch signifikant. Wie im vorigen Abschnitt erläutert, braucht es mindestens 3 bis 9 Punkte Unterschied, um die Untergrenze der klinischen Bedeutsamkeit (klinische Signifikanz) zu erreichen. Daher ist die beobachtete Effektivität fraglich klinisch bedeutsam. In den Abbildungen 1-3 sind die Hauptergebnisse der TRANSFORM Studien grafisch dargestellt.\n\nAbb. 1. Ergebnis der TRANSFORM 1 Studie (Fedgchin et al. 2019). Auf der y-Achse ist der Rückgang der Depressionswerte gemessen mit der MADRS-Skala zu sehen. Grau: Placebo, Grün: Esketamin 56mg, Blau: Esketamin 84mg \n\n\n \nAbb. 2. Ergebnis der TRANSFORM 2 Studie (Popova et al. 2019). Auf der y-Achse ist der Rückgang der Depressionswerte gemessen mit der MADRS-Skala zu sehen. Orange: Placebo, Grün: Esketamin 56mg oder 86mg. Statistische Signifikanz wurde nur am Ende der Doppelblind-Phase erreicht (mit einem Stern markiert). \n\n \n\nAbb. 3. Ergebnis der TRANSFORM 3 Studie (Ochs-Ross et al. 2020). Diese Studie wurde mit älteren PatientInnen durchgeführt. Auf der y-Achse ist der Rückgang der Depressionswerte gemessen mit der MADRS-Skala zu sehen. Grau: Placebo, Schwarz: Esketamin (flexible Dosierungen 28-84mg). Die Grafik wurde den FDA Dokumenten entnommen, da Ochs-Ross et al. die Daten nur getrennt nach zwei Altersgruppen berichteten."
  },
  {
    "objectID": "blogs/Esketamin_Wirksamkeit/index.html#kritische-anmerkungen",
    "href": "blogs/Esketamin_Wirksamkeit/index.html#kritische-anmerkungen",
    "title": "Wie wirksam ist Esketamin?",
    "section": "Kritische Anmerkungen",
    "text": "Kritische Anmerkungen\nZunächst ist, wie schon erwähnt, festzuhalten, dass die Effektivität fraglich klinisch bedeutsam ist. Zur Interpretation der Ergebnisse ist es zudem wichtig, typische Verzerrungseffekte (Biases) in klinischen Studien zu beachten. Ein Problem in klinischen Studien ist oft, dass eine Verblindung schwer möglich ist, so auch in den Esketamin-Studien. Denn Esketamin hat typische psychotrope Effekte, sodass PatientInnen und KlinikerInnen in den Studien gut erraten können, wer das Medikament bekommt und wer Placebo. Es ist bekannt, dass diese Entblindung mit einer Überschätzung der tatsächlichen Wirksamkeit einhergeht [@hengartner2018]. Zudem wurden alle Studien vom Hersteller durchgeführt bzw. gesponsert. Es ist gut untersucht, dass dies ebenfalls zu einer Überschätzung der tatsächlichen Wirksamkeit führt. Daher kann mit hoher Wahrscheinlichkeit davon ausgegangen werden, dass die Wirksamkeit von Esketamin in Wirklichkeit kleiner als die beobachteten 4 MADRS Punkte sind. Somit ist auch die klinische Bedeutsamkeit wahrscheinlich nicht gegeben. \nDie Studien zeigen, dass es auch in den Placebo-Gruppen zu einem deutlichen Rückgang der Depressionssymptome kam. Es scheint also wichtig zu sein, in der Studie behandelt zu werden, und kaum relevant, ob man dann Esketamin oder Placebo bekommt. Zur Erklärung der Verbesserung in allen Gruppen spielen vermutlich unspezifische Wirkfaktoren wie viel Kontakt mit KlinikerInnen eine tragende Rolle. Von VertreterInnen von Esketamin ist in diesem Zusammenhang zu hören, dass in den Studien “leider” der Placebo-Effekt so groß sei. Aber für wen trifft dieses “leider” zu? Wenn PatientInnen auch mit unspezifischen Wirkfaktoren (z.B. viel Kontakt) profitieren, dann ist das doch gut so, denn damit müssen PatientInnen nicht unnötig mit den Nebenwirkungen von Esketamin belastet werden und das Gesundheitssystem nicht mit den hohen Kosten von Esketamin. Immerhin kostet eine 4-Wöchige Behandlung mit Esketamin 84mg über 8000 Euro (Spießl 2021). Zudem sind Nebenwirkungen mit Esketamin durchaus häufig und es kam deshalb auch zu deutlich mehr Behandlungsabbrüchen mit Esketamin als mit Placebo. \nEin weiteres enttäuschendes Ergebnis der Studien war Folgendes: man erwartete sich, ähnlich wie bei der Behandlung mit intravenösem Ketamin, eine rasche und anhaltende Wirksamkeit. Dies wurde in den TRANSFORM Studien als eine zumindest 50%-ige Reduktion der Depressionssymptomatik (z.B. von 30 auf 14 MADRS Punkte) definiert, die in der ersten Woche erreicht werden und bis zum Behandlungsende (4 Wochen) andauern sollte. Dieses Kriterium wurde aber nur von 11% der PatientInnen mit Esketamin erreicht und von 6% mit Placebo. \nEin weiterer Kritikpunkt ist die Definition von “behandlungsresistenter Depression”. In den Studien wird das zumeist als zwei erfolglose Therapieversuche mit verschiedenen Antidepressiva definiert, selbst wenn es sich um zwei Antidepressiva aus der gleichen Substanzklasse handelt, etwa zwei verschiedene SSRIs. Eine erfolglose Behandlung mit Psychotherapie oder anderen Ansätzen spielt dabei keine Rolle. Man müsste daher also von Antidepressiva-resistenter Depression sprechen. \nEs sollte auch kritisch angemerkt werden, dass Esketamin trotz der eher enttäuschenden Wirksamkeitsergebnisse zugelassen wurde. Normalerweise werden zwei positive (statistisch signifikante) Phase-3 Studien benötigt. Erstmals in der Geschichte senkte die FDA die Zulassungskriterien derart. Diese Kritikpunkte und einige mehr finden Sie in den Reaktionen auf die Publikationen der Zulassungsstudien (Gastaldon et al. 2020; Horowitz and Moncrieff 2020; Naudet and Cristea 2020; Schatzberg 2019; Turner 2019).\nErst nach der Zulassung erschienen weitere Studien zu Esketamin zur Behandlung einer behandlungsresistenten Depression von Janssen, und in beiden Studien kamen noch enttäuschendere Ergebnisse zu Tage. So gab es in der japanischen Phase-2a Studie (Takahashi et al. 2021) überhaupt keinen Unterschied zwischen verschiedenen Dosen von Esketamin und Placebo (Abb. 4). In der größeren Phase-3 Studie mit PatientInnen aus China und USA (Chen et al. 2023) gab es ebenfalls keine signifikanten Unterschiede zwischen Esketamin und Placebo (Abb. 5). Berücksichtigt man diese Ergebnisse, dann untermauert das zusätzlich, dass die Effektivität von Esketamin nicht klinisch bedeutsam ist. \n\nAbb. 4. Ergebnis der japanischen Studie zur behandlungsresistenten Depression (Takahashi et al. 2021). Diese Studie erschien nach der Zulassung von Esketamin. \n\n\n\n\n\n\nAbb. 5. Ergebnis der jüngsten Studie zur behandlungsresistenten Depression (Chen et al. 2023). Diese Studie erschien nach der Zulassung von Esketamin."
  },
  {
    "objectID": "blogs/Esketamin_Wirksamkeit/index.html#die-phase-3-studien-zur-suizidalen-depression-aspire-12",
    "href": "blogs/Esketamin_Wirksamkeit/index.html#die-phase-3-studien-zur-suizidalen-depression-aspire-12",
    "title": "Wie wirksam ist Esketamin?",
    "section": "Die Phase-3 Studien zur suizidalen Depression ASPIRE 1+2",
    "text": "Die Phase-3 Studien zur suizidalen Depression ASPIRE 1+2\nMit den zwei ASPIRE Studien Ionescu et al. (2020) hat Janssen eindrucksvoll bewiesen, dass gute klinische Studien auch mit suizidgefährdeten PatientInnen machbar sind. Üblicherweise werden suizidale PatientInnen nämlich immer aus Studien ausgeschlossen. Im Falle der ASPIRE Studien wurden PatientInnen sogar nur dann eingeschlossen, wenn sie stärkere Suizidgedanken mit einem gewissen Drang, diese auch in die Tat umzusetzen hatten, sodass eine stationäre Aufnahme indiziert schien. Etwa 85% der PatientInnen in den ASPIRE Studien wurden als moderat bis extrem stark suizidgefährdet eingeschätzt. \nPatientInnen in den ASPIRE Studien wurden wieder zufällig in eine Behandlung mit Esketamin 84mg oder Placebo (zwei Mal in der Woche) im Doppelblind-Design zugeordnet. Die Doppelblindphase dauerte 4 Wochen, und es gab eine Nachbeobachtungsphase von 2 Monaten. Zudem erhielten alle PatientInnen eine optimierte Behandlung mit herkömmlichen Antidepressiva und eine im Durchschnitt dreiwöchige stationäre psychiatrische Behandlung. \nDie Studien waren mit insgesamt 456 PatientInnen relativ groß, sodass ziemlich genaue Schätzungen der Effektivität möglich waren. Das vorab festgelegte Hauptergebnis war die Reduktion der Depressivität (gemessen mit der MADRS), und zwar 24 Stunden nach Verabreichung von Esketamin bzw. Placebo. Sekundäres geplantes Ergebnis war die Reduktion der Suizidgedanken, gemessen mit dem Modul für Suizidalität aus der revidierten Version der Clinical Global Impression Scale (CGI-SS-r). In Abb. 6 und 7 sind die Ergebnisse grafisch dargestellt. \nPrimäres Ergebnis: der Rückgang der Depressionssymptome nach 24 Stunden war in der Esketamingruppen um knapp 4-Punkte stärker als in der Placebogruppen. Dieser Unterschied war in beiden Studien statistisch signifikant. Nachdem die Untergrenze für klinische Bedeutsamkeit 3-9 MADRS Punkte beträgt, sind die Ergebnisse allerdings fraglich klinisch bedeutsam.\nSekundäres Ergebnis: der Rückgang der Suizidgedanken unterschied sich nicht statistisch signifikant zwischen PatientInnen in den Esketamingruppen im Vergleich zu jenen in den Placebogruppen. Auch vom Ausmaß her war der Effekt klein. Nachdem es keine Untersuchungen zur klinischen Signifikanz bei Suizidgedanken gibt, kann man die sogenannte Effektstärke heranziehen (standardisierter Mittelwertsunterschied). Dieser betrug -0.14 in der ASPIRE 1 Studie und -0.12 in der ASPIRE 2 Studie. Nach üblichen Konventionen sind Effektstärken unter 0.3 als klein zu bezeichnen, und klinisch relevante Wirksamkeiten entsprechen einer Effektstärke von mindestens 0.5. Die Effekte für Suizidgedanken sind daher ziemlich sicher nicht klinisch Bedeutsam.\n\nAbb. 6. Ergebnis der ASPIRE 1 Studie (Ionescu et al. 2020). Auf der y-Achse ist der Rückgang der Depressionswerte gemessen mit der MADRS Skalas zu sehen. \n\n\n\nAbb. 7. Ergebnis der ASPIRE 2 Studie (Fu et al. 2020). Auf der y-Achse ist der Rückgang der Depressionswerte gemessen mit der MADRS Skalas zu sehen. \n\n\nIm weiteren Verlauf bis zum Ende der Doppelblindphase (4 Wochen) waren die Unterschiede zwischen Esketamin und Placebo klein, zumeist nicht statistisch signifikant, und in der Nachbeobachtungsphase zum Teil gänzlich verschwunden."
  },
  {
    "objectID": "blogs/Esketamin_Wirksamkeit/index.html#kritische-anmerkungen-1",
    "href": "blogs/Esketamin_Wirksamkeit/index.html#kritische-anmerkungen-1",
    "title": "Wie wirksam ist Esketamin?",
    "section": "Kritische Anmerkungen",
    "text": "Kritische Anmerkungen\nZur Interpretation der ASPIRE Studien sollten ähnliche methodische Limitationen wie bei den Studien zur Behandlungsresistenten Depression berücksichtigt werden. Neben dem Umstand, dass die gefundenen Effekte fraglich klinisch relevant sind, ist auch hier eine Überschätzung des ohnehin kleinen Effektes durch das Problem der kaum möglichen Verblindung gegeben. Dieser Bias könnte hier sogar noch stärker sein, weil das primäre Ergebnis kurz nach der Verabreichung erfolgte. Zudem wurden alle Studien von Janssen gesponsert. Außerdem gab es keinen positiven Effekt für die Reduktion von Suizidgedanken. Aber gerade darauf kommt es natürlich in der Behandlung der suizidalen Depression an. Man würde ja erwarten, dass sich der geringfügig stärkere Rückgang in der Depressivität mit Esketamin im Vergleich zu Placebo auch in den Suizidgedanken niederschlägt. In diesem Zusammenhang ist es interessant, auf wirklich “harte” Studienergebnisse hinzuschauen, nämlich Suizidversuche und Suizide. Dadurch dass die ASPIRE Studien an suizidalen PatientInnen durchgeführt wurde, kamen suizidale Handlungen erwartungsgemäß deutlich häufiger vor als in den Studien zur behandlungsresistenten Depression. Es zeigte sich dass in der Doppelblindphase je 4 Suizidversuche in der Esketamingruppe und der Placebogruppe passierten (Tab. 1). In der Nachbeobachtungsphase gab es 7 Suizidversuche und einen Suizid in der Esketamingruppe und 3 Suizidversuche in der Placebogruppe. Tendenziell gab es also mehr suizidale Handlungen in der Esketamingruppe. Der Unterschied ist zwar nicht statistisch signifikant, aber dennoch sind das Ergebnisse, die man sich nicht von einem Medikament erwarten würde, das einen Durchbruch in der Behandlung von suizidal depressiven Patienten darstellen soll. \nTabelle 1. Suizide und Suizidversuche in den ASPIRE Studien\n\n\n\n\n\n\n\n\n\n\nPhase\nEsketamin\n\nPlacebo\n\n\n\n\nSuizidversuche\nSuizide\nSuizidversuche\nSuizide\n\n\nDoppelblindphase\n(4 Wochen)\n4\n0\n4\n0\n\n\nNachbeobachtung (2 Monate)\n7\n1\n3\n0\n\n\nGesamt\n11\n1\n7\n0\n\n\n\n\n\nSo wie in den Studien zur Behandlungsresistenten Depression kam es auch in den ASPIRE Studien zur suizidalen Depression zu einem deutlichen Rückgang an Depressivität und Suizidgedanken sowohl unter Esketamin als auch unter Placebo. Die Teilnahme an der Studie war also relevant, und kaum (für Depressivität) bzw. nicht (für Suizidgedanken) ob PatientInnen das Medikament oder Placebo erhielten. Vermutlich ist es also der intensivere Betreuungsaufwand und eine optimierte Behandlung, was zählt.\nDie Ergebnisse der ASPIRE Studie werfen auch ein kritisches Licht auf die Praxis der wiederholten Gaben von Esketamin, da die Wirksamkeit dennoch eher nachlässt und kaum klinisch relevant ist. Interessanterweise erreichen Studien mit einer einmaligen Gabe von Ketamin IV kurzfristig stärkere Effekte, zumindest in den ersten drei bis fünf Tagen. Allerdings ist die Evidenzlage hier mit mehr Unsicherheit verbunden (Plöderl, Hengartner, and Volkmann 2022). Die fehlenden langfristigen Effekte trotz wiederholter Verabreichungen lassen auch Zweifel an der Neuroplastizitäts-Annahme der Wirksamkeit von Ketamin oder Esketamin aufkommen. Würde es zu mehr Neuroplastizität kommen und dadurch auch zu mehr Veränderungs- und Lernpotential, dann nähme die Effektivität mit der Zeit zu- und nicht ab. Die kurzfristige deutliche Wirksamkeit von Ketamin scheint eher die Annahme einer Musterunterbrechung zu stützen. Es kann aber auch sein, dass der Effekt maßgeblich auf Erwartungseffekten beruht. In einer bemerkenswerten weil wirklich verblindeten Studie wurden depressiven PatientInnen, welche aufgrund einer organischen Problematik einen medizinischen Eingriff mit Vollnarkose brauchten, während der Vollnarkose entweder Ketamin oder Placebo verabreicht (Lii et al., n.d.). Es kam zwar in beiden Gruppen zu einem Rückgang der Depressivität, aber es war überhaupt kein Unterschied zwischen der Ketamin- und der Placebogruppe feststellbar, und PatientInnen konnten auch nicht erraten, in welcher Gruppe sie waren. \nAbschließend ist die deutsche Übersetzung der Indikation zu hinterfragen. Untersucht und zugelassen wurde Esketamin für depressive PatientInnen mit starken Suizidgedanken (engl. “Depression with suicide ideation or behavior”). Die Deutsche Übersetzung (psychiatrischer Notfall) ist demnach nicht präzise. Natürlich ist eine suizidale Depression oft eine psychiatrischen Notfall, aber umgekehrt ist ein psychiatrischer Notfall im Rahmen einer Depression nicht immer mit einer suizidalen Depression verbunden."
  },
  {
    "objectID": "recorded_talks/index.html",
    "href": "recorded_talks/index.html",
    "title": "Recorded Talks",
    "section": "",
    "text": "Ketamine and esketamine in suicide prevention. Breakthrough or hype? 9th Vilnius Conference on Suicide Intervention Methods. 22.11.2024. Youtube\nSuizid und Suizidprävention. Vortrag gehalten anläßlich des Welt-Suizidpräventionstages, organisiert von MeinMed.at, 18.07.2023. Link\nSind Antidepressiva gute Medizin? Grams’ Sprechstunde, 22.12.2022 (Interview mit Natalie Grams). https://detektor.fm/wissen/grams-sprechstunde-antidepressiva\nMoon and suicide. An example of debunking a likely false positive finding. 2023 Workshop on Reproducibility, University of Toronto, 22.02.2023. Youtube\nKann man sich auf die Evidenzbasierte Medizin verlassen? Beispiel Antidepressiva. Vortrag im Rahmen der “Sceptics in the Pub”, GWUP Wien, 27.10.2022. Youtube\nSuicide Risk Among LGBT+ individuals: Facts, Explanatory Models, and Prevention. 6th Vilnius Conference on Suicide Intervention Methods. 26.11.2021. Youtube"
  },
  {
    "objectID": "blogs/Perlis_response/index.html",
    "href": "blogs/Perlis_response/index.html",
    "title": "Response to ‘The time has come for over-the-counter antidepressants’ by Roy Perlis",
    "section": "",
    "text": "Roy Perlis, Harvard professor of psychiatry, recently suggested that SSRIs should be available over the counter, as they “have repeatedly been shown to be safe and effective for treating major depression and anxiety disorders”.1 In the following, I will examine some of his arguments, as they are either in contradiction to the evidence or give a biased, uncritical summary on the evidence.\nAre SSRI’s save and effective? The scientific discussion is ongoing.2–4 The average efficacy (around 2 points on the Hamilton Depression Scale) in short-term clinical trials is below typical thresholds of clinical significance.5 Recently, it has been argued that the average drug-placebo difference should not be used because of a non-normal distribution of the outcome. However, even taking this into account, the drug-placebo difference in „responder“ status is about 11% at best, and only 6% when considering a reduction of 16 Hamilton points from baseline as criterion for „responder“.6,7 It has been estimated that, compared to natural course, only 15% more benefit from treatment with antidepressants, and given the costs and harms, this would be below the smallest worthwhile difference for about 2 of 3 patients.8\nReferring to the STAR*D study, Perlis writes that “one in three people with depression get well with an initial antidepressant medication”. However, the STAR*D study had no placebo control group, thus we do not know how many people would have got better without treatment, with placebo, or treatments other than medication. A critical look at long-term outcomes raises doubts on the long-term efficacy and relapse-preventive effect of antidepressants.9 A review of longer-term studies without the problematic discontinuation designs reveals that psychotherapy alone or a combination of psychotherapy with antidepressants is superior to antidepressants.10 Of note, hardly any long-term study included a tapering phase and potential problems with stopping medication after the recommended period of treatment. This has to be taken into account when considering the finding that a combination of antidepressants with psychotherapy is equally effective to psychotherapy alone.\nFurthermore, with the modest efficacy of antidepressants, which is likely overestimated due to methodological biases,3 it does not take much harms so that the harm/benefit ratio is problematic for the majority of patients. Most common side effects for SSRIs are sexual dysfunctions, with up to 80% reporting these, compared to about 12% treated with placebo.11,12 Another common problem is withdrawal symptoms after trying to stop medication.13,14 To sum up, the notion that antidepressants are safe and effective is not supported by the evidence, at least not for the average patient. On the contrary, there is substantial evidence that, for most patients on antidepressants, the harm/benefit ratio is problematic. Interestingly, even Key Opinion Leader David Nutt and colleagues, who once defended antidepressants (“one of the most effective of all drugs”)15 now conclude that “Even the best-performing antidepressant drugs show modest efficacy, non-negligible side effects, discontinuation problems and high relapse rates, highlighting the need for new, improved treatments”.16\nI agree that access to alternative treatments is often difficult. I also agree with Perlis that Psychotherapy is often not accessible, acceptable, or helpful, but psychotherapy is not the only alternative to treat depression. There are also other alternatives. For example, it has been suggested to consider basic interventions as the only intervention or at least as complementary.17 These include a therapeutic alliance, psycho-education, problem-solving, structuring the day, activation, sleep-hygiene, sleep-restriction, exercise, etc.\nFor antidepressants and suicide risk, Perlis says that “Among people age 25 and older, there is clear evidence that taking antidepressants does not increase the risk for suicide — in fact, the risk of suicidal thoughts or acts is reduced in this group, particularly among those 65 and older.”\nThis summary of the evidence is misleading, as it only refers to an older review of short-term studies on adults submitted to the FDA.18 In our re-analysis of the FDA database, there was a statistically significant drug-placebo difference for suicide attempts, whereas for suicides, statistical significance depended on the statistical method.19,20 Our results may have overestimated or underestimated the problem. However, it can be said with quite some certainty that antidepressants do not reduce suicide risk. Furthermore, longer-term studies on adults also reported an increase for suicide attempts for those on antidepressants compared to placebo.21,22 Numerically, the risk was also increased for suicides, but not statistically significant, thus the evidence is inconclusive here. Because of the rarity of suicidal behavior in clinical trials, observational studies should be considered, too. In our systematic review, which was an update of an older review,23 there was a significant increase of suicide attempts for those on antidepressants versus those without antidepressant treatment, and for suicide, the evidence was inconclusive.24 Therefore, even with a pro-drug-biased view on the evidence the conclusion that “there is clear evidence that taking antidepressants does not increase the risk for suicide” is not supported by the evidence. A statement such as “there is clear evidence that taking antidepressants does not decrease the risk for suicide for the average patient; rather, there is evidence that there is an increase of suicide risk” would be in accordance with the evidence. This is astonishing for a drug that is claimed to effectively reduce depression, one of the most important risk factor for suicide.\nThen there is the statement “Some still question the biological basis of this disorder”. What does the efficacy of antidepressant drugs have to do with the biological foundation of depression? Or is there the implicit assumption that antidepressants “cure” depression, that is, correct a chemical imbalance?\nPerlis then refers to a study which found associations of 100 genes with depression. However, genetic research into depression experienced major drawbacks, because candidate genes could not be replicated in large databases25,26 and genetic information could only explain a small fraction of the variance. In contrast, psychosocial factors are much more strongly associated with depression.\nPerlis also references a single neuroimaging study showing differences in the brains of people with depression. Thanks to the PubPeer browser plugin (highly recommended), I was lead to a study which could not replicate the findings (https://www.biorxiv.org/content/10.1101/416321v1 - The study was published in the meantime). Perlis missed systematic reviews and larger studies on the issue. These studies reported that brains of depressed people are remarkably similar to the brains of healthy individuals. That is, the observed differences are tiny,27 and using information from neuroimaging cannot be used to distinguish depressed from non-depressed people in any clinically meaningful way. In line with this, biomarkers of depression failed to predict depression prospectively.28\nTo sum up, to think of antidepressants as safe and effective is a very “optimistic” view on the evidence. An unbiased, evidence-based view leads to the conclusion that most patients do not benefit from antidepressants but are exposed to the harms, thus leading to a problematic harm/benefit ratio. A minority of of patients may benefit from the drugs, compared to placebo or no treatment, but we still lack robust predictors of who these patients are. Over the counter availability of the drugs without proper information about harms and benefits, and without monitoring the context of a therapeutic alliance likely leads to more harm then benefit, as I tried to show here.\nThis is how Perlis responded to my first reaction on Twitter (somebody sent it to me – I could not see it because I was already blocked).\n\n\n\nMy reply to Perlis’ tweet\n\nAnd my commented retweet\n\n\n\n\n\n\n\nReferences\n\n1. Perlis, R. The time has come for over-the-counter antidepressants. (2024).\n\n\n2. Hengartner, M. P. Evidence-Biased Antidepressant Prescription: Overmedicalisation, Flawed Research, and Conflicts of Interest. (Springer, 2021).\n\n\n3. Hengartner, M. P. & Plöderl, M. Statistically significant antidepressant-placebo differences on subjective symptom-rating scales do not prove that antidepressants work: Effect size and method bias matter! Frontiers in Psychiatry 9, (2018).\n\n\n4. Munkholm, K., Paludan-Müller, A. S. & Boesen, K. Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis. BMJ Open 9, e024886 (2019).\n\n\n5. Hengartner, M. P. & Plöderl, M. Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evidence-Based Medicine (2021) doi:10.1136/bmjebm-2020-111600.\n\n\n6. Plöderl, M. Some thoughts on the massive recent FDA patient level meta-analysis. (2022).\n\n\n7. Stone, M. B. et al. Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis. BMJ (Clinical research ed.) 378, e067606 (2022).\n\n\n8. Sahker, E. et al. Estimating the smallest worthwhile difference of antidepressants: a cross-sectional survey. BMJ Mental Health 27, e300919 (2024).\n\n\n9. Hengartner, M. P. How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding. Therapeutic Advances in Psychopharmacology 10, 204512532092169 (2020).\n\n\n10. Furukawa, T. A. et al. Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. World psychiatry: official journal of the World Psychiatric Association (WPA) 20, 387–396 (2021).\n\n\n11. Serretti, A. & Chiesa, A. Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis. Journal of Clinical Psychopharmacology 29, 259–266 (2009).\n\n\n12. SALSEX Working Study Group et al. A real-world study on antidepressant-associated sexual dysfunction in 2144 outpatients: The SALSEX I study. Archives of Sexual Behavior 48, 923–933 (2019).\n\n\n13. Davies, J. & Read, J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addictive Behaviors (2018) doi:10.1016/j.addbeh.2018.08.027.\n\n\n14. Fava, G. A., Gatti, A., Belaise, C., Guidi, J. & Offidani, E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: A systematic review. Psychotherapy and Psychosomatics 84, 72–81 (2015).\n\n\n15. Nutt, D. J., Goodwin, G. M., Bhugra, D., Fazel, S. & Lawrie, S. Attacks on antidepressants: signs of deep-seated stigma? The Lancet Psychiatry 1, 102–104 (2014).\n\n\n16. Daws, R. E. et al. Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine 28, 844–851 (2022).\n\n\n17. Selalmazidou, A.-M. & Bschor, T. Depression: Niedrigschwellige Kardinalmaßnahmen als Basis jeder Behandlung. Fortschritte der Neurologie · Psychiatrie 91, 523–534 (2023).\n\n\n18. Stone, M. B. et al. Risk of suicidality in clinical trials of antidepressants in adults: Analysis of proprietary data submitted to US food and drug administration. BMJ 339, 1–10 (2009).\n\n\n19. Hengartner, M. & Plöderl, M. Newer-Generation Antidepressants and Suicide Risk in Randomized Controlled Trials: A Re-Analysis of the FDA Database. Psychotherapy and Psychosomatics 88, 247–248 (2019).\n\n\n20. Plöderl, M., Hengartner, M. P., Bschor, T. & Kaminski, J. A. Commentary to \"antidepressants and suicidality: A re-analysis of the re-analysis\". Journal of Affective Disorders 273, 252253 (2020).\n\n\n21. Baldessarini, R. J., Lau, W. K., Sim, J., Sum, M. Y. & Sim, K. Suicidal risks in reports of long-term treatment trials for major depressive disorder. The international journal of neuropsychopharmacology 19, pyv107 (2015).\n\n\n22. Braun, C., Bschor, T., Franklin, J. & Baethge, C. Suicides and suicide attempts during long-term treatment with antidepressants: A meta-analysis of 29 placebo-controlled studies Including 6,934 patients with major depressive disorder. Psychotherapy and Psychosomatics 85, 171–179 (2016).\n\n\n23. Barbui, C., Esposito, E. & Cipriani, A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. Canadian Medical Association Journal 180, 291–297 (2009).\n\n\n24. Hengartner, M. P. et al. Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: a systematic review and meta-analysis of observational studies. Journal of Epidemiology and Community Health 75, 523–530 (2021).\n\n\n25. Border, R. et al. No Support for Historical Candidate Gene or Candidate Gene-by-Interaction Hypotheses for Major Depression Across Multiple Large Samples. American Journal of Psychiatry 176, 376–387 (2019).\n\n\n26. Curtis, D. Analysis of 50,000 exome-sequenced UK Biobank subjects fails to identify genes influencing probability of developing a mood disorder resulting in psychiatric referral. Journal of Affective Disorders 281, 216–219 (2021).\n\n\n27. Winter, N. R. et al. Quantifying Deviations of Brain Structure and Function in Major Depressive Disorder Across Neuroimaging Modalities. JAMA Psychiatry 79, 879 (2022).\n\n\n28. Kennis, M. et al. Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. Molecular Psychiatry 25, 321–338 (2020)."
  },
  {
    "objectID": "blogs/Perlis_response/index.html#references",
    "href": "blogs/Perlis_response/index.html#references",
    "title": "Response to ‘The time has come for over-the-counter antidepressants’ by Roy Perlis",
    "section": "References",
    "text": "References"
  },
  {
    "objectID": "blogs/Response-Lewis/index.html",
    "href": "blogs/Response-Lewis/index.html",
    "title": "Response to the talk by Lewis et al.",
    "section": "",
    "text": "In their talk titled “The antidepressant wars”, Glen Lewis, Tania Gergel, and Edoardo Ostinelli from the Royal College of Psychiatrists, argue that critical views on antidepressants parallel climate change denial, post-truth, Trumpism etc. and thus creating discrimination and harm. Issues that I see as deeply problematic and harmful, too. I was provided a recording of this talk and realized that some of my/our scientific work was misrepresented. The talk also includes too many problematic statements from an evidence-based medicine point of view, so I felt like I need to respond.\nA goal of their talk was to provide a nuanced summary of the evidence on antidepressants so to “Be able to explain the evidence for and against antidepressants to patients and their families.” Indeed, Lewis et al. do mention some critical points about antidepressants. For example, the ever increasing rates of prescriptions and long-term use is “alarming”. Or that there are some problems with the evidence base (old trials, industry trials, narrow focus, smaller effect sizes in newer trials). This creates some nuance. However, the overall picture emerging from the talk is still too problematic and does not keep the promise of nuance, as I will outline below.\nGiving the impression that there is scientific consensus about the efficacy of antidepressants\nLewis et al. claim that there is a lot of evidence about the effectiveness of antidepressants, with the large Cipriani et al. systematic review of clinical trials as highlight (Cipriani et al., 2018). Despite the substantial evidence showing that antidepressants were significantly superior to placebo, Lewis et al. wonder why there is still the “massive” controversy. There is a straighforward answer which Lewis et al. don’t mention clearly enough: when taking into account clinical significance, drug-placebo differences are most likely not clinically meaningful. Furthermore when considering methodological biases, the (small) effects are likely overestimations of actual effects. Consequently, a critical view on antidepressants is the logical conclusion, for example that the efficacy is uncertain (Munkholm et al., 2019) or even that, when considering the harms of antidepressants, these meds should not be used (Jakobsen et al., 2019). These conclusions are from respected researchers and were published in BMJ journals. In our paper in response to Cipriani et al, we come to comparable conclusions, too (Hengartner and Plöderl, 2018).\nMisleading reporting and spinning of the PANDA results\nThe criticism around industry trials done in secondary care is a reason for Lewis et al. to bring in the PANDA trial, where Lewis was author of the related publication (Lewis et al., 2019). They tell the audience that, in the PANDA trial, the main benefit of sertraline is for anxiety, where the effects were clinically significant. Later, they also mention the result for a single item where patients were asked if they felt better: 59% felt better on sertraline and 42% on placebo. For listeners not familiar with the PANDA trial, this sounds like a success story. However, these are case in point examples of spin and outcome-switching, two problematic research practices. To spin a results means the selective reporting of favorable results and hiding of unfavorable results. Outcome switching refers to changing the primary outcome with a secondary outcome which shows more convenient findings. In this case, Lewis et al. did not inform the audience about the pre-specified primary outcome in PANDA, which was the drug-placebo difference in the reduction of depression symptoms as measured with the Patient Health Questionnaire. This primary outcome was not statistically significantly and very small, with an effect size (ES) of 0.09 at week 6 and 0.18 at week 12. Interestingly, in the appendix, there are a lot of subgroup differences and it can be explored if efficacy is better for severely depressed people, but there was no evidence for this. Instead of reporting the results for the PHQ, the primary outcome, Lewis et al. selectively mentioned secondary outcomes with significant drug-placebo differences, but missed to report that the effect sizes were again small (ES &lt; 0.25). Later in the talk, when discussing clinical significance, Lewis et al. said that the efficacy in the PANDA was clinically meaningful for anxiety but “perhaps” not for depression. Both is wrong or at least misleading, because the effects for anxiety were small too, and thus likely not statistically significant. The finding for depression was not of “uncertain” clinical significance but it was clearly not so when using common thresholds of clinical significance. It wasn’t even statistically significant. This kind of spin is also found in the abstract of the original publication in the high-impact Journal of the American Medical Association (JAMA). Despite that PANDA failed in the primary outcome, authors concluded: “Our findings support the prescription of SSRI antidepressants in a wider group of participants than previously thought, including those with mild to moderate symptoms who do not meet diagnostic criteria for depression or generalized anxiety disorder”. This should never have passed peer review. We summarized the criticism in a letter (Hengartner et al., 2020).\nMoreover, when giving a talk about the efficacy of antidepressants, instead of relying on results from a single RCT, the audience should have an overview on other existing “real world” studies.\nLewis et al. also referred to the recent FDA study (Stone et al., 2022) where, compared to placebo, an additional 15% of patients on antidepressants were were categorized as having a “large response”, with a mean symptom reduction of 16 points on the Hamilton Depression Rating Scale (HDRS). As many others, Lewis et al. made the error of interpreting this as “15% difference in patients experiencing a large response”. This is erroneous because the latent classes in the statistical model are substantially overlapping. Taking this into account, the drug-placebo difference in „responder“ status is about 11% at best, and only 6% when using a reduction of 16 HDRS points as criterion for “response”, which is the mean symptom reduction in the “large response” category (Plöderl, 2022).\nIgnoring the work on clinical significance and accounting for harms of treatment\nNext, Lewis et al. talk about how to interpret the clinical importance of the drug-placebo differences. They say that Cipriani et al. reported an ES of 0.2 but that it is difficult to judge if this is clinically important. What they miss to mention is that there is a lot of work about this. In our review of different approaches to estimate clinical significance/importance, it became clear that the efficacy of antidepressants found in clinical trials is not exceeding the lower limit of different cut-offs for clinical significance (Hengartner and Plöderl, 2021). Instead of providing the bigger picture, Lewis et al. again focused on the PANDA trial. And they again do not present the main outcome, that is, the effect on depression symptoms, but on a secondary outcome, anxiety. As already mentioned above, the effect size for anxiety is also small: ES = 0.25 at 6 weeks (estimated from results in Table 3 in the PANDA publication). Clinical meaningful difference usually start at ES = 0.5, thus the efficacy for anxiety is most likely not clinically significant.\nFrom a broader view, which should be taken in a talk about the efficacy of antidepressants, it is important to also look at the harm/benefit ratio. Here, the concept of the “smallest worthwhile difference” is important (Barrett et al., 2005), where patients judge how efficacious a drug must be to be worth using, when also considering costs and harms. According to Barrett, the smallest worthwhile difference is equal or larger then the minimal important difference (clinical significance). Strikingly, despite the longstanding controversy and the ever increasing prescription rates, only very recently a first study on the smallest worthwhile difference appeared for antidepressants (Sahker et al., 2024). The study authors have a high reputation within psychiatry. They found that only two out of three patients (Sahker et al., 2024) considered antidepressants as worthwhile. Put differently, two-thirds of patients would not consider antidepressants as worthwhile, if they really knew about the efficacy and harms.\nThe incomplete picture on antidepressants and suicides and its controversy\nThen there is the section about antidepressants and suicide risk, where our research (Hengartner and Plöderl, 2019a) was criticized for using the wrong method but that a correct method used by others (Hayes et al., 2019) came to different conclusions. Because this was about our research, I provide a more thorough description of the misleading information.\nOur study was actually only a short letter in response to a study about the FDA data-set by Khan et al. (2018) who used “patient exposure years” as outcome and concluded that there was no significant drug-placebo difference in suicide risk. However, it is known that most suicidal behavior occurs at the beginning of clinical trials, and when the risk for such events is not constant across time, analysis of patient exposure years is misleading (interestingly, nobody seemed to have issues with this misleading analysis). Therefore, we ran a simple analysis based on the proportion of suicidal events in drug and placebo arms, finding a statistically significant elevated risk for suicides (OR = 2.83, 95% CI = 1.13–9.67, p = 0.02) and suicide attempts (OR = 2.38, 95% CI = 1.63–3.61, p &lt; 0.01) (Hengartner and Plöderl, 2019a). This was not a meta-analysis, as Lewis et al. incorrectly told the audience but only a letter to show that a more appropriate analysis revealed significantly more suicides and suicide attempts with antidepressants than with placebo.\nLewis et al. explained that their colleague Joe Hayes performed “all these other meta-analysis that he and everybody else know of” and these analyses showed that there is no significant increase of suicides with antidepressants. Lewis was coauthor of the letter which was published in response to our letter (Hayes et al., 2019). In the talk, the impression arose that an appropriate statistical analysis leads to a different picture and that we failed to apply these appropriate methods. Is this true? In response to Hayes et al., we agreed that a meta-analytic method is more appropriate than our crude analysis, but this would have gone beyond the scope of our original letter where we only wanted to show how misleading analysis based on patient exposure years may be. We only had two weeks to reply to the letter by Hayes et al. and our reply, which included different meta-analytic approaches, was then published together with Hayes’ letter (Hengartner and Plöderl, 2019b). The results are summarized in the table below. There are two problems with Hayes et al.’s meta-analyses. First, some of their methods are not optimal for the data at hand, where events were rare and sometimes there we no events at all. There is no consensus how to deal with such data, but some of the methods Hayes et al. used are not recommended in these instances (Ren et al., 2019; Xu et al., 2022). Several methods are recommended, but this was missed by Hayes et al. (e.g, the exact method or the arcsine risk difference method). This gives the impression that Hayes et al. were selective in choosing methods and not aware that some of them are inappropriate. In contrast, in our meta-analyses, we provided more methods and more appropriate ones, and we did it in a transparent way, making the data and code publicly available. In line with Hayes et al., we found that the drug-placebo differences for suicides were not statistically significant anymore. But I want to stress that we described the evidence for suicides as weak already in our original crude analysis. However, for suicide attempts, the drug-placebo differences remained consistently statistically significant. Strikingly, Hayes et al. did not provide any results for suicide attempts! It seems that they not only selectively had chosen the methods but also selectively reported the outcomes.\nBecause we became aware that two suicides in the placebo groups in the paroxetine trials actually happened in the placebo lead-in phase and were falsely added to the placebo group, we also provided an additional corrected analysis in our reply to Hayes et al. (see third column in the table below). This resulted in three statistically significant findings for suicides out of the five analysis.\nLater, two psychiatrists from Germany published a full paper about our letter and the controversy between Hayes et al. and us and and provided their own meta-analysis of the data (Kaminski and Bschor, 2020), which is also summarized in the table below. They provided a wider range of meta-analytical methods (with some of them ending up in a significant difference for suicides) and a more appropriate Bayesian analysis, which is likely the superior approach with the data at hand. Overall, it became clear that, for suicides, the results are sensitive to the choice of the meta-analytic methods. Not so for suicide attempts, where results were statistically significant in most analyses. We then invited Kaminski and Bschor to publish a response together. They accepted, and a collaborative commentary where we outlined our consensus was published (Plöderl et al., 2020). We agreed that it is important to use the corrected data-set (removing the two misclassified suicides) and that their Bayesian method was the method of choice for such data. We also addressed the (fierce) debate on Twitter about our initial analysis. The most important caveat that Micheal Hengartner and me did not discuss in our initial publication (and I regret that until today), but that also Hayes et al., and Kaminski and Bschor missed, is that the analysis may be biased because the trial data-base also included some extension phases where patients on the drug but not on placebo are observed longer. If suicidal behavior occurs in this phase, than this would lead to an overestimation of the harmful effect of antidepressants. On the other hand, it is known that there is selective misclassification, leading to an underestimation of harmful effects of antidepressants, including suicides and suicide attempts (Le Noury et al., 2015; Sharma et al., 2016). Taking these uncertainties into account, we concluded with “Nonetheless, the analyses consistently hint at an elevated risk for suicide attempts and, less reliably, also for suicides in cohorts of adults. This is remarkable for drugs that are used to treat depressive symptoms” (Plöderl et al., 2020). This is a humble and unbiased look at the evidence and can hardly be dismissed.\nUnfortunately, Lewis et al. did not provide a more complete summary of the controversy surrounding antidepressants and suicides. Whereas the findings for suicides and antidepressant use may be considered as inconclusive for adults, suicide attempts were consistently more often found in antidepressants than placebo among young adults (Stone et al., 2009) and among children/adolescents for SSRIs as a group compared to placebo (Hetrick et al., 2021). The RCT-data for older adults is inconclusive for suicides but reduced suicide attempt rates were found with antidepressants (Stone et al., 2009). Furthermore, results from longer-term RCTs on adults again show a significant increased risk for suicide attempts for patients on antidepressants compared to placebo, and rates of suicides are higher too, but not statistically significant (Baldessarini et al., 2015; Braun et al., 2016). Then there are the many observational studies, which found an increased risk for suicide attempts and suicides among children and adolescents who used antidepressants compared to non-users (Barbui et al., 2009; Dragioti et al., 2019). Among adults, for suicide attempts the results are also unfavorable for antidepressants, but perhaps inconclusive for suicides (Hengartner et al., 2021). During our systematic review we also found that favorable results from observational studies are selectively published in psychiatric journals and that there is strong evidence for the presence of publication bias, suggesting that unfavorable results are not published/reported (Plöderl et al., 2023a). For a discussion with more updated evidence, see my discussion with Awais Aftab https://www.psychiatrymargins.com/p/antidepressants-and-the-tangle-of.\nIn summary, an unbiased view on the evidence about antidepressants and suicides should be cause for concern. It is striking that, in their talk, Lewis et al. only mentioned our study and their correction, but missed to give a broader view on the evidence. Instead, they say they wonder why there is still the controversy despite no evidence for an increase of suicides with antidepressants. This is obviously a misleading and biased view on the evidence.\nUndermining the scientific consensus, headlines, populism, post-truth, Trumpism,…\nIn their conclusion, Lewis et al. draw parallels between the antidepressant controversy and conspiracy, post-truth, Trumpism, anti-elite, undermining liberal democracy, undermining scientific consensus such as with climate change and that “facts seem less influential almost than a kind of opinion an emotional personal belief”. In my opinion, these are very bad comparisons. For example, for climate change, no serious scientist would doubt the scientific consensus that human carbon emission is causally responsible for global warming. Critical positions were perhaps possible many years ago, but scientific data converged.\nFor antidepressants, the picture is quite different. With more and better research and the consideration of unpublished trials, efficacy got smaller, and it is now more certain that the efficacy is poor and most likely not clinically meaningful for a majority of patients. New research about the smallest worthwhile difference confirmed this. Furthermore, we now know that efficacy is not better (or not much better) for severe depression (also confirmed with the PANDA data), as often claimed, and guidelines had changed accordingly. Now antidepressant are one of several options even for severe depression, whereas previous guidelines clearly recommended antidepressants as first line here. Even in the latest analysis of the FDA database, it became clear that the vast majority does not improve more on antidepressants compared to placebo (Stone et al., 2022). Therefore, in contrast to climate change debates, there is simply no scientific consensus that antidepressants are “working”, therefore the ongoing controversy within the scientific community. I don’t like the binary “work” vs. “does not work” because “work” is an ambiguous term, but the evidence base is more compatible with a “does not work” conclusion than with the claim that antidepressant work. The widespread (over)prescription and the common public believe that antidepressants correct a chemical imbalance contrasts with the evidence about the poor efficacy and the problematic harm/benefit ratio for most patients who take antidepressants. No wonder that journalists and people are surprised or angry to be informed about this discrepancy. And of course I totally agree it is not good to see how this fuels conspiracy and causes further loss of trust. Here it is important to mention that one does not need to assume conspiracy, as many do on social media. Much simpler, it is just typical for systems to confirm their own beliefs and to prevent criticism. That’s just human. But this shows that critical viewpoints from outside are urgently needed (BTW, as someone working in psychiatry, I consider myself as insider).\nThere’s hypocrisy in Lewis et al.s’ line of argumentation. When there was enthusiasm about the new generation antidepressants with overblown news headlines, it was already discussed that the efficacy is not so good and that there are safety issues (Prozac, for example, was initially rejected in Germany until a key opinion leader took action). Where was the complaint of serious, evidence based psychiatrists about the overly optimistic media presentations? I want to give some more examples where psychiatry reacted with silence mainly/only.\nFirst, when newer generation antidepressants were introduced and increasingly prescribed, there was a reduction of suicide rates in many countries and this was seen as evidence that antidepressants reduced suicide rates and that antidepressants might be a medical breakthrough in suicide prevention (Isacsson, 2000; Mann et al., 2005; Zalsman et al., 2016). However, in the past 10-20 years, the association between antidepressant prescriptions (which are ever increasing) and suicide rates were not in favor of antidepressants anymore (Amendola et al., 2024; Högberg and Bremberg, 2018). No related papers appeared in typical psychiatric journals anymore. Second, in the new Cochrane review on antidepressants for children and adolescents (Hetrick et al., 2021), efficacy of fluoxetine imploded and was only around ES = 0.2 anymore. This is an example of novelty bias where it turns out that drugs loose efficacy in trials not done by the sponsor and where the older drug is used as comparator drug. In contrast, the effect size of fluoxetine was around ES = 0.5 in an influential older meta-analysis (Cipriani et al., 2016) and also the only drug with a significant drug-placebo difference and thus the only recommended drug according to Cipriani et al. Since the appearance of the Hetrick et al. meta-analysis I did not come across any correction of the now outdated recommendation for fluoxetine, increasing the risk of exposing children and adolescents unnecessarily with flouxetine. Third, there was the recent approval of escitalopram for generalized anxiety disorders in children and adolescents. However, in the approval study, it turned out that it was more likely that children/adolescents became suicidal during the trial than to improve in anxiety symptoms (Plöderl et al., 2023b). I am not aware of any critical response from mainstream psychiatry. And it was impossible for us so far to publish a short letter in psychiatric journals, despite several attempts. I want to add another recent very disturbing study which found that most patients who start an antidepressant prescribed by GPs are not monitored as recommended (Hansen et al., 2024), potentially creating harm. I wonder if this study, which did not appear in a psychiatric journal, will be discussed in mainstream psychiatry and efforts will be taken to improve the situation.\nUnfortunately, in their attempt to provide a nuanced view on antidepressants, Lewis et al. made too many problematic and misleading claims. They should have done better. Having published several critical papers on antidepressants myself, I experienced that this only can be done very carefully and with much rigor and with way more nuance than what can be found in the talk by Lewis et al., or in typical reviews in psychiatric journals. For example, I would never have chosen strong titles such as “The war on antidepressants.” In the figure below I try to visualize the the double-standards as landscape of biases”.\nInterestingly, in a study where psychiatrists were asked what they would do when they were depressed themselves, the majority of psychiatrists would not take antidepressants but would nonetheless recommend antidepressants to depressed patients. Furthermore, if asked by patients what they would do for themselves, they would not admit not to take antidepressants (Mendel et al., 2010) (this study was replicated recently with similar findings and should be published soon). Fortunately, there is an increasing number of physicians and psychiatrists who take the evidence seriously and change their practice accordingly.\n\nReferences\nAmendola S, Plöderl M and Hengartner MP. Suicide Rates and Prescription of Antidepressants: Trends in the United States, 1999–2020, by Sex and Race/Ethnicity. Crisis 2024;45(3):225–233; doi: 10.1027/0227-5910/a000941.\nBaldessarini RJ, Lau WK, Sim J, et al. Suicidal Risks in Reports of Long-Term Treatment Trials for Major Depressive Disorder. Int J Neuropsychopharmacol 2015;19(3):pyv107; doi: 10.1093/ijnp/pyv107.\nBarbui C, Esposito E and Cipriani A. Selective Serotonin Reuptake Inhibitors and Risk of Suicide: A Systematic Review of Observational Studies. Can Med Assoc J 2009;180(3):291–297; doi: 10.1503/cmaj.081514.\nBarrett B, Brown D, Mundt M, et al. Sufficiently Important Difference: Expanding the Framework of Clinical Significance. Med Decis Making 2005;25(3):250–261; doi: 10.1177/0272989X05276863.\nBraun C, Bschor T, Franklin J, et al. Suicides and Suicide Attempts during Long-Term Treatment with Antidepressants: A Meta-Analysis of 29 Placebo-Controlled Studies Including 6,934 Patients with Major Depressive Disorder. Psychother Psychosom 2016;85(3):171–179; doi: 10.1159/000442293.\nCipriani A, Salanti G, Furukawa TA, et al. Network Meta-Analysis of Antidepressants - Authors’ Reply. Lancet 2018;392(10152):1012–1013; doi: 10.1016/S0140-6736(18)31780-X.\nCipriani A, Zhou X, Del Giovane C, et al. Comparative Efficacy and Tolerability of Antidepressants for Major Depressive Disorder in Children and Adolescents: A Network Meta-Analysis. The Lancet 2016;388(10047):881–890; doi: 10.1016/S0140-6736(16)30385-3.\nDragioti E, Solmi M, Favaro A, et al. Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review. JAMA Psychiatry 2019;76(12):1241; doi: 10.1001/jamapsychiatry.2019.2859.\nHansen AB, Hetlevik Ø, Baste V, et al. Variation in General Practitioners’ Follow-up of Depressed Patients Starting Antidepressant Medication: A Register-Based Cohort Study. Fam Pract 2024;cmae063; doi: 10.1093/fampra/cmae063.\nHayes JF, Lewis G and Lewis G. Newer-Generation Antidepressants and Suicide Risk. Psychother Psychosom 2019;88(6):371–372; doi: 10.1159/000502295.\nHengartner MP, Amendola S, Kaminski JA, et al. Suicide Risk with Selective Serotonin Reuptake Inhibitors and Other New-Generation Antidepressants in Adults: A Systematic Review and Meta-Analysis of Observational Studies. J Epidemiol Community Health 2021;75:523–530; doi: 10.1136/jech-2020-214611.\nHengartner MP and Plöderl M. Statistically Significant Antidepressant-Placebo Differences on Subjective Symptom-Rating Scales Do Not Prove That Antidepressants Work: Effect Size and Method Bias Matter! Front Psychiatry 2018;9; doi: 10.3389/fpsyt.2018.00517.\nHengartner MP and Plöderl M. Newer-Generation Antidepressants and Suicide Risk in Randomized Controlled Trials: A Re-Analysis of the FDA Database. Psychother Psychosom 2019a;88(4):247–248; doi: 10.1159/000501215.\nHengartner MP and Plöderl M. Reply to the Letter to the Editor: “Newer-Generation Antidepressants and Suicide Risk: Thoughts on Hengartner and Plöderl’s Re-Analysis.” Psychother Psychosom 2019b;88(6):373–374; doi: 10.1159/000502485.\nHengartner MP and Plöderl M. Estimates of the Minimal Important Difference to Evaluate the Clinical Significance of Antidepressants in the Acute Treatment of Moderate-to-Severe Depression. BMJ Evid-Based Med 2021;(2021); doi: 10.1136/bmjebm-2020-111600.\nHengartner MP, Plöderl M, Braillon A, et al. Sertraline in Primary Care: Comments on the PANDA Trial. Lancet Psychiatry 2020;7(1):17; doi: 10.1016/S2215-0366(19)30381-5.\nHetrick SE, McKenzie JE, Bailey AP, et al. New Generation Antidepressants for Depression in Children and Adolescents: A Network Meta-Analysis. Cochrane Common Mental Disorders Group. ed. Cochrane Database Syst Rev 2021;2021(5); doi: 10.1002/14651858.CD013674.pub2.\nHögberg GN and Bremberg SG. Antidepressant Medication Might Increase the Risk of Self-Harm Injuries: Findings in 17 OECD Countries. Eur J Public Health 2018; doi: 10.1093/eurpub/cky268.\nIsacsson G. Suicide Prevention - a Medical Breakthrough? Acta Psychiatr Scand 2000;102(2):113–117; doi: 10.1034/j.1600-0447.2000.102002113.x.\nJakobsen JC, Gluud C and Kirsch I. Should Antidepressants Be Used for Major Depressive Disorder? BMJ Evid-Based Med 2019;bmjebm-2019-111238; doi: 10.1136/bmjebm-2019-111238.\nKaminski JA and Bschor T. Antidepressants and Suicidality: A Re-Analysis of the Re-Analysis. J Affect Disord 2020;266:95–99; doi: 10.1016/j.jad.2020.01.107.\nKhan A, Fahl Mar K, Gokul S, et al. Decreased Suicide Rates in Recent Antidepressant Clinical Trials. Psychopharmacology (Berl) 2018;235(5):1455–1462; doi: 10.1007/s00213-018-4856-1.\nLe Noury J, Nardo JM, Healy D, et al. Restoring Study 329: Efficacy and Harms of Paroxetine and Imipramine in Treatment of Major Depression in Adolescence. BMJ 2015;h4320; doi: 10.1136/bmj.h4320.\nLewis G, Duffy L, Ades A, et al. The Clinical Effectiveness of Sertraline in Primary Care and the Role of Depression Severity and Duration (PANDA): A Pragmatic, Double-Blind, Placebo-Controlled Randomised Trial. Lancet Psychiatry 2019;6(11):903–914; doi: 10.1016/S2215-0366(19)30366-9.\nMann JJ, Apter A, Bertolote J, et al. Suicide Prevention Strategies: A Systematic Review. JAMA 2005;294(16):2064–2074; doi: 10.1001/jama.294.16.2064.\nMendel R, Hamann J, Traut-Mattausch E, et al. ‘What Would You Do If You Were Me, Doctor?’: Randomised Trial of Psychiatrists’ Personal v. Professional Perspectives on Treatment Recommendations. Br J Psychiatry 2010;197(6):441–447; doi: 10.1192/bjp.bp.110.078006.\nMunkholm K, Paludan-Müller AS and Boesen K. Considering the Methodological Limitations in the Evidence Base of Antidepressants for Depression: A Reanalysis of a Network Meta-Analysis. BMJ Open 2019;9(6):e024886; doi: 10.1136/bmjopen-2018-024886.\nPlöderl M. Some Thoughts on the Massive Recent FDA Patient Level Meta-Analysis by Stone et Al. 2022. Available from: https://graz.social/@ploederl/109466156260340519.\nPlöderl M, Amendola S and Hengartner MP. Observational Studies of Antidepressant Use and Suicide Risk Are Selectively Published in Psychiatric Journals. J Clin Epidemiol 2023a;162:10–18; doi: 10.1016/j.jclinepi.2023.07.015.\nPlöderl M, Hengartner MP, Bschor T, et al. Commentary to “Antidepressants and Suicidality: A Re-Analysis of the Re-Analysis”. J Affect Disord 2020;273:252–253; doi: 10.1016/j.jad.2020.04.025.\nPlöderl M, Horowitz MA and Hengartner MP. Re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et al.—Concerning Harm–Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder. J Child Adolesc Psychopharmacol 2023b;33(7):295–296; doi: 10.1089/cap.2023.0029.\nRen Y, Lin L, Lian Q, et al. Real-World Performance of Meta-Analysis Methods for Double-Zero-Event Studies with Dichotomous Outcomes Using the Cochrane Database of Systematic Reviews. J Gen Intern Med 2019;34(6):960–968; doi: 10.1007/s11606-019-04925-8.\nSahker E, Furukawa TA, Luo Y, et al. Estimating the Smallest Worthwhile Difference of Antidepressants: A Cross-Sectional Survey. BMJ Ment Health 2024;27(1):e300919; doi: 10.1136/bmjment-2023-300919.\nSharma T, Guski LS, Freund N, et al. Suicidality and Aggression during Antidepressant Treatment: Systematic Review and Meta-Analyses Based on Clinical Study Reports. BMJ 2016; doi: 10.1136/bmj.i65.\nStone MB, Laughren TP, Jones ML, et al. Risk of Suicidality in Clinical Trials of Antidepressants in Adults: Analysis of Proprietary Data Submitted to US Food and Drug Administration. BMJ 2009;339:1–10.\nStone MB, Yaseen ZS, Miller BJ, et al. Response to Acute Monotherapy for Major Depressive Disorder in Randomized, Placebo Controlled Trials Submitted to the US Food and Drug Administration: Individual Participant Data Analysis. BMJ 2022;378:e067606; doi: 10.1136/bmj-2021-067606.\nXu C, Furuya-Kanamori L, Islam N, et al. Should Studies with No Events in Both Arms Be Excluded in Evidence Synthesis? Contemp Clin Trials 2022;122:106962; doi: 10.1016/j.cct.2022.106962.\nZalsman G, Hawton K, Wasserman D, et al. Suicide Prevention Strategies Revisited: 10-Year Systematic Review. Lancet Psychiatry 2016;3(7):646–659; doi: 10.1016/S2215-0366(16)30030-X.\n\n\nTable\n\n\n\n\n\n\n\n\n\n\nSuicide attempts\nSuicides\nSuicides,\ncorrected data b\n\n\nKhan et al. 2018 (PEY)\np &gt; 0.05\np &gt; 0.05\n\n\n\nHengartner & Plöderl 2019a\n2.4 (1.6–3.6)*\n2.8 (1.1–9.7)*\n\n\n\nHayes et al. 2019\n\n\n\n\n\nBayesian\nnothing reported\n1.2 (0.5–2.3)\n\n\n\nPeto\nnothing reported\n1.7 (0.8–3.9)\n\n\n\nMH without cc c\nnothing reported\n0.7 (0.2–2.2)\n\n\n\nMH with cc\nnothing reported\n1.4 (0.6–3.2)\n\n\n\nInverse variance heterogeneity model (with cc)\nnothing reported\n1.1 (0.5–2.6)\n\n\n\nDerSimonian and Laird (with cc)\nnothing reported\n1.1 (0.5–2.6)\n\n\n\nReciprocal of opposite treatment arm\ncorrection (including both-armed zero event studies)\nnothing reported\n1.6 (0.7–3.5)\n\n\n\nHengartner & Plöderl 2019b\n\n\n\n\n\nBayesian\n1.7 (1.1-2.9)*a\n2.5 (0.8–45.3)\n5.7 (1.4–427.5)*\n\n\nExact method\n1.6 (1.1-2.50*a\n1.9 (0.6–15.0)\n3.5 (0.8–768.6)\n\n\nPeto\n1.5 (1.1-2.2)*a\n1.7 (0.8-3.9)\n2.4 (1.1–5.5)*\n\n\nMH\n1.6 (1.1-2.4)*a\n2.00 (0.7-5.5)\n4.0 (1.00–16.2)\n\n\nArcsine (% risk difference)\n\n0.1 (0.0-0.2)\n0.1 (0.0–0.2)*\n\n\nKaminski & Bschor (2020)\n\n\n\n\n\nBayesian (replication Hengartner & Plöderl)\n1.7 (1.1-2.9)*\n2.5 (0.8-38.2)\n\n\n\nBayesian 2 (weakly informative prior)\n1.7 (1.1-3.0)*\n2.0 (0.8-6.1)\n\n\n\nPeto without cc\n1.5 (1.1-2.2)*\n1.7 (0.8-3.9)\n\n\n\nMH without cc\n1.6 (1.1-2.4)*\n2.0 (0.7-5.5)\n\n\n\nMH with cc\n1.6 (1.1-2.4)*\n1.8 (0.7-4.4)\n\n\n\nBeta binomial model\n1.6 (0.6-4.5)\n2.3 (1.1-4.8)*\n\n\n\nArcsine,fixed effect (risk difference)\n0.02 (0.0-0.03)*\n0.01 (0.0-0.02)*\n\n\n\nArcsine, random effects (risk difference)\n0.2 (0.0-0.4)*\n0.02 (0.0-0.05)*\n\n\n\nInverse variance with cc (risk difference)\n1.5 (1.0-1.3)\n1.1 (0.5-2.6)\n\n\n\nInverse variance with treatment arm cc\n1.5 (1.0-2.27)\n1.1 (0.4 to 3.0)\n\n\n\nPlöderl, Hengartner, Bschor,\nKaminski (2020)\n\n\n\n\n\nBayesian, noninformative prior\n1.7 (1.1 - 3.0)*\n\n3.7 (1.2 - 18)*\n\n\nBayesian, weakly informative prior\n1.7 (1.1 - 3.0)*\n\n3.5 (1.2 - 15)*\n\n\nBayesian, very informative prior\n1.7 (1.1 - 2.9)*\n\n2.9 (1.1 - 10)*\n\n\n\na Not reported in paper but, Median instead of mean (skewed distribution)\nb There were misclassified suicides\nc cc: continuity correction\n* 95%-confidence interval or 95%-credible interval excluding the null-effect (OR = 1)\n\n\nFigure"
  },
  {
    "objectID": "blogs/MAHA-responses/index.html",
    "href": "blogs/MAHA-responses/index.html",
    "title": "A call for evidence based, fear-free practice",
    "section": "",
    "text": "October 02, 2025\nIn this blog I will take a closer look at two statements by leading psychiatrists (Olfson, 2025; Strawn & Walkup, 2025) in response to the criticism about psychiatric drugs raised by “Make America Healthy Again” (MAHA) (The White House, 2025). Without doubt, there are good reasons to be critical of MAHA. For example, as I am writing this (22. September 2025), the US Department of Health and Human Services suggested explanations for the seeming rise in autism based on poor arguments and at odds with the evidence. Some statements by Robert F. Kennedy are bizarre and not consistent with evidence based medicine. In general, the eroding of democracy and fascisic changes in the US and in other countries are deeply concerning, and this includes attacks on scientific freedom and the foundation of scientific reasoning.\nWhen criticizing MAHA, this should be done with scientific rigor. Furthermore, scientists need to be open to arguments independent of who bring the issues forward. For this reason, manuscripts are often blinded for peer review. In this regard, political divides aside, there likely would be consensus about the importance of topics in the MAHA report, such as childhood obesity, overprescription, or the problematic influence of the pharmaceutical industry. One topic in the MAHA report is the harm/benefit of psychiatric drugs for children and adolescents, including antidepressants. Indeed, for antidepressants, which is the focus of my article, there is evidence for overprescription and a long-standing debate within evidence based medicine about whether their benefit can be considered clinically meaningful and outweigh harm (Cipriani et al., 2016; Hengartner, 2021; Hetrick et al., 2021; Jakobsen et al., 2019; Munkholm et al., 2019).\nAfter the release of the MAHA report, influential psychiatrists have published responses in scientific journals. I was struck by the sometimes poor arguments and biases regarding antidepressants in these responses. Since this is an area where I published myself and have some knowledge of the evidence base, I decided to publish my viewpoints on the responses by leading psychiatrists (Olfson, 2025; Strawn & Walkup, 2025).\n\n“Psychotropic medications and child health” by Marc Olfson, JAMA Pediatrics\nWhen discussing antidepressants, Olfson focuses on the issue of suicide risk. I agree with Olfson that “depression is a key risk factor for suicide.” But he is wrong in how he selects and interprets evidence about the suicide protective effects of antidepressants. He wrote: “The NIMH Treatment for Adolescents With Depression Study [TADS] demonstrated that fluoxetine, especially when combined with cognitive behavioral therapy, can reduce suicidal thoughts.”\nAs pointed out by child and adolescent psychiatrist Dr. Lyus in a commentary, Olfson misrepresents the findings for suicide ideation in the TADS study. In fact, there was a near zero difference between fluoxetine and placebo, and a modest superiority of cognitive behavior therapy (CBT) alone and CBT combined with fluoxetine, compared to placebo (effects sizes ca. 0.3). Therefore, authors of the TADS concluded: “Suicidal ideation decreased with treatment, but less so with fluoxetine therapy than with combination therapy or CBT” (March et al., 2004).\nMoreover, Olfson also ignored the findings for suicide attempts in the TADS study, which are the more important “hard” outcome, telling more about actual risk for suicide than suicide ideation. In fact, there were significantly more suicide attempts with patients on fluoxetine (alone or in combination with CBT) than patients not on fluoxetine (CBT alone or placebo).\nFurthermore, by using the TADS study, Olfson is ignorant of the biases in psychiatric research, because the TADS study seems to be a case-in-point example. For example, in a separate publication of suicidal events occurring in the TADS study (Vitiello et al., 2009), the outcome for patients treated with fluoxetine were spun (see here for a detailed account). The TADS authors reported that suicidal events, of which 55% were associated with hospitalization, were not significantly elevated in patients on fluoxetine (14.7%, n = 16) than placebo (10.7%, n = 12). However, as later pointed out by Högberg et al. (2015), “it is of note that of those 12 placebo cases, 9 subjects were in fact taking fluoxetine medication”. For suicide attempts, this means that only 1 suicide attempts occurred in patients treated without fluoxetine, versus 17 suicide attempts in patients treated with fluoxetine. Only in a footnote in a table of the original publication it was mentioned that with a correct classification, suicidal events occurred significantly more often in patients with fluoxetine vs. placebo or CBT only. Högberg et al. also presented an overview about how the findings for suicidality were spun in the abstracts of the original TADS publications. In addition, very recently the “Restoring Invisible and Abandoned Trials” (RIAT) re-analysis of the TADS study was published, and it again revealed biases and spin (Aboustate et al., 2025). The RIAT team found that “In contrast to the original TADS Team’s reporting, there was a higher level of harm uncovered in allocation groups taking ﬂuoxetine, including 11 unreported suicide-related adverse events.”\nOlfson also omitted to mention that fluoxetine’s efficacy shrank into the range of clinical equivalence with placebo in a Cochrane meta-analysis from 2021 (Hetrick et al., 2021). This important finding has generally not been acknowledged in recent guidelines which still refer to outdated reviews of the evidence (Plöderl et al., 2025). Of note, in the Cochrane meta-analysis, the efficacy findings for other antidepressants were underwhelming as well, and there was also a small but statistically significant increase of suicide attempts among children and adolescents treated with SSRIs compared to placebo.\nWhen Olfson discusses the putative harmful effects of the FDA black box warning, he seems one-sided and uncritical about the evidence supporting the view that the warning led to an increase of suicides in young people due to reduced prescriptions. He references a systematic review of correlational and ecological data (Soumerai et al., 2024). Fortunately, Olfson addresses methodological limitations for this type of study. However, Olfson should also have been aware that important studies in this review have been debunked and that there is contradictory evidence (Spielmans et al., 2020; Stone, 2014, 2018). For example, one study included in the review (Lu et al., 2014) reported an increase of drug-poisonings after the black box warning. However, as immediately pointed out by commentators in the BMJ or in the New England Journal of Medicine (Stone, 2014), the authors used drug-poisonings with any intent (suicidal vs. nonsuicidal). When using intentional drug-poisoning as the more appropriate outcome, there was actually a decrease of such events after the black box warning. Moreover, the results of the statistical modelling approach (interrupted time series) are sensitive to the selection of the time-frame around the black box warning and the timing of the warning itself (Stone, 2018). Using a longer-time frame contradicts claims of a harmful effect of the black box warning (Plöderl & Hengartner, 2023). Instead, longer-term trends of antidepressant prescriptions and suicides leads to the conclusion that the black box warning became ineffective, given the increasing prescription rates and also suicides rates since the warning (see Figure). Finally, such observational/ecological data are inherently limited and cannot replace findings from the gold-standard randomized clinical trials which revealed significantly increased rates of suicide attempts in the drug arms, at least for SSRIs (Hetrick et al., 2021). Given the short-term nature of clinical trials and the rarity of suicides and suicide attempts, a look at observational studies is useful, despite their methodological limitations. Here, an increase of suicide attempts and even suicides with SSRIs vs. no treatment with SSRIs in well-controlled observational studies judged to be of high quality was found (Barbui et al., 2009; Dragioti et al., 2019). Consequently, even when considering uncertainty, the evidence does support the view that antidepressants increase suicidality in young people, and that the black box warning is justified.\nOlfson warns that “Downplaying the established effectiveness of psychotropic medications for children and adolescents, while overstating their risks, can lead to serious consequences.” But it seems he is biased too, just in the opposite direction. He could be blamed for exaggerating the effectiveness of psychotropic medications for children and adolescents, while downplaying their risks, which can harm patients and damage the reputation of evidence based medicine.\n\n\n“Fact versus Fear” by Jeffrey Strawn & John Walkup\nStrawn and Walkup present strong claims such as “When opinions trump scientiﬁc data and clinical pragmatism, children suffer the consequences, and clinicians are placed in a bind. Put simply, clinicians are faced with a dilemma: to adhere to clinical evidence and treat when appropriate with appropriate caution, or yield to opinion, anecdotal data, and political pressures”. Who would disagree that clinicians should follow the science and not political pressure. Clinicians also need access to unbiased summaries of the evidence and it seems that Strawn and Walkup don’t do a good job here.\nThey directly start with the black box warning as example of unintended consequences of “fear and alarm, despite that there were no suicides in the clinical database” and “too few actual attempts to identify any between-group differences”, so that the FDA had to mix any suicidal events, that is, suicide ideation and suicide attempts combined.\nThis suggests that a treatment related increase of suicide ideation alone does not warrant a black box warning. While this can be debated, Strawn & Walkup fail to mention evidence that there is also a significant increase of actual suicide attempts with SSRIs vs. placebo, as later confirmed in meta-analyses (Hetrick et al., 2021; Stone et al., 2009). It is also not surprising that no suicides occurred in the trial database, as suicides are rare events, especially in this age-group, and the trial database is underpowered to detect a signal for suicide. However, as already mentioned, a significant increase for both suicide attempts and suicides was reported in high-quality, well-controlled observational studies (Barbui et al., 2009; Dragioti et al., 2019). All this confirms the FDA’s decision to issue a black box warning.\nStrawn & Walkupp write: “In hindsight, these concerns were prescient. Following the boxed warning, antidepressant prescriptions for youth dropped sharply, 3 and suicide rates rose significantly in untreated adolescents. 4 “\nBoth claims are not supported with the selective and outdated evidence Strawn and Walkup use. Reference #3 is a study by Nemeroff et al. (2007), which only looked at the time to 2005. In our study where we looked at a longer time-frame to search for changes in trends of suicides, we could not detect change points in line with the assumption that the black box warning increased suicide rates (Plöderl & Hengartner, 2023). A change in the trend of suicide rates already occurred before the black box warning (around 2000) and the fluctuation seen around 2004 are compatible with noise. The decline in prescriptions was short-lived and both prescription rates and suicide rates started to rise again afterwards.\nFor the claim that “suicide rates rose significantly in untreated adolescents”, Strawn and Walkup reference to a study by Gibbons et al. (2012). However, this study is not about untreated depression at all, but is a meta-analysis of clinical trials investigating fluoxetine and venlafaxine. Interestingly this study reported that “For youths, no significant effects of treatment on suicidal thoughts and behavior were found,” and “The marginal ORs indicated a 61.3% decrease in the probability of suicidal thoughts or behavior for control [placebo] patients after 8 weeks of study participation and a 50.3% decrease for treated patients.” So referencing this study not only doesn’t make sense because it is not about untreated depression but it also confirms that treatment with antidepressants is not helpful or even harmful regarding suicidality as outcome.\nStrawn and Walkup then go on with “The unintended, but resultant, stigmatization of antidepressants and their prescribers is the lasting legacy of the boxed warning. Perception of the actual risk has morphed from suicidal thinking to an impression of more serious risk —“suicidal behavior” which can be interpreted as attempts and deaths.”\nThis claim implies that the actual risk associated with antidepressants does not extend to suicidal behavior. But this is wrong, as there is evidence from reviews of clinical trials for an increase of suicide attempts (vs. placebo) and evidence from observational studies regarding suicide attempts and suicides (vs. no treatment) in the treatment with antidepressants (see references above). None of this evidence is mentioned by Strawn and Walkup. Furthermore, a look at the ever increasing antidepressant prescriptions does not suggest that stigmatization is a problem. On the contrary, as already mentioned, this trend could support the view that the black box warning became ineffective and also that the finding of the poor efficacy of antidepressants is not acknowledged.\nThey then have issues comparing antidepressants with psychotherapy: “Medications may be more effective for addressing physiological symptoms (eg, insomnia, appetite disturbance), while therapy targets behavioral and cognitive dimensions (eg, avoidance, distortions).” Interestingly, they don’t give a reference here. They also ignore the fact that for their example of insomnia there is significantly increased risk in young people treated with antidepressants than with placebo (Türkmen et al., 2025). Gastrointestinal issues are also occurring more frequently with antidepressants than with placebo (Jakobsen et al., 2017). Given the minor benefit of antidepressants over placebo and these side effects, it may be more favorable to treat the two examples of physiological symptoms with placebo or non-pharmacological approaches. At least we lack data to support their view.\nThere is also no reference for the claim that “For some children with anxiety, OCD, and depression, medication, even medication monotherapy, may be the appropriate ﬁrst-line treatment, not a fallback.” If the goal is to be more evidence based, then such a statement should be framed as opinion or supported with evidence.\nStrawn and Walkup go on with a positive evaluation of the efficacy of SSRIs: “For example, ﬂuoxetine, as the ﬁrst SSRI brought to market, has the most robust evidence base.18–22 In terms of this evidence for the use of SSRIs in depression, in one of the most methodologically rigorous studies of an SSRI in adolescent MDD, both ﬂuoxetine and ﬂuoxetine combined with CBT were more efﬁcacious than unblinded cognitive-behavioral therapy (CBT) and a blinded placebo.16 “\nAgain they referenced an outdated meta-analysis and ignored more recent findings. They also only cited the first few RCTs on fluoxetine with favorable results but not the 9 more recent trials of which 5 failed to be statistically significant and efficacy of all 9 trials were largely in the area of equivalence with placebo (Plöderl et al., 2025). They also misrepresent findings from the TADS study. The meta-analysis they reference is Cipriani et al. (2016), where fluoxetine was the only antidepressant which was significantly superior to placebo. Cipriani et al. concluded: “When considering the risk–beneﬁt proﬁle of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to oﬀer a clear advantage for children and adolescents. Fluoxetine is probably the best option to consider when a pharmacological treatment is indicated.” Anybody really familiar with Cipriani’s meta-analysis should know that the certainty of the evidence for fluoxetine (but also for other antidepressants) was judged to be “very low”, and this is quite different from a “very robust” evidence interpretation as judged by Strawn and Walkup. Therefore, in contrast to Strawn and Walkup, Cipriani et al. actually give a sobering view on the efficacy of antidepressants.\nFurthermore, similar to Olfson, Strawn and Walkup do not mention that a more recent meta-analysis found a substantially smaller overall efficacy for fluoxetine, being now clinically equivalent with placebo (Hetrick et al., 2021). In our own re-analysis of the trial data for fluoxetine we provided potential explanations why efficacy melted down in the clinically irrelevant range (Plöderl et al., 2025). Initially, fluoxetine was investigated by the sponsor (Eli Lilly) or authors with ties to the sponsor, and fluoxetine was only compared to placebo. These trials were positive. Later, fluoxetine was used as a comparator drug in trials done by competing companies or by the same company but for a competing drug (duloxetine). Moreover, later trials often had 3 or 4 study arms, which means that the chance to receive placebo is smaller (&lt; 50%) than in the initial trials (50%) and this could have led to different expectancy effects, impacting efficacy estimates (Plöderl et al., 2025). Of note, fluoxetine is the only antidepressant which was used as a comparator in pediatric depression trials. No other drug was put to test as a comparator so far, and this is important when judging the efficacy of other antidepressants. We also found another explanation for the larger efficacy of fluoxetine in the influential early meta-analysis by Cipriani et al. (2016). They included a small outlier trial with erroneous/impossible results which boosted the efficacy of fluoxetine. This remained undetected in Cipriani’s study and caused inconsistencies which remained unexplained. Once this problematic trial was removed, the inconsistencies within Cipriani’s meta-analysis disappeared, and the results were then comparable with the recent Cochrane meta-analysis from 2021 (Lyus et al., 2025).\nStrawn and Walkup are optimistic regarding other antidepressants, at odds with what Cipriani et al. 2016 concluded: “However, despite the strong data supporting ﬂuoxetine in MDD, this doesn’t mean it is the “best.” Rather, ﬂuoxetine is one of a class of medications, many of which are likely to be effective across these conditions. While there are subtle differences among SSRIs, such that one might be better than another for a particular patient, they are likely all effective, albeit supported by fewer trials or trials of lower or questionable quality.23,24”\nThis interpretation ignores that all other antidepressants were never put to test with other antidepressants (at least for the treatment of depression) and it is thus not fair to compare these drugs with fluoxetine. Strawn and Walkups’s optimistic view on the efficacy of antidepressant not only are at odds with the sobering conclusion in Ciprian’s meta-analysis, but also with the more recent Cochrane review from 2021 which concludes that: “Findings suggest that most newer antidepressants may reduce depression symptoms in a small and unimportant way compared with placebo. Furthermore, there are likely to be small and unimportant differences in the reduction of depression symptoms between the majority of antidepressants.”\nRegarding adverse events, Strawn and Walkup write: “Many adverse effects parallel pre-existing symptoms of anxiety, OCD, and depression, which makes it hard to distinguish between the disorder and the drug” - This is an awkward argument because results from randomized controlled trials are not affected by such confounding, and drug-placebo differences in adverse events, which occur more frequently with antidepressants than with placebo, can be causally attributed to effects of the drug.\nThey continue with “it can be difﬁcult for patients and families (and for clinicians) to differentiate the symptoms of their condition from the adverse effects of the new medication.” I agree, and this is why we need randomized controlled trials. However, I believe that patients and clinicians can in principle differentiate treatment emerging symptoms unrelated to previous experiences of the mental health problem. In my opinion, the problem is rather that strong prior beliefs about medication can lead to biased evaluations of side effects. With restricted time for thorough assessments and with clinician biases in favor of the medications they prescribe, adverse events caused by the medication tend to be falsely attributed to the mental health problem.\nStrawn and Walkup state that “Perhaps the most pragmatic reﬂection of tolerability is discontinuation. Across trials, SSRI discontinuation rates are similar to placebo.” This is true but not the full story. It is known that in antidepressant trials, discontinuation due to adverse events occurs more frequently in antidepressant arms than in placebo arms. Discontinuation due to lack of efficacy events occurs more often with placebo than with the drugs. Therefore, and not surprisingly, antidepressants are less tolerable than placebo with respect to adverse events. Furthermore, the fact that drop out rates are about the same in drug arms and placebo arms is, in my opinion, a rather disappointing finding. In fact, drop-out occurs slightly more in drug arms than placebo arms; 31 vs. 29% in adult trials and 18% vs. 17% in pediatric samples (Stone et al., 2022). If antidepressants are truly safe and effective, one would expect a lower drop-out rate in the drug arms than in placebo arms.\nIn the discussion of adverse events, Strawn and Walkup discuss the assessment of suicidality: “the FDA’s boxed warning on antidepressants was largely informed by studies that lacked structured assessments of suicidality and had a number of additional methodologic limitations.1 The studies included in these analyses relied on spontaneous reporting to a generic prompt or single-item dichotomous queries on symptom rating scales,2 which limited both interpretability and clinical applicability.”\nI agree that the assessment of suicidality has limitations, but the interpretation is misleading. The crucial question is what this means in terms of related biases and it seems that Strawn and Walkup are ignorant of the available research. In fact, important evidence about biases in medical research originates from antidepressant research, including research on bias for suicidality as adverse events in clinical trials. For example, the RIAT re-analysis of Study 329 found that suicide ideation and suicide attempts were underreported and misclassified in the original publication, and that there was a larger paroxetine-placebo difference for suicidal events than reported in the original publication (Le Noury et al., 2015). I recommend readers to read more about Study 329, which continues to be a problem because the original (ghostwritten) publication with misleading results is still not retracted or corrected, leading to the absurd situation that two coexisting publications of the same data-set with two different conclusions coexist: in the original publication, “Paroxetine is generally well tolerated and effective for major depression in adolescents” (Keller et al., 2001), while in the RIAT reanalysis the conclusion was “Neither paroxetine nor high dose imipramine showed efficacy for major depression in adolescents, and there was an increase in harms with both drug” (Le Noury et al., 2015). Another study compared study reports with publications and found that suicidal behavior was often misclassified into “emotional worsening”, and in one instance, a patient in the drug arm who died several days after trying to strangulate himself arm was classified as after-study event despite that the patient died in the double blind phase (Sharma et al., 2016). Another re-analysis showed that some suicidal behavior occurring in the placebo washout phase before randomization were nonetheless counted into the placebo arm of the double blind phase and this biased the drug-placebo differences, which in fact actually showed an elevated risk for suicidal behavior in the drug arms (Healy & Aldred, 2005). When Strawn and Walkup raise methodological issues, it seems they implicitly suggest that the actual drug-placebo differences in suicidality is perhaps not so problematic. However, the available evidence suggests that the drug-placebo differences in clinical trial publications are underestimations of the actual increase of suicide risk associated with antidepressants. This is in line with findings from meta-research in medicine which suggests that the harms of treatments are generally underestimated in trial publications (Golder et al., 2016). Underreporting of harms perhaps peaks for sexual dysfunctions, a common adverse event of SSRIs and SNRIs, where clinical trials relying on spontaneous reports found much smaller drug-placebo differences than systematic assessments, where up to 80% reported sexual dysfunctions with SSRIs, compared to 12% with placebo (Serretti & Chiesa, 2009). A similar issue occurred in a study by Strawn et al., too: while there was no increase of treatment emergent suicidality with escitalopram versus placebo based on spontaneous reports, a statistically elevated risk occurred for systematically assessed suicidality.\nStrawn and Walkup are correct when they criticize that adverse events are assessed with dichotomous items (adverse event present/absent), as this leads to a loss of information, for example about the degree of severity. In contrast, efficacy is usually assessed with fine-grained symptom rating scales. This leads to the situation that similar drug-placebo differences in benefit and harm are more likely statistically significant for benefit than for harm. We need to consider this by lowering the bar for evidence on adverse events.\nAnother problematic claim is that “Critically, the analyses also failed to establish a mechanism of risk [for suicide].” This is again an awkward argument as clinical trials are not intended to establish mechanisms of benefit or harm. What can be inferred from randomized clinical trials is that drug-placebo differences are caused by the drug. Moreover, it is old clinical wisdom, which is also supported by evidence (Jakobsen et al., 2017; Sharma et al., 2016) that antidepressants can cause agitation, akathisia, irritability, sleep problems, and aggression (in children and adolescents). In a depressed state, these side-effects can make the situation unbearable and can trigger acute suicidality. While this is rare, it nonetheless can happen and for this reason, close monitoring is necessary when starting antidepressants. Unfortunately, adequate monitoring is rather the exception than the rule, as known from a recent excellent register study from Norway on adult patients (Hansen et al., 2024). While guidelines recommend follow-up within two weeks for depressed patients starting medication, only one in four patients was followed up by a general practitioner or specialist within two weeks.\nThen Strawn and Walkup are cherry picking: “In addition, subsequent investigations have not replicated the original signal and even have suggested that some SSRIs may decrease the likelihood of suicidality.” They reference a network meta-analysis of pediatric anxiety disorders only, where, compared to placebo there was a significant increase of treatment emergent suicidality for duloxetine, a reduced risk for sertraline, and no significant difference for any other antidepressant. Strawn and Walkup are very selective in presenting evidence and ignore the other subsequent investigations of clinical trials which did replicate the increased risk for suicide ideation and suicide attempts combined, but also suicide attempts (see references above).\nStrawn and Walkup state that “Lastly, the risk was very low compared with the beneﬁt,39 a fact that is often overlooked and sometimes even exaggerated in our discourse.”\nThis statement is especially noteworthy when considering a recent publication of Strawn himself, where he was “overlooking” harms and exaggerating efficacy (Strawn et al., 2023). In this study on escitalopram for pediatric generalized anxiety disorder, the primary outcome, reduction of anxiety symptoms was just below the magic threshold of statistical significance, but with a small effect size. An independent FDA analysis of this trial found that the primary outcome was not significant in some planned sensitivity analysis (Food and Drug Administration, 2023), but this was not reported by Strawn et al. Of note, none of the six secondary outcomes (response or remission on different symptom scales) were statistically significant and in fact close to zero or numerically even in favor of placebo. When I say that Strawn overlooked harm, I mean that in his study publication, treatment emergent suicidality was reported in the results section, but no statistical test was run and it was not discussed in the results section at all. This caught my attention and a statistical test showed that treatment emergent suicidality occurred significantly more often with escitalopram than with placebo (Plöderl, Horowitz, et al., 2023): “relative to treatment with placebo, 8% more patients treated with escitalopram developed suicidal ideation (1.5% placebo vs. 9.5% escitalopram) but only 6.2% more patients achieved clinical response (33.3% vs. 39.5%) and 1.5% fewer achieved remission (17.7% vs. 18.8%)”. Consequently, in our letter to the editor, we concluded that ”relative to placebo, children and adolescents exposed to escitalopram were more likely to become suicidal than to experience an improvement in anxiety”. Moreover, there were significantly more adverse events other than suicidal ideation with escitalopram than with placebo (55.5% vs. 37.5%). The conclusion by Strawn et al. that “Escitalopram reduced anxiety symptoms and was well tolerated” is therefore at odds with the actual findings and the conclusion should be that escitalopram likely has a problematic benefit-harm ratio for the average patient.\nMore problematic claims by Strawn and Walkup:\n“Subsequent studies, including registry data from Sweden and meta-analyses of placebo-controlled trials, suggest that suicidality may actually decline following the initiation of antidepressant treatment. In a large Swedish registry study (N = 538,577), suicidal behavior peaked during the month before starting an SSRI and declined thereafter.40 Speciﬁcally, the risk of suicidal behavior in the 30 days before SSRI initiation was more than 7 times higher than the risk during the same period 1 year earlier. In contrast, the 30 days following SSRI initiation were associated with a signiﬁcantly reduced risk across age groups.”\nThis study using Swedish registry data does not say anything about the effects of treatment, as there was no control group. We pointed this out in our letter titled “Learning about the course of suicidal behavior but not about the effects of SSRIs” (Plöderl & Hengartner, 2022). A study which used the same Swedish register data, but with a case-crossover control design found an increased risk for suicide at initiation of SSRI, especially in the second week after initiation (Björkenstam et al., 2013). So, Strawn and Walkup cite a single observational study without a control group but missed to cite systematic reviews of observational studies. As already mentioned, high quality observational studies showed an increased risk for suicides and suicide attempts in depressed children using antidepressants (Barbui et al., 2009; Dragioti et al., 2019). In our own systematic review of observational studies on antidepressant for adults, we also found an increased risk for suicidal behavior among those treated with antidepressants (Hengartner et al., 2021). Moreover, we again found evidence for biases favoring antidepressants in these observational studies (Plöderl, Amendola, et al., 2023). First, there is clear evidence for publication bias, that is, studies with favorable results for antidepressants are selectively published. Second, studies with favorable results for antidepressants occur more frequently in psychiatric journals (this is not surprising, as we also experience that inconvenient findings are often rejected in mainstream psychiatric journals). Third, studies with authors who had financial ties to the pharmaceutical industry reported more favorable results for antidepressants compared to studies with authors without such ties, and this was independent of study quality.\n“In addition, several placebo-controlled trials, including TADS and CAMS, have shown that suicidal thinking tends to decline across all treatment arms, including placebo” Again, Strawn and Walkup misrepresent the findings from the TADS study, where suicidal events occurred more often in children and adolescents treated with fluoxetine than with placebo or CBT only and that there was no significant drug-placebo difference in the reduction of suicide ideation (see comments to Olfson).\nStrawn and Walkup argue that suicidality is often caused by the psychiatric illness and psychosocial stressors, not by antidepressants and that “linking medication use as a direct cause of suicidal thoughts and behaviors reduces a complex phenomenon to a misleading narrative.” Here I agree with them, because the increased relative risk for suicidality found in clinical trials is small and this supports the view that most suicides are independent of harmful effects of the drugs. Nonetheless, and despite the inherent uncertainty in the evidence base, the evidence for an increased risk for suicidality associated with antidepressants in children and adolescents should be taken seriously, and this fully justifies the black box warning. Moreover, with the minor, clinically irrelevant benefit of antidepressants (at least for the majority of patients), even minor harms or severe harms in few patients are problematic, especially in light of inadequate monitoring after initiation of antidepressants (Hansen et al., 2024).\n“Unfortunately, it [the black box warning] has also contributed to clinician hesitancy among pediatric primary care clinicians who are often at the front lines of the mental health crisis” Again, this statement is at odds with the evidence, as antidepressant prescriptions have increased in all age-groups since the black box warning in Europe (Fassmer et al., 2025) and in the US (Chua et al., 2024), reaching an all time high in the US (see Figure).\n\n\n\nAntidepressant prescriptions in the US, based on the Medical Expenditure Survey. Data and code are available upon request.\n\n\n\n\nSpreading hope, not fear\nA common argument in responses by both Olfson and Strawn & Walkup is that untreated depression is far more dangerous than the discussed harms associated with antidepressants. Nobody would argue that depressed people should be left without support or “untreated”. However, in my experience, all too often “treated” is equaled with “prescribing antidepressants”, and there seems to be a widespread automatism in prescribing antidepressants, driven by the assumption that antidepressants are safe and effective and that “something must be done”, and because of a seeming lack of alternatives. With the known poor efficacy of antidepressants and their harms, alternatives to antidepressants should be offered more often, such as watchful waiting, or basic interventions such as sleep management, light exposure etc (Selalmazidou & Bschor, 2023).\nWith the repeated claim that untreated depression is most dangerous, critics of MAHA are doing the same fear-mongering as proponents of MAHA do for the harms of the drugs. Usually, authors who claim that untreated depression is super risky either did not reference related studies or they misrepresent the evidence. For example, cited studies often did not investigate untreated patients or even showed a lower risk for untreated versus treated patients (Raven, 2019). Of course confounding by indication can explain why untreated patients have a better outcome than treated patients, but nonetheless these studies have been misinterpreted by those who want to point out the harms of untreated depression. Taking the evidence seriously would mean that we don’t know very much about untreated depression. However, the few available studies show that people who do not seek treatment fare well in the longer term (Whiteford et al., 2013). And as repeatedly pointed out above, treatment with antidepressants hardly outperforms treatment with placebo, at least for the majority of patients. Thus, instead of spreading fear we should provide hope. And this is evidence based hope.\nIn contrast, we read alarmist messages in the article by Strawn and Walkup: ”The threat is not the medication. The threat is untreated psychiatric illness”, or “While SSRIs are not without limitations, they are clearly preferable to past treatments such as tricyclic antidepressants and far better than no treatment at all.” Again, no references are given.\nThe claim that treatment with SSRIs is “far better” than no treatment is also at odds when compared to what patients would expect from antidepressants. In a first study of this sort on adults done recently (Sahker et al., 2024), patients were informed about the harms and costs of antidepressants and then asked what minimum of efficacy they would expect to outweigh the costs/harms (“smallest worthwhile difference”), measured as expected increased chance of achieving response compared to no treatment. It turned out that for the majority of patients antidepressants fared below this smallest worthwhile difference. For context, this study was rather careful not to describe the full range of harms of antidepressants (e.g., the actual frequency of sexual dysfunctions or withdrawal issues). Finally, when psychiatrists are asked what they would do themselves when becoming depressed, most would not start with an antidepressants, but most would nonetheless recommend antidepressants to patients (Mendel et al., 2010).\n\n\nConclusion\nI titled this article “A call for evidence based, fear-free practice”. This call was used in a header by Strawn and Walkup in their paper. Unfortunately, it seems the two responses by leading psychiatrists are at least as biased and fear-mongering as the MAHA reports, just in the opposite direction. Both articles are published in scientific journals and it is telling that they passed peer review. Scientists need to do better by separating beliefs from evidence and by embracing facts, uncertainty, and critical views.\n\n\nReferences\nAboustate, N., Jureidini, J., Woodman, R., Le Noury, J., Klau, J., Abi-Jaoude, E., & Raven, M. (2025). Restoring TADS: RIAT reanalysis of the Treatment for Adolescents with Depression Study. The International Journal of Risk & Safety in Medicine, 9246479251337880. https://doi.org/10.1177/09246479251337879\nBarbui, C., Esposito, E., & Cipriani, A. (2009). Selective serotonin reuptake inhibitors and risk of suicide: A systematic review of observational studies. Canadian Medical Association Journal, 180(3), 291–297. https://doi.org/10.1503/cmaj.081514\nBjörkenstam, C., Möller, J., Ringbäck, G., Salmi, P., Hallqvist, J., & Ljung, R. (2013). An Association between Initiation of Selective Serotonin Reuptake Inhibitors and Suicide—A Nationwide Register-Based Case-Crossover Study. PLoS ONE, 8(9), e73973. https://doi.org/10.1371/journal.pone.0073973\nChua, K.-P., Volerman, A., Zhang, J., Hua, J., & Conti, R. M. (2024). Antidepressant Dispensing to US Adolescents and Young Adults: 2016–2022. Pediatrics, 153(3), e2023064245. https://doi.org/10.1542/peds.2023-064245\nCipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., Cuijpers, P., Pu, J., Cohen, D., Ravindran, A. V., Liu, Y., Michael, K. D., Yang, L., Liu, L., & Xie, P. (2016). Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: A network meta-analysis. The Lancet, 388(10047), 881–890. https://doi.org/10.1016/S0140-6736(16)30385-3\nDragioti, E., Solmi, M., Favaro, A., Fusar-Poli, P., Dazzan, P., Thompson, T., Stubbs, B., Firth, J., Fornaro, M., Tsartsalis, D., Carvalho, A. F., Vieta, E., McGuire, P., Young, A. H., Shin, J. I., Correll, C. U., & Evangelou, E. (2019). Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review. JAMA Psychiatry, 76(12), 1241. https://doi.org/10.1001/jamapsychiatry.2019.2859\nFassmer, A. M., Wandscher, K., Bedri, A., Jobski, K., Poustka, L., Bachmann, C. J., & Hoffmann, F. (2025). Change of antidepressant utilization in children, adolescents and young adults in Europe before and during the COVID-19 pandemic: A systematic review. European Child & Adolescent Psychiatry. https://doi.org/10.1007/s00787-025-02839-x\nFood and Drug Administration. (2023, December 5). Multi-disciplinary Review and Evaluation LEXAPRO (escitalopram) tablets / oral solution. https://www.fda.gov/media/170239/download?attachment\nGolder, S., Loke, Y. K., Wright, K., & Norman, G. (2016). Reporting of Adverse Events in Published and Unpublished Studies of Health Care Interventions: A Systematic Review. PLOS Medicine, 13(9), e1002127. https://doi.org/10.1371/journal.pmed.1002127\nHansen, A. B., Hetlevik, Ø., Baste, V., Haukenes, I., Smith-Sivertsen, T., & Ruths, S. (2024). Variation in general practitioners’ follow-up of depressed patients starting antidepressant medication: A register-based cohort study. Family Practice, cmae063. https://doi.org/10.1093/fampra/cmae063\nHealy, D., & Aldred, G. (2005). Antidepressant drug use & the risk of suicide. International Review of Psychiatry, 17(3), 163–172. https://doi.org/10.1080/09540260500071624\nHengartner, M. P. (2021). Evidence-biased antidepressant prescription: Overmedicalisation, flawed research, and conflicts of interest. Springer.\nHengartner, M. P., Amendola, S., Kaminski, J. A., Kindler, S., Bschor, T., & Plöderl, M. (2021). Suicide risk with selective serotonin reuptake inhibitors and other new-generation antidepressants in adults: A systematic review and meta-analysis of observational studies. Journal of Epidemiology and Community Health, 75, 523–530. https://doi.org/10.1136/jech-2020-214611\nHetrick, S. E., McKenzie, J. E., Bailey, A. P., Sharma, V., Moller, C. I., Badcock, P. B., Cox, G. R., Merry, S. N., & Meader, N. (2021). New generation antidepressants for depression in children and adolescents: A network meta-analysis. Cochrane Database of Systematic Reviews, 2021(5). https://doi.org/10.1002/14651858.CD013674.pub2\nHögberg, G. N., Antonuccio, D. O., & Healy, D. (2015). Suicidal risk from TADS study was higher than it first appeared. The International Journal of Risk & Safety in Medicine, 27(2), 85–91. https://doi.org/10.3233/JRS-150645\nJakobsen, J. C., Gluud, C., & Kirsch, I. (2019). Should antidepressants be used for major depressive disorder? BMJ Evidence-Based Medicine, bmjebm-2019-111238. https://doi.org/10.1136/bmjebm-2019-111238\nJakobsen, J. C., Katakam, K. K., Schou, A., Hellmuth, S. G., Stallknecht, S. E., Leth-Møller, K., Iversen, M., Banke, M. B., Petersen, I. J., Klingenberg, S. L., Krogh, J., Ebert, S. E., Timm, A., Lindschou, J., & Gluud, C. (2017). Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and trial sequential analysis. BMC Psychiatry. https://doi.org/10.1186/s12888-016-1173-2\nKeller, M. B., Ryan, N. D., Strober, M., Klein, R. G., Kutcher, S. P., Birmaher, B., Hagino, O. R., Koplewicz, H., Carlson, G. A., Clarke, G. N., Emslie, G. J., Feinberg, D., Geller, B., Kusumakar, V., Papatheodorou, G., Sack, W. H., Sweeney, M., Wagner, K. D., Weller, E. B., … Mccafferty, J. P. (2001). Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial. Journal of the American Academy of Child & Adolescent Psychiatry, 40(7), 762–772. https://doi.org/10.1097/00004583-200107000-00010\nLe Noury, J., Nardo, J. M., Healy, D., Jureidini, J., Raven, M., Tufanaru, C., & Abi-Jaoude, E. (2015). Restoring Study 329: Efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ, h4320. https://doi.org/10.1136/bmj.h4320\nLu, C. Y., Zhang, F., Lakoma, M. D., Madden, J. M., Rusinak, D., Penfold, R. B., Simon, G., Ahmedani, B. K., Clarke, G., Hunkeler, E. M., Waitzfelder, B., Owen-Smith, A., Raebel, M. A., Rossom, R., Coleman, K. J., Copeland, L. A., & Soumerai, S. B. (2014). Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: Quasi-experimental study. BMJ, 348(jun18 24), g3596–g3596. https://doi.org/10.1136/bmj.g3596\nLyus, R., Naudet, F., van Valkenhoef, G., & Plöderl, M. (2025). A Re-Appraisal of Three Network Meta-Analyses to Explain the Discrepancy in Findings for the Efficacy of Fluoxetine for the Treatment of Depression in Children and Adolescents. MedRxiv, 2025.09.07.25334757. https://doi.org/10.1101/2025.09.07.25334757\nMarch, J., Silva, S., Petrycki, S., Curry, J., Wells, K., Fairbank, J., Burns, B., Domino, M., McNulty, S., Vitiello, B., Severe, J., & Treatment for Adolescents With Depression Study (TADS) Team. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA, 292(7), 807–820. https://doi.org/10.1001/jama.292.7.807\nMendel, R., Hamann, J., Traut-Mattausch, E., Bühner, M., Kissling, W., & Frey, D. (2010). ‘What would you do if you were me, doctor?’: Randomised trial of psychiatrists’ personal v. professional perspectives on treatment recommendations. British Journal of Psychiatry, 197(6), 441–447. https://doi.org/10.1192/bjp.bp.110.078006\nMunkholm, K., Paludan-Müller, A. S., & Boesen, K. (2019). Considering the methodological limitations in the evidence base of antidepressants for depression: A reanalysis of a network meta-analysis. BMJ Open, 9(6), e024886. https://doi.org/10.1136/bmjopen-2018-024886\nOlfson, M. (2025). Psychotropic Medications and Child Health. JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2025.3024\nPlöderl, M., Amendola, S., & Hengartner, M. P. (2023). Observational studies of antidepressant use and suicide risk are selectively published in psychiatric journals. Journal of Clinical Epidemiology, 162, 10–18. https://doi.org/10.1016/j.jclinepi.2023.07.015\nPlöderl, M., & Hengartner, M. P. (2022). Learning about the course of suicidal behavior but not about the effects of SSRIs. Neuropsychopharmacology, 47(4), 803–803. https://doi.org/10.1038/s41386-021-01224-x\nPlöderl, M., & Hengartner, M. P. (2023). Effect of the FDA black box suicidality warnings for antidepressants on suicide rates in the USA: Signal or noise? Crisis, 44(2), 128–134. https://doi.org/10.1027/0227-5910/a000843\nPlöderl, M., Horowitz, M. A., & Hengartner, M. P. (2023). Re: “A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder” by Strawn et al.—Concerning Harm–Benefit Ratio in a Recent Trial About Escitalopram for Generalized Anxiety Disorder. Journal of Child and Adolescent Psychopharmacology, 33(7), 295–296. https://doi.org/10.1089/cap.2023.0029\nPlöderl, M., Lyus, R. J., Horowitz, M., & Moncrieff, J. (2025). The loss of efficacy of fluoxetine in pediatric depression: Explanations, lack of acknowledgment, and implications for other treatments. https://doi.org/10.31234/osf.io/wk4et_v1\nRaven, M. (2019). 24 Untreated mental illness: Ideology trumps evidence, fuelling overdiagnosis. Oral Presentations, A18.2-A18. https://doi.org/10.1136/bmjebm-2019-POD.38\nSahker, E., Furukawa, T. A., Luo, Y., Ferreira, M. L., Okazaki, K., Chevance, A., Markham, S., Ede, R., Leucht, S., Cipriani, A., & Salanti, G. (2024). Estimating the smallest worthwhile difference of antidepressants: A cross-sectional survey. BMJ Mental Health, 27(1), e300919. https://doi.org/10.1136/bmjment-2023-300919\nSelalmazidou, A.-M., & Bschor, T. (2023). Depression: Niedrigschwellige Kardinalmaßnahmen als Basis jeder Behandlung. Fortschritte der Neurologie · Psychiatrie, 91(12), 523–534. https://doi.org/10.1055/a-2169-2120\nSerretti, A., & Chiesa, A. (2009). Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis. Journal of Clinical Psychopharmacology, 29(3), 259–266. https://doi.org/10.1097/JCP.0b013e3181a5233f\nSharma, T., Guski, L. S., Freund, N., & Gøtzsche, P. C. (2016). Suicidality and aggression during antidepressant treatment: Systematic review and meta-analyses based on clinical study reports. BMJ. https://doi.org/10.1136/bmj.i65\nSoumerai, S. B., Koppel, R., Naci, H., Madden, J. M., Fry, A., Halbisen, A., Angeles, J., Koppel, J., Rubin, R., & Lu, C. Y. (2024). Intended And Unintended Outcomes After FDA Pediatric Antidepressant Warnings: A Systematic Review. Health Affairs (Project Hope), 43(10), 1360–1369. https://doi.org/10.1377/hlthaff.2023.00263\nSpielmans, G. I., Spence-Sing, T., & Parry, P. (2020). Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified. Frontiers in Psychiatry, 11, 18. https://doi.org/10.3389/fpsyt.2020.00018\nStone, M. B. (2014). The FDA Warning on Antidepressants and Suicidality—Why the Controversy? New England Journal of Medicine, 371(18), 1668–1671. https://doi.org/10.1056/NEJMp1411138 Stone, M. B. (2018). In Search of a Pony: Sources, Methods, Outcomes, and Motivated Reasoning. Medical Care, 56(5), 375–381. https://doi.org/10.1097/MLR.0000000000000895 Stone, M. B.,\nLaughren, T. P., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., Hammad, T. A., Temple, R., & Rochester, G. (2009). Risk of suicidality in clinical trials of antidepressants in adults: Analysis of proprietary data submitted to US Food and Drug Administration. BMJ, 339, 1–10.\nStone, M. B., Yaseen, Z. S., Miller, B. J., Richardville, K., Kalaria, S. N., & Kirsch, I. (2022). Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: Individual participant data analysis. BMJ (Clinical Research Ed.), 378, e067606. https://doi.org/10.1136/bmj-2021-067606\nStrawn, J. R., Moldauer, L., Hahn, R. D., Wise, A., Bertzos, K., Eisenberg, B., Greenberg, E., Liu, C., Gopalkrishnan, M., McVoy, M., & Knutson, J. A. (2023). A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder. Journal of Child and Adolescent Psychopharmacology, 33(3), 91–100. https://doi.org/10.1089/cap.2023.0004\nStrawn, J. R., & Walkup, J. T. (2025). Fact Versus Fear: Antidepressants in Children and Adolescents. Journal of Clinical Psychopharmacology, 45(5), 413–417. https://doi.org/10.1097/JCP.0000000000002054\nThe White House. (2025). The MAHA Report. https://www.whitehouse.gov/wp-content/uploads/2025/05/MAHA-Report-The-White-House.pdf\nTürkmen, C., Machunze, N., Lee, A. M., Bougelet, E., Ludin, N. M., de Cates, A. N., Vollstädt-Klein, S., Bach, P., Kiefer, F., Burdzovic Andreas, J., Kamphuis, J., Schoevers, R. A., Emslie, G. J., Hetrick, S. E., Viechtbauer, W., & van Dalfsen, J. H. (2025). Systematic Review and Meta-Analysis: The Association Between Newer-Generation Antidepressants and Insomnia in Children and Adolescents With Major Depressive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, S0890-8567(25)00013-9. https://doi.org/10.1016/j.jaac.2025.01.006\nVitiello, B., Silva, S. G., Rohde, P., Kratochvil, C. J., Kennard, B. D., Reinecke, M. A., Mayes, T. L., Posner, K., May, D. E., & March, J. S. (2009). Suicidal events in the Treatment for Adolescents With Depression Study (TADS). The Journal of Clinical Psychiatry, 70(5), 741–747.\nWhiteford, H. A., Harris, M. G., McKeon, G., Baxter, A., Pennell, C., Barendregt, J. J., & Wang, J. (2013). Estimating remission from untreated major depression: A systematic review and meta-analysis. Psychological Medicine, 43(08), 1569–1585. https://doi.org/10.1017/S0033291712001717"
  }
]